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ABSTRACT 
 
GENOMIC APPROACHES TO UNDERSTANDING VARIABLE EXPRESSIVITY IN ALAGILLE 
SYNDROME AND GENETIC SUSCEPTIBILITY TO BILIARY ATRESIA 
Ellen A. Tsai 
Nancy B. Spinner, PhD 
Marcella Devoto, PhD 
 
The biliary system facilitates transport of bile from the liver, where it is produced, to the gall 
bladder, where it is stored and later released to aid digestion. Obstruction and defects in the 
biliary system are a primary indication of liver transplantation in children. Alagille syndrome 
(ALGS) and biliary atresia (BA) are two cholangiopathies with different etiopathology, but both 
affect bile flow and can lead to end-stage liver disease. ALGS is a dominant, multisystemic 
disease caused by mutations in JAG1 or NOTCH2 characterized by intrahepatic ductopenia and 
variable expressivity. BA is a multifactorial disease characterized by necroinflammatory 
obliteration of the extrahepatic biliary tree with unknown etiology. I used genomic tools including 
genome-wide gene expression analysis, genome-wide association (GWA) studies of single 
nucleotide polymorphisms (SNPs) and copy number variation (CNVs), and exome sequence 
analysis to uncover the genetic component to variable expressivity in ALGS and susceptibility to 
BA. In the first part of this thesis, I searched for genetic modifiers of the ALGS phenotype by 
investigating the effects of the non-mutated JAG1 allele, characterizing downstream gene 
expression of Notch signaling, and performing a SNP and CNV GWA studies of liver disease 
severity. This work revealed that cardiac defects are correlated with liver disease severity and the 
presence of butterfly vertebrae. I uncovered an enhancer element upstream of THBS2 that may 
affect the progression of liver disease in ALGS patients. In the second part of this thesis, I looked 
for markers of genetic susceptibility to BA, using an association study, exome sequencing of 
unrelated patients, and exome sequencing and CNV analysis of familial recurrence of BA-
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associated phenotypes. This work suggested several BA candidate genes, including FOXA2, 
which we propose as a BA susceptibility gene. Additionally, fine mapping of a previously reported 
susceptibility locus demonstrated an intronic risk allele in ADD3. Exome sequencing of candidate 
genes and a pathway-enriched analysis revealed alterations in several other genes that support 
the hypothesis that BA is a genetically heterogeneous disorder. This work identifies multiple 
areas for future research to better understand the genetics of these two biliary disorders. 
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CHAPTER 1: Introduction 
1.1 Approaches to Understanding the Complexity of Genetic Disorders 
1.1.1 Genetic Models for Modifier and Susceptibility Genes 
The recurrence of genetic diseases has been observed long before the characterization 
of the underlying genetic cause of the disorder. Some of the most notable diseases initially 
recognized to run in families are Huntington’s disease (autosomal dominant), cystic fibrosis 
(autosomal recessive), and Duchenne muscular dystrophy (X-linked) (Strachan and Read 2011). 
These are classical cases of monogenic disorders that follow Mendelian inheritance and have 
been mapped by linkage analysis (Burmeister and Lehrach 1986; Gusella et al. 1983; White et al. 
1985). 
The identification of the molecular mutations that cause these disorders led to further 
insight on the underlying genetic models. In dominant disorders such as Huntington’s disease, 
which is caused by trinucleotide expansions in the huntingtin (HTT) gene, unaffected individuals 
have been observed to carry known pathogenic mutations (Rubinsztein et al. 1994). This notion 
of incomplete penetrance in Huntington’s disease was further elucidated by an exhaustive 
characterization of the mutation. Normal individuals have 12-35 CAG repeats in HTT, and nearly 
everyone with more than 41 CAG repeats will develop Huntington’s disease by the age of 75 
years. However, there is incomplete penetrance when the number of repeats is between 36 and 
41. The penetrance of the mutation is correlated to the length of the repeat. A HTT allele with 36 
CAG repeats has the lowest observed penetrance of this disorder, and a 40-year-old carrying this 
mutation will have a 14% chance of onset by the age of 75 (Langbehn et al. 2004). Thus, even 
after the identification of a pathogenic mutation, incomplete penetrance can introduce a layer of 
complexity to Mendelian traits. 
In addition to incomplete penetrance, variable expressivity is another characteristic found 
in many genetic diseases. Variable expressivity in qualitative traits is measured by characteristics 
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of the disease such as its clinical severity, presence of secondary phenotypes, and the age of 
onset. It has been known that disease-causing mutations on genes can take on the form of an 
allelic series, where a range of phenotypes is associated with specific mutations (Romeo and 
McKusick 1994). An example of this diversity can be found in mutations of dystrophin (DMD), 
located on Xp21.2. Mutations in DMD are known to cause two forms of muscular degeneration in 
males, Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). DMD 
causes progressive muscular weakness with high morbidity, while BMD is now thought to be a 
milder form of this disorder and has a slower rate of progression of muscle degeneration. 
Originally characterized as two different disorders, the identification of a common disease-
causing gene for DMD and BMD suggests that differences in the phenotypic presentation of 
these disorders are attributed to the underlying genetic mutation. In DMD, the mutated gene does 
not produce a protein product, while a truncated form of the protein is produced from the mutated 
gene in BMD. Another example of variable expressivity occurs with mutations in ABCB11 that 
cause progressive familial intrahepatic cholestasis 2 (PFIC2). Both missense and nonsense 
mutations in ABCB11 are responsible for PFIC2, but the truncating form of the allele is associated 
with severe liver disease (Strautnieks et al. 2008). 
Variable expressivity could also be caused by a combination of stochastic effects, 
environmental factors, and genetic factors, such as the presence of a modifier gene. For example, 
environmental factors have been shown to play a role in the severity of lung disease of cystic 
fibrosis patients, and positive correlations to severe lung disease have been found with tobacco 
smoke, poor nutrition, and stress (Collaco et al. 2008; Schechter 2003). There is also evidence of 
many genetic factors that may modify secondary features of cystic fibrosis (Salvatore et al. 2002). 
For instance, !-1 antitrypsin deficiency (A1AT) is caused by mutations in SERPINA1. Functional 
analysis of the coding sequence of this gene demonstrated that two missense mutations 
characterized as the Z allele, which produces very little protein, and the S allele, which produces 
moderately low protein levels, are responsible for various degrees of lung and liver disease in 
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cystic fibrosis (Bartlett et al. 2009). Variable expressivity is another aspect of Mendelian disorders 
that cannot always be accounted for by the pathogenic mutation. 
 Although there can be a wide range of phenotypic diversity in monogenic, Mendelian 
disorders, the complexity of the phenotype could also stem from a complex, multifactorial genetic 
composition. Genetically heterogeneous disorders such as Bardet-Biedl syndrome and 
Hirschsprung’s disease are examples of multigenic disorders. In Bardet-Biedl syndrome, the 
presence of three or more mutant alleles in the known disease genes gives rise to this phenotype 
(Katsanis et al. 2001). There are several major genes known to cause Hirschsprung’s disease, 
including RET (Iwashita et al. 1996), EDNRB (Amiel et al. 1996), GDNF (Salomon et al. 1996), 
and EDN3 (Bidaud et al. 1997), where mutations in these genes can give rise to dominant, 
recessive, or polygenic patterns of inheritance.  
While multiple genes can give rise to the same phenotype, these genes can behave and 
interact in different ways. Epistasis is one form of genetic interactions where multiple alleles can 
alter the same trait. Bateson first defined epistasis in 1909 as the masking effect of variants at 
one locus due to alterations at a second locus (Bateson 2007). For instance, loss-of-function of 
both copies of TYR on 11q14.3 can cause albinism (Kwon et al. 1987). In the context of hair color, 
white hair caused by this form of albinism is epistatic to all other loci that govern hair color. In 
addition to epistasis, cell-to-cell signaling defects can also give rise to genetic disorders. These 
diseases can arise from defects in the receptor protein or the ligand that binds to the receptor that 
induce the signaling process. Oftentimes, a receptor can recognize multiple ligands, so it is not 
surprising that defects in the receptor can lead to a more severe phenotype than those on the 
ligand. The binding mechanism requires precise interaction between the receptor and ligand, so it 
is also not surprising that mutations disrupting both the receptor and the ligand can cause a more 
severe phenotype than mutations in either alone. In Hirschsprung’s disease, it has been shown 
that defects in RET or GDNF, a receptor-ligand pair, can be responsible for the disease 
phenotype. Moreover, the mutations in RET, a receptor tyrosine kinase, have a stronger effect 
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than mutations in GDNF (Salomon et al. 1996). Other models of gene interactions are more 
complex, including genes that participate in parallel pathways, genes that directly interact with 
each other, and genes whose expression is dependent on one another. 
Modifier genes have small quantitative effects on the level of expression of another gene. 
When modifier genes alter the function or expression of disease genes, they can be responsible 
for phenotypic diversity of the disorder by affecting the penetrance, dominance, and expressivity 
of the phenotype. For example, retinitis pigmentosa is an autosomal recessive disorder that can 
be caused by defects in peripherin 2 encoded by the PRPH2 gene. However, it was observed 
that individuals with one damaged copy of PRPH2 and one damaged copy of ROM1 also 
developed retinitis pigmentosa. The additional defect in one copy of this modifier gene encoding a 
retinal outer segment membrane protein was responsible for the disease phenotype due to 
dominance modification (Kajiwara et al. 1994). In addition, these genes can modify transcriptional 
levels of other genes, alter immediate gene transcript expression, or even impact phenotype by 
modifications at a cellular or organismal level (Nadeau 2001). 
In polygenic traits, many genetic loci each contribute to the phenotype, but each has a 
modest effect. These loci are referred to as susceptibility loci in dichotomous traits for diseases 
such as diabetes or heart disease and quantitative trait loci in continuous traits such as weight or 
height. Because of the complexity of their genetic composition, these phenotypes are also 
referred to as “complex traits.” Correspondingly, gene-gene interactions, the interaction between 
two or more genetic loci, add another layer of complexity to predicting the effect size of each 
locus. Many methods have been derived to identify the genetic loci of complex traits and 
understand how they interact with one each other (Strachan and Read 2011). 
1.1.2 Methods to Detect Genes for Complex Disorders 
 There are four principle approaches to studying complex genetic disorders. These are 
linkage analysis, genome-wide association studies, copy number variation (CNV) association 
studies, and whole genome or exome analysis. These strategies can successfully identify a 
5 
disease locus, the contributing gene, or the pathogenic mutation that gives rise to genetic 
disorders. Classically, linkage studies of diseases segregating in families have been used to 
coarsely map the locations of each disease locus. The advancement of technology has enabled a 
cost efficient method to interrogate hundreds of thousands of genomic markers for large sample 
sizes. This provides the opportunity to perform association tests on unrelated individuals, for both 
DNA sequence changes and copy number changes. Each of these methods has strengths and 
weaknesses summarized below. 
Linkage Analysis 
Familial genetic linkage studies were proposed as a method to identify chromosomal 
regions that contain disease-causing alterations. The completion of human linkage maps 
constructed with restriction fragment length polymorphisms enabled the identification of many 
disease loci such as Huntington’s disease and early-onset breast cancer (Gusella et al. 1983; 
Hall et al. 1990). This powerful method led to many important discoveries, but only highly 
penetrant disorders with a high recurrence risk could be used for these familial studies. 
Because of these limitations, linkage analysis for complex disorders was not as 
successful. With few exceptions such as the NOD2 gene for Crohn’s disease originally mapped 
by sib-pair linkage analysis on 16q12.1 (Hugot et al. 1996), complex disease loci mapped by 
linkage analysis were difficult to replicate. Oftentimes, a disease gene at the risk loci could not be 
identified. The lack of success demonstrated that linkage analysis lacks power to detect genes for 
disorders with polygenic inheritance as well as disorders with low penetrance (Risch and 
Merikangas 1996). 
Genome-Wide Association Study 
Lander et al. proposed a new hypothesis on the etiology of complex diseases in 1994 
and suggested that complex diseases are caused by the accumulation of common variants, each 
conferring a small risk to disease (Lander and Schork 1994). This common disease, common 
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variant model could explain why linkage analysis of complex traits was unsuccessful, because 
linkage studies lack power to detect loci with small effect sizes. Subsequently, the completion of 
the Human Genome Project enabled researchers to identify millions of polymorphisms that are 
present in the general population (International Human Genome Sequencing Consortium 2004; 
Sachidanandam et al. 2001). These single nucleotide polymorphisms (SNPs) could be rapidly 
genotyped using very dense arrays. This technology allowed researchers to test loci on a 
genome-wide level to identify common variants that cause disease. Thus, SNP genotyping arrays 
became a powerful tool for mapping disease loci.  
The statistical approach developed to test SNPs as complex disease susceptibility 
variants at a genomic level is known as a genome-wide association (GWA) study. In GWA 
studies, unrelated affected and unaffected individuals are genotyped, and each marker is tested 
for association with the disease by comparing its allele frequencies between the two groups. If a 
marker shows association with a disease, it could be directly affecting disease risk or in linkage 
disequilibrium with the disease-causing variant. In 2005, the first successful GWA study utilized 
96 cases of age-related macular degeneration and 50 controls typed for 116,204 markers (Klein 
et al. 2005). This report found a susceptibility locus on 1q31 for age-related macular degeneration. 
Two markers reached significance after Bonferroni correction for multiple testing, and analysis of 
SNPs in linkage disequilibrium with these markers identified a non-synonymous polymorphism of 
Complement Factor H as a risk allele for this disorder. 
The advancement of technology has led to higher density SNP arrays that can now 
detect millions SNP markers simultaneously. To properly adjust for multiple testing, higher marker 
density also requires a more stringent p-value significance threshold. Since many SNP genotypes 
are correlated due to linkage disequilibrium, the estimation of the number of independent tests is 
less than the observed number of markers. A p-value of 5x10-8 has been widely regarded as the 
threshold for genome-level significance. An estimation of the multiple testing burden found the 
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threshold for the Caucasian population is actually less stringent, with p < 10-7 achieving a Type I 
error rate < 0.05 (Pe'er et al. 2008). 
To date, there are almost two thousand trait- and disease-associated SNPs identified for 
various diseases reported from GWA studies (Hindorff et al. 2013). The quality metrics and 
analysis tools used to perform GWA studies have been relatively standardized (Devlin and 
Roeder 1999; Laurie et al. 2010; Price et al. 2006; Purcell et al. 2007). This approach has proven 
to be a powerful, hypothesis-neutral method for investigating the genetic bases of complex 
disorders. 
Even so, GWA studies are not suitable to solve all genetic problems. The large sample 
size requirement to detect disease loci with modest effect sizes may be hard to achieve for rare 
disorders. Moreover, GWA studies are often underpowered to detect associations with rare 
variants. Studies have found that after more than a decade’s work using GWA studies to uncover 
susceptibility loci in complex diseases, much of the genetic heritability is still left unexplained 
(Manolio et al. 2009). For example, human height has an estimated heritability of 80%, but even 
with tens of thousands of people genotyped, GWA studies could only identify a few dozen 
susceptibility loci associated with height that explain approximately 5% of the phenotypic variance 
(Visscher 2008). More sophisticated models including testing for height as a polygenic trait may 
explain up to 45% of the heritability (Yang et al. 2010a), but this number is still considerably 
smaller than the estimated heritability. Lessons learned from this classic complex trait suggest 
that the remaining heritability is due in part to incomplete linkage disequilibrium between causal 
variants and the tested SNP markers. Larger sample sizes and denser SNP arrays may lead to 
more discoveries of additional susceptibility loci. 
This missing heritability has also been coined the “dark matter” of genome-wide 
associations, because there is a gap between the estimated heritability and the amount of 
phenotypic variance explained by the identified loci (Manolio et al. 2009). More sophisticated 
methods such as pathway-based approaches have been developed to further analyze SNP array 
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data and detect associations that have been missed due to the stringent metrics of a standard 
GWA (Wang et al. 2010a). Additionally, this “dark matter” left unexplained by GWA studies led to 
the investigation of CNV association and next-generation sequencing techniques that can directly 
identify causal variants that could be in low linkage disequilibrium with SNP markers (Maher 2008; 
McCarroll 2008). 
Copy Number Association Study 
 Classical genetic studies have demonstrated that genes can be very sensitive to dosage 
changes. Alterations in gene dosages such as increasing or decreasing levels of expression can 
lead to disease. The investigation of structural variants identified from the mapped genome led to 
several initial findings of disease trait associations with copy number alterations (Aitman et al. 
2006; Fanciulli et al. 2007; Gonzalez et al. 2005; Hollox et al. 2008). The healthy samples 
genotyped by the HapMap Consortium uncovered CNVs, or copy number changes in fragments 
of DNA spanning hundreds of bases to several megabases, and this demonstrated that CNVs 
were a naturally occurring phenomenon in normal individuals (Redon et al. 2006). 
Findings from genome-wide studies have detected associations of these CNVs with 
genetic diseases. It has been shown that the intensity scores from oligonucleotide or SNP 
genotyping arrays can be used to identify CNVs, including pathogenic and often de novo CNVs 
that cause severe genetic defects (Friedman et al. 2006; Sebat et al. 2007; Xu et al. 2008). The 
scalability of CNV calling algorithms allowed for rapid identification of CNVs in large cohorts 
(Wang et al. 2007; Winchester et al. 2009). However, the determination of CNV breakpoints is 
heavily dependent on the quality of SNP array data and the CNV-calling algorithm. Furthermore, 
the resolution of the CNV is also highly dependent on the SNP array marker density, so combined 
CNV datasets from multiple array platforms should be interpreted cautiously. Large CNV 
association studies of disease cases and normal controls identified that both common and rare 
CNVs could contribute to disease risk (Glessner et al. 2009; Marshall et al. 2008; Yang et al. 
2008). Most CNVs with strong effect sizes also affect gene expression directly by a whole-gene 
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deletion or by gene disruption. These genome-wide CNV association studies have proven to be 
complementary to SNP association studies, and together, they comprise an integral part of 
genetic research. 
Exome Sequencing Analysis 
Sequencing the human genome was an arduous task that required a large international 
effort to complete in 13 years using traditional sequencing methods (International Human 
Genome Sequencing Consortium 2004; Lander et al. 2001). Although Sanger sequencing is still a 
vital tool for geneticists that study a few genes of interest, it does not scale well and cannot 
simultaneously interrogate hundreds of genes. In contrast, next-generation sequencing (NGS) is 
a powerful tool that can generate hundreds of gigabases of sequence data in a very short amount 
of time (Shendure and Ji 2008). The decreasing cost of NGS is breaking down the cost barrier, 
and consequently, an increasing number of researchers are using techniques such as exome 
sequencing to identify genes for genetic diseases. Exome sequencing has an advantage over 
GWA studies, as it directly interrogates the causal exonic variants that are responsible for 
disease. This technology can address different questions such as the presence of rare or de novo 
variants that cause disease. 
NGS protocols require a few of micrograms of DNA, which are randomly sheared into 
fragments approximately 500bp in size, and adaptor ends are added to these DNA fragments. 
This shotgun library construction is common to all NGS protocols. For exome sequencing, there 
is an extra step of exome enrichment through the use of baits that target the exons. Capture kits 
are commercially available from vendors including Agilent, Illumina, and Nimblegen. The different 
capture kits vary slightly in their target region, with differential capture of regions around genes 
such as the 3’ and 5’ untranslated regions. NGS can be performed across many different platform 
solutions, but the most common is 100bp paired-end sequencing using the Illumina HiSeq 2000 
sequencers. From this instrument, FASTQ files which contain sequenced reads with associated 
quality scores for every base pair can be aligned to the reference genome using software 
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including BWA (Li and Durbin 2009), Bowtie (Langmead and Salzberg 2012; Langmead et al. 
2009), or Novoalign by Novocraft (Selangor, Malaysia). Each software program has its own 
strengths and behaves differently aligning reads from various experimental datasets (Li and 
Homer 2010). Variant calling software built into bioinformatics software including SAMtools (Li et 
al. 2009a) and Genome Analysis Toolkit (GATK) (DePristo et al. 2011) are commonly executed to 
identify differences from the reference genome. From the variants called from these tools, 
researchers can identify those that may be potentially pathogenic for experimental validation. 
Although many sequence alignment and variant calling software are available for 
processing NGS reads, this has become a relatively standardized procedure. In the academic 
environment, BWA and GATK are often integrated into sequence alignment and variant calling 
pipelines to process NGS data (DePristo et al. 2011; Li and Durbin 2009; Lin et al. 2013). 
Although these pipelines have proven to accurately identify variants, the presence of de novo or 
rare variants is often still validated using Sanger sequencing. Variants identified in large cohorts 
have proven to be reliable enough to be reported without extensive external validation. 
In recent years, exome sequencing has emerged to be a powerful tool to identify causal 
variants for various genetic disorders. An area of active research in the academic community is 
standardization of methods for variant prioritization to identify disease genes. This data analysis 
portion is highly dependent on the study design and the underlying genetic model. The 
interpretation of exome data can be categorized into two major categories: investigation of highly 
penetrant disorders through family studies or homogenous patient cohorts and studies of complex 
disorders in a large cohort. Oftentimes, Mendelian disorders can be identified using parental 
exomes in addition to affected probands to screen for variants transmitted in a dominant, 
recessive, or de novo manner. Familial investigations of a rare Mendelian disorder demonstrated 
proof-of-principle for the utility of exome sequencing (Ng et al. 2010b). A subsequent identification 
of a gene causing another rare disorder through investigation of a cohort of severely affected 
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unrelated individuals for mutations in the same gene demonstrated that analysis of unrelated 
individuals can also be an effective technique to identify disease genes (Ng et al. 2010a).  
The first Mendelian disease to be solved using exome sequence was Miller syndrome, a 
rare disorder associated with developmental abnormalities of the face and limbs (Ng et al. 2010b). 
Miller syndrome is an extremely rare disease with only a few dozen reported worldwide cases, 
and exome sequencing was carried out on 4 probands. Variants not previously seen in the 
available public data (dbSNP and 8 HapMap exomes) were prioritized for further investigation. 
From Sanger sequencing confirmation of parents and additional probands, they described 
compelling evidence for recessive transmission of truncating and missense mutations of DHODH, 
which is now the confirmed disease gene for this disorder.  
Another utilization of exome sequencing is the analysis of a group of probands all 
presenting with the same clinical diagnosis to look for variants in common genes. However, this 
experimental design assumes the absence of genetic heterogeneity and mutations in the same 
gene explain the disease for every proband in the cohort. Following the success with Miller 
syndrome, Kabuki syndrome was the next genetic disorder that was tackled in an exome 
sequencing study of 10 patients. Because the diagnosis of Kabuki syndrome is not always clear, 
heterogeneity could not be ruled out. The 10 patients were ranked by certainty of the diagnosis, 
and the requirement for a variant to be shared by all probands was relaxed. Variants observed in 
public databases were also filtered out of the downstream analysis resulting in identification of 
MLL2 as the disease-causing gene (Ng et al. 2010a). The success of this study was aided 
ranking of the affected children in decreasing order of severity to identify a common disrupted 
gene in 7 of the 10 patients. Further analysis by Sanger sequencing confirmed a MLL2 loss-of-
function variant in 2 additional patients missed by exome sequencing. Still, even Sanger 
sequencing could not identify an obvious loss-of-function variant in the patient who was ranked 
fifth in the lineup of patients by certainty of diagnosis. Without prioritizing probands by their 
clinical features and relaxing constraints on the presence of variants in a single gene, MLL2 
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would not have passed the filtering criteria. This report outlines two important considerations for 
analyzing unexplored genetic disorders using exome sequencing technology. Targeted 
sequencing is susceptible to biased amplification, so stringent requirements on the presence of 
variants in the same gene across all affected individuals may yield negative results even for 
genetically homogenous diseases. The target region could lack coverage of high quality reads to 
adequately detect variants, like the two missed in Kabuki syndrome from exome analysis. Also, 
negative findings may be due to an inadequate understanding of disease-causing variants or the 
underlying genetics, and relaxing stringent assumptions on the genetic model can help identify 
disease genes and further our understanding of the disorder. 
With a better understanding of many unsolved genetic disorders, there are fewer 
unmapped genetic diseases that follow Mendelian inheritance, but even after the identification of 
the major gene, there may be other genes that contribute to the phenotype. The simplicity of a 
monogenic disorder is constantly challenged by new findings of other genes that produce the 
same phenotype. Moreover, the basis of variable expressivity and genetic underpinnings of 
complex disorders are actively being resolved into their precise genetic and environmental factors 
using newer technology and larger cohorts of individuals sharing the same phenotype. For 
instance, consortiums studying complex disorders such as autism spectrum disorder and 
congenital heart defects have recently sequenced hundreds of affected individuals as part of an 
effort to better understand complex diseases (Neale et al. 2012; O'Roak et al. 2012; Zaidi et al. 
2013). To the best of our knowledge, there are no reports in the literature of exome sequencing 
studies in cohorts of patients with liver disease.  
The exome sequencing studies of large cohorts with autism spectrum disorder and 
congenital heart defects used a trio study design for both cases and controls to measure the rate 
of de novo mutations (Neale et al. 2012; O'Roak et al. 2012; Zaidi et al. 2013). In all three cases, 
they were able to detect an increased rate of de novo mutations in their disease cohort. The study 
of congenital heart disease included several cardiac phenotypes. While many potential disease-
13 
causing variants were identified, there was no single gene that explained a significant proportion 
of the cases, but rather many different genes were identified with at most two cases in a given 
gene (Zaidi et al. 2013). Future investigation of these genes with de novo mutations, especially 
functional studies using animal models, may help identify more genes involved in the 
pathogenesis of complex diseases. 
Since the first genetic finding in 2010, exome sequencing has exponentially increased in 
popularity and become commonplace for studying genetic disorders (Bamshad et al. 2011). 
Reports of the identification of causal mutations for over a hundred genetic disorders have been 
published in just these few years, with many more projects and exome publications to look 
forward to in the future (Rabbani et al. 2012). 
1.2 The Hepatobiliary System 
1.2.1 Bile Duct Development 
The hepatobiliary system consists of the organs and ducts involved in the production and 
transportation of bile, an alkaline fluid secreted during digestion that is produced by hepatocytes 
in the liver and stored in the gall bladder. The intrahepatic biliary system is comprised of the liver 
and the intrahepatic bile ducts (IHBDs), while the extrahepatic biliary system is comprised of the 
gall bladder, cystic duct, common bile duct, and extrahepatic bile ducts (EHBDs). The IHBDs 
develop during the maturation of fetal liver, but the EHBDs share a closer lineage with the 
developing pancreas than with the liver or the primordial gall bladder (Spence et al. 2009).  
Intrahepatic Bile Duct Development 
 In a developing mammalian embryo, the ventral foregut endoderm gives rise to cells that 
constitute an integral part of many organ systems including the respiratory, hepatic, hepatobiliary, 
and digestive systems (Fukuda and Mizuno 1978; Le Douarin 1988; Rosenquist 1971; Serls et al. 
2005). The anterior part of the ventral foregut endoderm gives rise to the liver, biliary system, and 
ventral pancreas. In mouse embryos, expression of Hhex identifies the cells that form the hepatic 
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domain in the ventral foregut endoderm (Zong and Stanger 2011). Hepatoblasts occupy this 
domain, and they are bipotent progenitor cells that can give rise to hepatocytes, which constitute 
most of the liver parenchyma, and biliary epithelial cells (BECs), which line intrahepatic bile ducts 
(Zaret and Grompe 2008). As early as E8.5, the liver-specific proteins, albumin and !-fetoprotein, 
and transcription factors can be detected in the hepatic endoderm (Raynaud et al. 2011). 
 Prior to blood vessel formation, the inductive signals provided by the vasculogenic, 
endothelial cells and nascent vessels dictate thickening of hepatic endoderm forming the liver bud 
and invasion of the septum transversum mesenchyme (STM). Matsumoto et al. observed that 
Flk1 mutant embryos lacking these endothelial cells have arrested growth and formation of the 
liver prior to invading the STM (Matsumoto et al. 2001). After delamination in the foregut and the 
subsequent STM invasion, the hepatoblasts proliferate quickly to form the developing liver. At this 
time, these bipotential cells fix their cell fate to differentiate into hepatocytes or cholangiocytes. 
This decision is regulated by many signaling and transcription factors in the localized regions. A 
gradient of TGF" and Notch signaling is found most concentrated in the periportal region, with the 
lowest levels in the pericentral region of the liver lobule (Clotman et al. 2005; Raynaud et al. 2011; 
Zong et al. 2009). Combined with factors from the Wnt and fibroblast growth factor signaling 
pathways (Decaens et al. 2008; Yanai et al. 2008), the hepatoblasts in the periportal region give 
rise to the cholangiocytes that go on to organize into bile ducts, whereas the hepatoblasts in the 
pericentral region adopt a hepatocyte cell fate.  
 The differentiated biliary cells in the periportal mesenchyme form a ductal plate. These 
BECs go on to organize into biliary structures. Tubulogenesis and biliary duct maturation are 
controlled by key transcription factors such as Hnf1!, Hnf6, and Hhex. Lack of Notch signaling at 
this critical stage disrupts biliary morphogenesis (Lemaigre 2008), and this is a key feature of 
Alagille syndrome, a genetic disorder that causes intrahepatic bile duct paucity. The mature 
IHBDs associate with the portal vein and hepatic artery to constitute the portal triad. Bile is 
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secreted from the polarized hepatocyte cell through the bile canaliculi at its apical pole. Through 
the canals of Hering, the bile then flows into a connected network of IHBDs. 
Extrahepatic Bile Duct Development 
As bile flows out of the liver, it continues through the EHBDs and the cystic duct before it 
is finally stored in the gall bladder. During digestion, bile is secreted from the gall bladder and 
flows through the common bile ducts to make its way into the duodenum. This extrahepatic biliary 
system develops initially as the biliary primordium, which is the precursor of the EHBDs, common 
bile duct, cystic duct, and gall bladder. 
Unlike the intrahepatic biliary system that arises from hepatoblast precursors, the 
extrahepatic biliary system is differentiated directly from the endoderm. Spence et al. studied the 
biliary primordium during the maturation of the posterior ventral foregut as part of their 
investigation of Pdx1 and Sox17 expression in the embryonic development of mice. At E8.5, the 
ventral pancreas and the biliary primordium expressed Sox17 and Pdx1. Sox17+/Pdx1+ is a 
signature mark of the pancreatobiliary domain, and it separates the pancreatobiliary domain from 
the Sox17-/Pdx1- hepatic domain. At E10.5, continued Pdx1 expression marks the ventral 
pancreas, but Pdx1 is now absent in the biliary primordium. This traces the lineage of the biliary 
primordium to a Pdx1-expressing progenitor cell. Although intrahepatic and extrahepatic biliary 
systems connect together to form a continuous biliary network, this observation suggests that the 
extrahepatic biliary system has a distinct origin from the intrahepatic biliary system. 
In addition, studies of conditional knockouts in mice support the observation of a closely 
developing pancreas and biliary primordium that is separate from the developing liver bud. Sox17 
loss-of-function embryos at E10.5 do not form the biliary primordium and therefore do not go on 
to form the gall bladder and cystic duct. In addition, these mice also exhibit ectopic pancreatic 
tissue in the ducts (Spence et al. 2009). Hes1-deficient mice also have gall bladder agenesis and 
ectopic pancreatic tissue formation (Sumazaki et al. 2004). 
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Despite the differences in lineage, there are common genes central to biliary 
tubulogenesis of intrahepatic and extrahepatic bile ducts. Absence of any of the transcription 
factors Hnf1!, Hnf6, and Hhex leads to abnormal development of the intrahepatic and 
extrahepatic bile ducts (Clotman et al. 2002; Coffinier et al. 2002; Hunter et al. 2007). However, 
biliary disorders diagnosed in patients oftentimes only arise from either the IHBD or EHBD, and 
while disease progression can affect the entire biliary system, rarely are patients afflicted with 
both congenital intrahepatic and extrahepatic biliary defects. Thus, any distinctions in the 
development of the IHBD and EHBD may help us better understand the nature of the intrahepatic 
and extrahepatic biliary disorders. 
1.2.2 Genetic Disorders of the Bile Ducts: Alagille Syndrome (ALGS) 
Prevalence and Etiology 
ALGS is an autosomal dominant, multisystemic disorder that was historically diagnosed 
in children due to the common finding of intrahepatic ductular hypoplasia, in combination with 
abnormalities of other systems including the heart (Alagille et al. 1975). It is caused by mutations 
in one of two genes in the Notch signaling pathway, JAG1 and NOTCH2 (Li et al. 1997; McDaniell 
et al. 2006; Oda et al. 1997), with a worldwide incidence of approximately 1:70,000 (Kamath et al. 
2007). Upon investigation of JAG1 mutations and variable expressivity of the disease, the 
predicted frequency of a pathogenic mutation is closer to 1:30,000 (Kamath et al. 2003). Over 
90% of patients have a mutation in JAG1, one of five well-characterized Notch receptor ligands 
(which also include DLL1, DLL3, DLL4, and JAG2), and less than 5% of patients have a mutation 
in NOTCH2, one of the four human Notch receptors (NOTCH1-4). There is also a subset of 
patients with features similar to ALGS but no obvious mutation on JAG1 or NOTCH2. As 
expected from a defect in this critical developmental pathway, diagnostic features span multiple 
organ systems and include hepatic, cardiovascular, skeletal, and ocular defects as well as facial 
dysmorphism.  
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Many infants diagnosed with ALGS have liver disease characterized clinically by high 
conjugated hyperbilirubinemia and elevated #-glutamyl transferase levels, and liver disease 
severity can range from clinically insignificant biochemical findings to mild cholestasis and 
pruritus to progressive liver failure. These findings can be confused with those of biliary atresia, 
an extrahepatic biliary disorder, with overlapping biochemical, scintigraphic, and operative 
cholangiographic features, as well as metabolic disorders with elevated #-glutamyl transferase. 
The findings of intrahepatic bile duct hypoplasia on liver biopsy can distinguish ALGS from other 
causes of liver disease, although some patients with ALGS do not demonstrate bile duct paucity 
on biopsy (Kamath et al. 2007). 
Notch signaling is an important signaling pathway during liver development and it 
promotes the adoption of a cholangiocyte cell fate in maturing hepatoblasts. This is consistent 
with the findings of insufficient Jag1-Notch2 signaling in ALGS patients as many of them have bile 
duct paucity. The disease presentation includes features across several organ systems, but the 
penetrance and expressivity of this disorder are not uniform across patients or within organ 
systems (Shulman et al. 1984). 
Associated Symptoms 
Cardiovascular anomalies have been reported in approximately 90% of ALGS patients. 
The predominant defect is peripheral pulmonary stenosis, which usually presents as a heart 
murmur. More complex cardiac malformations including tetralogy of Fallot, ventricular septal 
defects, atrial septal defects, aortic stenosis, and coarctation of the aorta have also been reported 
in ALGS patients, and these severe forms of cardiac defects can lead to early mortality (Krantz et 
al. 1997). 
Most defects in the craniofacial, ocular, and musculoskeletal systems are innocuous, but 
they have proven to be important diagnostic indicators. A characteristic facies in children with 
ALGS includes a triangular appearance of the face as a result of the prominent forehead and a 
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pointed chin. In addition, deep-set eyes with moderate hypertelorism and a saddle or straight 
nose with a bulbous tip are also a frequent observation (Krantz et al. 1997). The facial 
characteristics are altered with age, and the protruding chin becomes the most striking feature in 
adults with ALGS. This common set of craniofacial anomalies found in patients who present with 
various ranges of disease severity suggests that facial bone formation may be very sensitive to 
JAG1 haploinsufficiency. Interestingly, ALGS patients with NOTCH2 mutations appear to exhibit 
different facial features, and only 20% of these children have the classic ALGS facies of a broad 
forehead, deep-set eyes, and a pointed chin (Kamath et al. 2012a). Anomalies in the 
musculoskeletal system are another common finding in many ALGS patients. Butterfly vertebrae 
or sagittal vertebral clefts are found in approximately 70% of the patients, and results from a 
vertebral body malformation in the early embryonic developmental period where the two lateral 
chondrification centers fail to fuse to form one vertebral body (Muller et al. 1986). This incidental 
finding is usually asymptomatic. Other skeletal findings in ALGS patients include spina bifida 
occulta, vertebral fusions (Shulman et al. 1984), and hemivertebrae (Greenwood et al. 1976). The 
incidence of fractures is notable in ALGS patients (Lykavieris et al. 2001), but it is unclear if these 
fractures arise from the underlying genetic mutation or are secondary to liver disease. 
Approximately 90% of ALGS patients have ophthalmological findings. The most common finding 
is posterior embryotoxon, a prominently visible Schwalbe’s ring delimiting the outer edge of the 
corneal endothelium present in 8-15% of the general population (Kamath et al. 2007). 
Approximately 13% of ALGS patients have Axenfeld anomaly, a prominent Schwalbe’s ring and 
peripheral iris strands that span the anterior chamber of the eye. Rieger anomaly, anterior 
segment dysgenesis marked by atrophy of the iris stroma, is another peripheral abnormality 
found in ALGS patients (Johnson 1990). Other ophthalmological findings include microcornea, 
keratoconus, congenital macular dystrophy, shallow anterior chambers, exotropia, ectopic pupil, 
band keratopathy, choroidal folds, and anomalous optic discs (Krantz et al. 1997). 
Structural, functional, and acquired renal disorders have been identified in approximately 
40% of ALGS patients (Kamath et al. 2012b). Ultrasound reports have identified patients with 
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small, solitary, or ectopic kidneys. Additionally, there are findings of unilateral or bilateral, 
dysplastic kidneys with or without the presence of renal cysts. The renovascular hypertension 
present in some patients is caused by renal artery stenosis. Functional defects including renal 
tubular acidosis, neonatal renal insufficiency (Emerick et al. 1999), and fatal juvenile 
nephronophthisis (Tolia et al. 1987) have also been reported in ALGS patients. Other defects in 
the renal system, or the urinary system, have been found in addition to the aforementioned renal 
abnormalities. They include ureteropelvic junction obstruction and duplex collecting system 
(Emerick et al. 1999). 
 Vascular anomalies are also a recurrent finding. Intracranial bleeding has been reported 
in dozens of ALGS cases, ranging from asymptomatic cerebral infarctions to fatal events 
(Emerick et al. 1999; Hoffenberg et al. 1995; Lykavieris et al. 2001). In a study by Lykavieris et al., 
38 of the 174 patients studied (22%) experienced bleeding episodes (Lykavieris et al. 2001). 
Some ALGS patients develop vascular abnormalities in the central nervous system such as 
Moyamoya disease (Connor et al. 2002). Emerick et al. detected cerebrovascular anomalies in 10 
of 26 patients (38%) screened using magnetic resonance imaging with angiography of the head 
(Emerick et al. 1999). Other minor and occasional features include jejunal atresia, temporal bone 
anomalies, chronic otitis media, hearing loss, diabetes, and pancreatic insufficiency (Emerick et al. 
1999; Quiros-Tejeira et al. 1999). 
 ALGS patients can suffer from severe nutritional deficiency due to malabsorption. Failure 
to thrive is a major concern for most infants diagnosed with this disease, as the majority of 
patients have severe growth failure and are in the bottom fifth percentile for weight and height in 
their respective age category (Rovner et al. 2002). Because of these nutritional deficits, some 
children will have delayed puberty and hypogonadism. Developmental delay is another feature of 
ALGS that presents in a small subset of patients. However, the high incidence of impaired 
cognitive function found in 9/30 patients in the initial report (Alagille et al. 1975) may be due to 
poor nutritional management and recognition of the disease (Krantz et al. 1997). 
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These diverse phenotypic features are hypothesized to derive from the underlying 
genetic defect in the Notch signaling pathway. With the exception of the central nervous system, 
it has been seen that in murine embryogenesis and fetogenesis, JAG1 is highly expressed is the 
systems which present abnormal findings in ALGS (Crosnier et al. 2000). In all organs involved, 
there is incomplete penetrance of the clinical phenotypes with varying levels of severity, and the 
severities of the affected systems appear to be independent. Because there are striking 
phenotypic differences in the degree of severity even within family members who share a similar 
environment and the same genetic mutation (Shulman et al. 1984), any genetic component 
responsible for this variability is likely to be independent of the JAG1 or NOTCH2 mutation. We 
predict there are genes that modify the clinical severity of ALGS. 
Animal Models 
A mouse model for ALGS was elusive for many years after the discovery of the 
pathogenic gene. Jag1 mouse knockouts are embryonic lethal and die due to vascular defects in 
the embryo and yolk sac. Conditional knockout mice with Jag1 removed at the hepatoblast stage 
developed BECs that properly organize into functional bile ducts (Loomes et al. 2007), and this 
suggested that signaling from hepatocytes and BECs are not responsible for ALGS-associated 
biliary defects. In contrast to ALGS patients, mice with heterozygous deletions of Jag1 were 
healthy, with no evidence for liver disease, and these mice only shared anterior chamber eye 
defects that were similar to posterior embryotoxon (Xue et al. 1999). It is likely that the 
redundancy of the Notch signaling pathway is different between humans and mice, which would 
explain why the phenotype could not be replicated in mice from the same mutations found in 
humans. Interestingly, the mouse mutant, Ozzy, isolated from an ENU-mutagenesis screen, 
carried a heterozygous missense mutation on Jag1 (p.Trp167Arg) and exhibits multi-systemic 
defects. Some of its phenotypic anomalies that overlapped with ALGS features were mild bile 
duct paucity, inner ear defects, and cardiac anomalies (Vrijens et al. 2006). 
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Given the limited success with developing a mouse model of ALGS by targeting Jag1, 
efforts turned to targeting Notch2, a receptor for Jag1. Homozygous mutations in Notch2 are 
lethal, and mice with two hypomorphic alleles, Notch2del1/del1, died perinatally from defects in 
glomerular development in the kidney. However, double heterozygous mice with Notch2del1/+ and 
Jag1dDSL/+, a deletion of the DSL domain that interacts with Notch receptors to activate Notch 
signaling, were able to successfully recapitulate the ALGS phenotype (McCright et al. 2001). 
These compound heterozygotes exhibited jaundice, poor growth, and bile duct hypoplasia 
(McCright et al. 2002) and also shared similar anterior chamber eye defects as their homozygous 
Notch2 mutant counterpart. The Jag1dDSL/+;Notch2del1/+ mice presented with kidney anomalies 
including defects in glomerulogenesis, but they were less severe than those presenting in 
Notch2del1/del1 mice. Cardiac defects were also prevalent, with most mice exhibiting either atrial 
and/or ventricular septal defects. Furthermore, the majority of the mice also had pulmonary artery 
stenosis. However, none of these mice had any craniofacial features or skeletal defects. Although 
the genetic defect is different than its human counterpart, this Jag1dDSL/+;Notch2del1/+ mouse 
model could successfully recapitulate most of the ALGS features. This finding lead to the search 
for NOTCH2 mutations in patients with ALGS without JAG1 mutations, and to date, more than 10 
patients with NOTCH2 mutations have been reported (Kamath et al. 2012a; McDaniell et al. 
2006). 
 More recently, a conditional knockout approach demonstrated that Jag1-induced Notch 
activation from the portal vein mesenchyme is essential to intrahepatic bile duct development 
(Hofmann et al. 2010). Interestingly, conditional knockouts of Jag1 in the endothelium did not give 
rise to any hepatic defects associated with ALGS. The Jag1lox/lox;SM22-Cre mice with a deletion 
of Jag1 in the vascular smooth muscle cells were jaundiced at birth with signs of developmental 
delay. These mice expressed Jag1 in the endothelium and had progressive loss of Jag1 in the 
perivascular mesenchyme at E14.5 during ductal plate morphogenesis. Examination of the liver 
histology revealed differentiated BECs that were unable to organize into functional bile ducts. 
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This model provides insight into the etiology of bile duct paucity in ALGS, pinpointing its cause to 
JAG1-activated Notch signaling from the portal vein mesenchyme. 
Genetic Modifiers  
Since ALGS is caused by haploinsufficiency in one of two central genes at the initial 
signaling step of the Notch pathway, genes that can compensate for this signaling defect or alter 
the downstream signal are potential genetic modifiers for the penetrance of various phenotypes 
as well as variable expressivity of disease severity. The HEY2 homolog in zebrafish, gridlock, 
was found to be mutated in a chemical screen, and this gene is required for development of the 
aorta and causes an arterial maturation defect (Zhong et al. 2000). This gene is a critical 
transcription factor induced by Notch signaling. The mouse knockout construct of Hey2 had fatal 
cardiac defects, and additional characterization of Hey2 deficiency in mice showed similarities 
with the zebrafish mutant of gridlock and suggested this zebrafish model was a result of a 
hypomorphic mutation (Gessler et al. 2002). Hey2 deficient mice exhibited ventricular septal 
defects, right ventricular hypertrophy, and pulmonic stenosis. Some of these mice also exhibited 
heart defects similar to tetralogy of Fallot, which is seen in patients with ALGS (Donovan et al. 
2002). Even mice with heterozygous deletions, Hey2lacZ/+, exhibited malformations of the heart 
similar to the ALGS phenotype, most commonly ventricular septal defects with overriding aorta. 
These findings suggest that a propagation of Notch signal inactivation downstream to HEY2 
inactivation may be the basis of the heart defects in ALGS patients. Accordingly, polymorphic 
variants of HEY2 or its interacting genes may contribute to the penetrance and varying severity of 
this phenotype.  
The phenotypic diversity in ALGS families suggests that the primary mutation, JAG1 or 
NOTCH2, is not the only factor contributing to disease presentation (Krantz et al. 1997). Because 
of the rare incidence of ALGS and the lack of a robust genetic model in animals, there are few 
opportunities to study the effects of the mutated and normal JAG1 alleles as well as the 
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association between different phenotypic presentations of the disorder. This is one of the 
unexplored aspects of this disease that will be addressed in the subsequent chapter. 
Understanding of the genes that modify the ALGS phenotype can be an important guide 
for clinicians treating this disorder. The 20-year life expectancy is 75% overall, but only about 
60% for patients requiring liver transplantation (Emerick et al. 1999). Approximately 50% of ALGS 
patients diagnosed with liver disease in their infancy require liver transplantation by 19 years of 
age (Hoffenberg et al. 1995). The identification of genetic modifiers of liver disease, which is the 
most clinically significant medical issue for many ALGS patients, is one of our primary fields of 
investigation, especially since this insight may improve the prognosis of liver disease progression 
and ensure close monitoring of children at high risk for end-stage liver disease. 
1.2.3 Genetic Disorders of the Bile Ducts: Biliary Atresia (BA) 
Pathogenesis and Etiology 
Biliary atresia (BA) is another rare, congenital biliary disorder that presents during the first 
months of life with a worldwide incidence of 1:12,000 newborns (Balistreri et al. 2007). While 
initially limited to the extrahepatic biliary tree, this progressive idiopathic disease ultimately 
destroys the extrahepatic bile duct lumen, obstructing the flow of bile and resulting in cholestasis 
and chronic liver damage. The excess of bile collecting in the liver may be responsible for bile 
duct proliferation, often found in wedge liver biopsies or liver histology slides at the time of 
surgical correction (a Roux-en-Y choledochojejunostomy, also known as a Kasai procedure). BA 
accounts for 40%-50% of all pediatric liver transplantations and is the most common indication for 
liver transplantation in children. Approximately half of all BA patients undergo transplantation by 2 
years of age, and 80% undergo transplantation by 20 years of age (Erlichman et al. 2009; Mack 
and Sokol 2005; Shneider et al. 2006). 
BA patients can be categorized into three categories: patients with non-syndromic, 
isolated BA with no major malformations, patients with at least one major malformation as defined 
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by the National Birth Defects Prevention Study but without laterality defects, and syndromic BA 
patients with laterality defects (Mack and Sokol 2005). Less than 10% of patients with BA have 
Biliary Atresia Splenic Malformation syndrome (BASM), the syndromic form of biliary atresia 
(Guttman et al. 2011; Schwarz et al. 2013). 
The etiology of BA is unknown, although it is proposed to be multifactorial with potential 
infectious, inflammatory, and genetic causes. Because BA has been reported as a secondary 
finding of some laterality disorders that are caused by genes critical in the establishment of body 
symmetry, the syndromic form of BA is likely to have a major genetic component. However, the 
pathogenesis of isolated BA remains elusive.  
An initial report by Shim et al. suggested an ethnic disparity in incidence rates (Shim et al. 
1974). There are several international efforts to study BA, and comparing across these studies 
demonstrated an increased prevalence among Asians. The reported incidence rates were 0.6, 
1.0, 1.7, 2.0, 3.0 per 10,000 live births for Caucasian, Japanese, Taiwanese, Filipinos in Hawaii, 
and Chinese in Hawaii populations, respectively (Muraji et al. 2009). While the underlying cause 
of this variation in incidence is unknown, ethnic disparities were further supported by data from 
both a cohort in England and Wales and one from metropolitan Atlanta (Livesey et al. 2009; Yoon 
et al. 1997). 
Danks et al. suggested time and geographic clustering of the disease based on their 
clinical experiences in Victoria, Australia (Danks et al. 1977). Between 1963 and 1974, this state 
averaged 5 cases of BA per year, but they observed two 18-24 month periods without an 
incidence as well as two 12-month periods with double the average incidence rate. For a rare 
disorder, they were surprised to find multiple incidences of BA in small towns within a few months 
time, ergo they suspected that exposure to an environmental agent, such as a viral outburst, 
could predispose the fetus to BA. Following this, two studies from the United States and England 
found a significant geographical clustering of reported cases, but these reports did not correct for 
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ethnic differences, which is a possible confounding factor (Livesey et al. 2009; Strickland and 
Shannon 1982). 
Because of the disease presentation and the human leukocyte antigen (HLA) biomarker 
similarities between BA and primary sclerosing cholangitis, an immune-mediated disease 
(Silveira et al. 1993), one hypothesis for the etiopathology of isolated BA predicts this occurrence 
to be an autoimmune response to a perinatal insult (Sokol et al. 2003). A comprehensive North 
American study found that a notable number of children with BA have a first-degree relative with 
some form of an autoimmune disease (44%), but there were no differences between the isolated 
and syndromic BA cases (Schwarz et al. 2013). The similar frequencies observed in isolated and 
syndromic BA may undermine the hypothesis of a unique, autoimmune etiopathology specific for 
isolated BA (Feldman and Mack 2012). 
Viral Associations 
Several pathogens have been implicated in BA susceptibility but with limited evidence 
and sometimes with negative results from independent replications. There are many reports of 
BA patients infected with cytomegalovirus, as well as 1-2 cases each of children infected with 
respiratory syncytial, Epstein-Barr, or human papillomavirus viruses (Chardot et al. 1999). 
Cytomegalovirus infections cause clinical features including liver disease and inflammation 
(Rosenthal 2007), and there have been several reported findings of this virus in children with BA 
(Fischler et al. 1998; Hart et al. 1991; Stern and Tucker 1965). The frequency of cytomegalovirus 
infections in BA patients appears to be very high, including a report finding 34% of BA patients 
infected, and although several groups implicate an association with BA (De Tommaso et al. 2005; 
Fischler et al. 1998; Hart et al. 1991), negative findings in one group suggest that this association 
may be weak or limited to certain geographic areas (Morecki et al. 1984). 
Positive findings from Reovirus 3 infections include a study in mice with biliary atresia-like 
cholangitis and a monkey with extrahepatic biliary atresia that were affected with this virus 
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(Chardot et al. 1999). A research group in New York has published several reports associating 
Reovirus 3 and BA (Morecki et al. 1982; Morecki et al. 1984), but mounting evidence from several 
groups suggests a small role of this virus in BA (Brown et al. 1988; Dussaix et al. 1984; 
Richardson et al. 1994; Saito et al. 2004; Steele et al. 1995). In addition, biliary defects in mice 
could not be replicated after infecting them with Reovirus 3 (Szavay et al. 2002). 
 Two initial reports of infants exposed to group C rotavirus led to the exploration of the 
pathogenic effects of this virus in mice (Riepenhoff-Talty et al. 1993), and findings indicated that 
rotavirus A could obstruct bile flow in the extraheaptic biliary tree, similar to the human phenotype 
of BA. This method was improved using the rhesus form of rotavirus A to infect newborn mice, 
which is now a standard technique used by many laboratories conducting BA research (Petersen 
et al. 1997a; Petersen et al. 1998). Interferon-! is a protein that stimulates innate immune 
responses against viral infections and from this murine model, it was further established that 
treatments with interferon-! before rotavirus infection could prevent the development of BA 
(Petersen et al. 1997b). Further investigation of these mice suggested that the immune system 
could play a role in the obliteration of bile duct and the formation of fibrotic tissue (Qiao et al. 
1999). Also, it has been shown that extrahepatic bile ducts could be obstructed by lymphocytes, 
and this process is regulated by interferon-# (Ifng), a gene found to be upregulated in these 
experimental BA mice (Shivakumar et al. 2004). 
There has been a report of mothers of patients with BA experiencing an increased 
number of miscarriages and stillbirths (Strickland and Shannon 1982). Spontaneous abortions 
and stillbirths can often be an indication of a fetus that is incompatible with life due to 
developmental problems. The most straightforward explanation for early termination of life is that 
the fetus carries lethal genetic abnormalities; 50-70% of miscarriages have an underlying genetic 
defect (Warren and Silver 2008). Endocrine disorders, immunological disorders, or uterine 
anatomic abnormalities in the mother as well as environmental conditions can also be the cause 
of miscarriages. Matovina et al. tested several pathogens and were unable to identify any 
27 
bacterial or viral infections that played a role in miscarriages (Matovina et al. 2004). The 
observation of miscarriages in BA families may suggest a genetic component to the disorder. 
Familial Recurrence 
Recurrence of BA in families is infrequent, possibly as a result of its genetic complexity 
as well as the low incidence rate. Even so, a few dozen familial cases of BA recurrence have 
been reported (Anneren et al. 1998; Gunasekaran et al. 1992; Kobayashi et al. 2008; Smith et al. 
1991). The largest nuclear case of familial recurrence of BA was in a family with three affected 
siblings, including a set of dizygotic twins. Additionally, their mother had two nieces with 
childhood cholestasis (Smith et al. 1991). BA can be a lethal disorder if it is not diagnosed early, 
and a corrective surgical procedure must be performed within the first few of months of life. The 
routine diagnosis and surgical procedure was only established in the 1970s, so there may be a 
disproportionately low number of parent-child transmissions reported given the actual genetic 
penetrance of the disease (Kasai et al. 1968). To date, there has only been one report of parental 
transmission of BA. After a successful hepatoportoenterostomy during her infancy, the affected 
mother gave birth to a daughter who also was diagnosed with BA (Kobayashi et al. 2008). There 
is also only one reported case of BA in half-siblings, where affected half-brothers shared the 
same biological father (Gunasekaran et al. 1992). Even though the father did not have BA, he 
had a duplicated gall bladder and cystic duct, a condition with an occurrence of 1:4,000 (Boyden 
1926). These documented familial cases suggest a genetic component to BA. 
In addition to the cases reported above, there are at least 32 reported cases of BA in 
twins, but only 2 sets of concordant twins have been described, a pair of dizygotic twins and a 
pair with unknown zygosity (Fallon et al. 2012; Hart et al. 1991; Hyams et al. 1985; Ikegami et al. 
2000; Khaimin 1969; Kobayashi et al. 2008; Moore and Hyman 1985; Morris et al. 1977; 
Poovorawan et al. 1996; Schweizer and Kerremans 1988; Silveira et al. 1991; Smith et al. 1991; 
Strickland et al. 1985; Werlin 1981). Of the discordant twin pairs remaining, 8 were monozygotic 
twins (zygosity in 4/8 pairs were experimentally confirmed) (Fallon et al. 2012; Hyams et al. 1985; 
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Ikegami et al. 2000; Moore and Hyman 1985; Poovorawan et al. 1996; Strickland et al. 1985), 
and 4 were confirmed to be dizygotic (Poovorawan et al. 1996; Strickland et al. 1985; Werlin 
1981). The remaining pairs of discordant twins had unknown zygosity, including 4 pairs with co-
twins that may have died too early to diagnose BA (Schweizer and Kerremans 1988). Based on 
the low concordance among reports of twins, there is likely to be a complex genetic component 
resulting in incomplete penetrance.  
Genetic Associations 
JAG1 is the major gene associated with ALGS that causes intrahepatic biliary atresia and 
interestingly, a different set of mutations on JAG1 have also been associated with extrahepatic 
biliary atresia. There were 9 missense mutations on JAG1 found in 109 cases of extrahepatic 
biliary atresia in 11 patients, including 2 familial cases (Kohsaka et al. 2002). While JAG1 
mutations in ALGS are hypothesized to act in a haploinsufficient manner, Kohsaka et al. 
demonstrated that these missense mutations could be responsible for overexpression of JAG1. 
The cohort was comprised of the severest form of biliary atresia, but none of these patients had 
any laterality issues. Unlike ALGS, only 8% of the tested BA cases are associated with mutations 
in JAG1. 
Two reports of genome-wide association studies implicate GPC1, XPNPEP1, and ADD3 
as disease genes. A study of 5 BA patients described two large, heterozygous deletion of 2q37.3 
encompassing GPC1 (Leyva-Vega et al. 2010). A larger investigation of this region in 61 BA 
patients and 5,088 healthy controls implicated a smaller CNV deletion region containing only 
GPC1, which conferred risk to BA (Cui et al. 2013). A SNP association study in a Chinese cohort 
of 324 patients with isolated BA and 471 healthy controls found an association at 10q25.1 (hg19). 
The most significant SNP, rs17095355 (p = 6.94x10-9), was upstream of two genes, XPNPEP1 
and ADD3 (Garcia-Barcelo et al. 2010). 
Case Reports of Syndromic BA 
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BA has been described as a secondary finding of several severe genetic disorders. There 
are two confirmed cases of biliary atresia with trisomy 18 (or E-Trisomy Syndrome, which refers 
to having 3 copies of one of the “E” group chromosomes: 16, 17 or 18) (Weichsel Jr and Luzzatti 
1965; Windmiller et al. 1965). A larger report found that 7 of 19 E-Trisomy Syndrome cases were 
affected with hepatitis, and 6 of 7 of these cases had hypoplasia of the extrahepatic biliary tract 
(Alpert et al. 1969). One patient with Mowat-Wilson syndrome had a mutation in the ZEB2 gene, 
and he presented with developmental delay, facial dysmorphism, and Hirschsprung disease as 
well as BA (Cui et al. 2011b). Another patient with a classic case of Long-chain 3-hydroxyl-CoA 
dehydrogenase (LCHAD1) deficiency had a compound heterozygous mutation of HADHB and 
also presented with BA (Matthews et al. 2002). The two case reports of BA in Mowat-Wilson 
syndrome and LCHAD1 deficiency are unusual, and it is unclear whether or not the underlying 
mutations for these disorders contributed to the pathogenesis of BA in these patients. 
 Defects in two genes known to cause laterality defects have been associated with a few 
incidences of BA. Heterotaxy is a genetically and phenotypically heterogeneous disorder. A 
secondary diagnosis of BA has been reported in heterotaxy patients with defects in CFC1 
(Jacquemin et al. 2002), associated with left-right laterality defects, and ZIC3, associated with X-
linked heterotaxy (Ware et al. 2004). Evidence of multiple genes causing this syndromic form of 
BA also suggests that BA is a genetically heterogeneous disorder. 
Genetic Animal Models 
Several other genes have been discovered to give rise to biliary defects, and they 
represent promising candidates for BA. Mice with homozygous mutations in Inversin (Invs) 
demonstrated intrahepatic bile duct proliferation, situs inversus, and jaundice, although the 
extrahepatic bile duct was intact (Shimadera et al. 2007). Because of the laterality defects and 
the biliary anomalies present in this mouse model, it has been suggested that the human 
homolog, INVS, may be a good disease gene candidate. Fast1 is a critical gene in the Nodal 
signaling pathway associated with laterality defects (Roessler et al. 2008), and the visceral and 
30 
diencephalic left-right symmetry and subsequent cardiac defects were recapitulated in mice and 
zebrafish (Long et al. 2003; Yamamoto et al. 2001). Moreover, the human homolog, FAST1, was 
significantly dysregulated in a microarray analysis of liver tissues from BA patients (Chen et al. 
2003). This gene is also a putative disease gene candidate for BA. 
Other genes potentially implicated in BA include HNF1B, which is known to cause 
diabetes syndrome and renal cysts, a common finding in BA patients. Mice with a liver-specific 
knockout of Hnf1! have bile duct paucity and bile duct dysplasia. Furthermore, HNF1B has been 
associated with ciliary anomalies in cholangiocytes, another finding in BA patients (Roelandt et al. 
2012). Additionally, FOXM1 is important for the proper development of intrahepatic bile ducts and 
blood vessels during liver morphogenesis. Interestingly, downregulation of FOXM1 leads to 
downregulation of HNF1B, but knockout constructs of Foxm1 in mice demonstrated intrahepatic 
bile duct paucity and normal extrahepatic bile duct development (Krupczak-Hollis et al. 2004). 
 Haploinsufficiency of Sox17 in mice causes defective perinatal development in the liver 
as well as the extrahepatic biliary system (Uemura et al. 2013). In Sox17+/- mice, insufficient 
Sox17 expression results in a hypoplastic gall bladder epithelia and BA. Additionally, loss-of-
function constructs in mice for crucial genes regulating gall bladder primordium specification that 
include the human homologs, FOXF1 (Kalinichenko et al. 2002), ONECUT1 (Clotman et al. 2002), 
HES1 (Sumazaki et al. 2004), HHEX (Hunter et al. 2007), and LGR4 (Yamashita et al. 2009), 
have also been reported with abnormal bile ducts morphogenesis and an absent gall bladder.  
 From microarray studies, it has been shown that DNA methylation was significantly 
reduced in bile ducts of BA patients compared to other infantile cholestatic disorders. Matthews et 
al. demonstrated that zebrafish treated with 5-azacytidine had inhibited DNA methylation, and 
genome-wide hypomethylation resulted in biliary defects and also elevated expression of 
inflammatory genes including INFG (Matthews et al. 2011).  
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 Loss of planar cell polarity was suspected to be a possible origin of BA, as this pathway 
has been shown to be important in tubule elongation in the kidneys and the formation of renal 
cysts. From zebrafish studies, morpholino antisense oligonucleotide-mediated knockdowns of 
genes including homologs of PRICKLE1, ANKRD6, and VANGL2 resulted in intrahepatic biliary 
defects and bile duct paucity (Cui et al. 2011a). The zebrafish model offers a rapid way to perform 
genetic screens as compared to the murine model. However, it is difficult to access the 
extrahepatic bile ducts of zebrafish, so the effects of these genes on extrahepatic biliary ducts are 
were not investigated. 
BA and Left-Right Asymmetry 
 The association between BA and specific developmental anomalies has long been 
evident. Most commonly, the associated defects are characterized by abnormalities in left-right 
(LR) asymmetry, defined as heterotaxy or situs ambiguus. In patients with heterotaxy, one or 
more chest or abdominal organs are localized inappropriately (e.g. children may present with 
splenic malformations or intestinal malrotation). Approximately 10% of BA patients have laterality 
defects (Schwarz et al. 2013). As previously mentioned, several patients have been identified 
with heterotaxy as their primary diagnosis and a secondary diagnosis of BA, with mutations in 
genes such as CFC1 and ZIC3 (Jacquemin et al. 2002; Ware et al. 2004). These genes, as well 
as a host of similar genes, have been well studied as mediators of LR axis determination during 
embryonic development. The etiology behind the co-occurrence of heterotaxy and BA has been 
obscure. If BA was a phenotype with incomplete penetrance in heterotaxy patients, then 
syndromic BA patients could be more similar to other heterotaxy patients than to isolated BA 
patients. However, it is still unclear if the BA findings in syndromic BA patients are genetically 
different than those in isolated BA patients. 
While clear connections between BA and heterotaxy and between ciliopathies and 
heterotaxy have been established, the connection between ciliopathies and BA is not well 
understood despite the overlapping features in these disorders. Cilia are important sensory 
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organelles in cholangiocytes (Singla and Reiter 2006). Interestingly, cholangiocytes appear to be 
the only ciliated cells in the liver; each cholangiocyte contains a single, primary (or non-motile) 
cilium that extends from the apical membrane into the ductal lumen (Huang et al. 2006). Within 
the bile ducts, the cilia probably work together to direct the flow of bile and detect changes in bile 
composition (Gradilone et al. 2007; Masyuk et al. 2008). In other cells, signaling pathways such 
as those involving Hedgehog, Wnt, and platelet-derived growth factor (PDGF) operate through 
cilia, but it is not clear whether these signaling pathways are necessary within the bile ducts.  
Abnormal findings in primary cilia as well as immotile cilia of epithelial cells of the bile 
ducts of patients with syndromic and non-syndromic forms of BA suggest that cilia could play a 
role in the pathogenesis of the disease (Chu et al. 2012). In a case of immotile cilia syndrome, the 
proband presented with polysplenia, abdominal situs inversus, and BA, and the outer dynein 
arms were absent from the epithelial cells (Teichberg et al. 1982). The familial recurrence of 
immobile cilia syndrome suggests a genetic component to their disorder, and the affected 
proband also presented with BA (Gershoni-Baruch et al. 1989). These findings suggest that the 
occurrence of BA may be a result of the underlying cilia abnormalities. 
Abnormalities in Nodal pathway genes are also associated with BA. The Nodal pathway 
plays an important role in the establishment of LR symmetry, primarily acting via cilia (Bisgrove 
and Yost 2006; Peeters and Devriendt 2006). Heterozygous mutations in CFC1, a critical co-
receptor for Nodal signaling, are associated with heterotaxy, and there are reports of 
heterozygous CFC1 gene mutations in BA patients with laterality defects (Jacquemin et al. 2002). 
Mutations in FOXH1, a downstream transcriptional co-activator of Nodal targets, have also been 
associated with heterotaxic cardiac malformations in patients (Roessler et al. 2008) as well as 
mice and zebrafish models (Long et al. 2003; Yamamoto et al. 2001). Furthermore, mice with 
targeted deletion of inversin have impaired nodal flow and a complete inversion of the LR body 
axis, visceral organ anomalies, and intrahepatic biliary proliferation (Morgan et al. 1998; 
Shimadera et al. 2007), recurring features in BA patients. The correlation between organ 
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malformations and BA suggests that the disorder could be caused by the dysregulation of genes 
involved in laterality. Nodal signaling relies on proper cilia function, and this dependence on cilia 
may transcend to the proper development of the biliary epithelia. 
Dysregulation of signaling pathways in BA 
 Disruption of critical signaling pathways in development has been shown to lead to 
abnormal biliary development in several animal model studies (Clotman et al. 2002; Cui et al. 
2011a; Shimadera et al. 2007). Although pathogenic mutations have been found in genes of the 
Nodal signaling pathway, other pathways such as Notch, Wnt, and Hedgehog signaling pathways 
have also been suggested to participate in the disease etiology.  
Notch signaling is a highly conserved pathway important in cell fate determination. The 
temporal activation and inhibition of Notch signaling during development is tightly regulated, and 
Notch signaling is critical in liver and bile duct development. JAG1 is an extremely conserved 
gene with very few polymorphisms in unaffected individuals, yet a handful of unique, missense 
mutations were observed in BA patients (Kohsaka et al. 2002). This suggests that the 
dysregulation of Notch signaling, a ubiquitously expressed cell signaling pathway, may be 
another underlying mechanistic cause of BA. 
The Wnt signaling pathway is comprised of a complex set of pathways that affect bile 
duct development and thus may have a role in BA. Canonical Wnt signaling, in which the 
presence of Wnt ligand at the cell surface prevents degradation of "-catenin, causes nuclear 
translocation of "-catenin and activation of target genes. Previous studies have indicated that one 
of the co-factors of "-catenin is SOX17 and together, they regulate Wnt signaling. SOX17 
activates genes that are required for normal endoderm formation (Sinner et al. 2004), and a 
recent described a SOX17 deficient model of BA in mice (Uemura et al. 2013). 
The planar cell polarity (PCP) pathway is part of the non-canonical Wnt signaling 
pathway, and it is hypothesized to be involved in BA. Inversin, a protein associated with 
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heterotaxy and BA, is known to act as a molecular switch for regulating the different Wnt signaling 
cascades (Simons et al. 2005). PCP generates polarity along the epithelial sheet, an essential 
property that establishes directional flow and proper formation of many ductal epithelia. Defects in 
the PCP pathway have been observed in polycystic kidney disease (PKD), a ciliopathy causing 
multiple cysts to develop in the kidneys. Intriguingly, PKD and other cystic kidney disorders have 
underlying ductal plate malformations, and renal cysts are a ductal abnormality recurrently 
observed with bile duct disorders including BA. Cui et al. hypothesized that like PKD, the proper 
establishment of PCP could also be important in BA (Cui et al. 2011a). They observed that 
zebrafish with morpholino antisense oligonucleotide-mediated knockdowns in homologs of 
PRICKLE1, ANKRD6, and VANGL2, genes central to the PCP pathway, caused developmental 
biliary abnormalities. PRICKLE1 caused the most severe phenotype including localization defects 
of the liver and other digestive organs. Although PKD and BA primarily affect different organ 
systems, liver and renal cysts appear in both disorders. Similarities between the two diseases 
suggest a common path to their pathogenesis. 
The establishment of PCP has also been associated with the proper function of signaling 
cilia as well as polarized ciliary beating. In a study by Chu et al., they observed that there were 
fewer cholangiocyte cilia in BA specimens and they were shorter with an abnormal orientation 
compared to normal and disease control specimens (Chu et al. 2012). Developmental studies 
have demonstrated that PCP has been associated with defects in ciliogenesis (Kim et al. 2010; 
Park et al. 2006). There seems to be interdependence between cilia and PCP signaling, although 
how they influence one another is not well understood (Wallingford and Mitchell 2011). However, 
observations of ciliary and PCP defects in BA indicate that both pathways may play an important 
role in the disease pathogenesis.  
The excessive Hedgehog (Hh) activation observed in BA patients has been implicated as 
an impediment to ductular morphogenesis as well as a contributing factor of fibrosis (Omenetti et 
al. 2011). This pathway is highly dependent on the proper establishment of PCP for proper 
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signaling (Heydeck et al. 2009). Hh signaling occurs on the ciliary surface of the cell, and other 
receptors on this surface may play a role in signal regulation. Glypicans also play an important 
role in the regulation of Hh signaling, although they also regulate other signaling pathways such 
as Wnt through stabilizing the interaction between the Wnt ligands and the Frizzled receptors. 
This protein family is named sequentially from GPC1 to GPC6, and they are expressed alongside 
the Patched receptor proteins on the ciliary surface. GPC3 null mice display increased Hh activity. 
GPC3 competitively binds Hedgehog, preventing it to bind to Patched and initiate the signaling 
cascade (Capurro et al. 2008). A hypothesis-free CNV association study of BA patients and 
healthy controls also found that BA patients were enriched for a deletion CNV containing the 
entire GPC1 gene (Leyva-Vega et al. 2010). A knockdown experiment of glypican-1 in zebrafish 
demonstrated that decreased expression of this gene causes biliary defects and increases 
hedgehog activity. The biliary defects could be rescued by inhibiting Hh signaling (Cui et al. 2013). 
Interestingly, a genome-wide association study of primary sclerosing cholangitis (PSC), another 
cholangiopathy presenting with inflammation and bile duct obstruction, implicates GPC6 as a 
likely disease gene (Karlsen et al. 2010). The examples of two bile duct disorders linked by 
defects in glypicans support the importance of Hh signaling in healthy development and 
maintenance of the biliary epithelia. In addition, Sonic Hedgehog plays a role in the regulation of 
ZIC proteins, a protein family important to proper body pattern formation (Nagai et al. 1997). 
Interestingly, mutations in ZIC3 are known to cause heterotaxy, situs abnormalites, and cardiac 
malformations, and there are also BA findings in some of these patients (Ware et al. 2004). 
 We hypothesize that BA is likely a disease with multiple disease etiologies, where some 
patients may have a strong genetic contribution while others may carry risk factors that interact 
with environmental factors to cause disease. The genetics of this disorder is poorly understood, 
and this is likely due to the genetic and phenotypic heterogeneity of the disease. In the 
forthecoming chapters, we used many approaches including familial studies, SNP marker 
association tests, and next generation sequencing to identify relevant genes and better 
characterize the genetic underpinnings of this disorder. 
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1.2.4 Other Genetic Disorders of the Bile Ducts 
 Cholangiopathies can arise from a diverse variety of etiopathologies ranging from a 
known underlying genetic defect of a multisystemic disorder such as Alagille syndrome or 
syndromic BA to an acquired disease such as bacterial, parasitic, or fungal cholangitis. Although 
the diagnostic criteria and hepatic manifestations may be different among these diseases, 
cholangiopathies oftentimes result in ductopenia. Furthermore, progression of these disorders 
can cause a chronic inflammatory response (Lazaridis et al. 2004).  
CFTR, a cAMP-activated Cl- channel, is a well-known gene that causes an autosomal 
recessive pulmonary disease called cystic fibrosis, but it has also been associated with biliary 
defects. The expression of CFTR in the liver is specific to cholangiocytes. Furthermore, patients 
with cystic fibrosis and liver disease are observed to have reduced cAMP-stimulated Cl- effect 
that impair HCO3- secretion and damage the cholangiocytes transporting toxic bile out of the liver 
(Zsembery et al. 2002). 
Fibropolycystic liver diseases are another set of genetic disorders characterized by 
defects in the bile duct. Examples include autosomal dominant polycystic kidney disease 
(ADPKD), autosomal recessive polycystic kidney disease (ARPKD), and autosomal dominant 
polycystic liver disease (ADPLD), Caroli’s syndrome, and congenital hepatic fibrosis (Lazaridis et 
al. 2004). Many of these disorders, including ADPKD, ARPKD, and ADPLD, have underlying 
ductal plate malformations due to necroinflammatory destruction of intrahepatic bile ducts. 
However, these diseases are due to different genetic defects. ADPKD is caused by mutations in 
PKD1 and PKD2, genes that code for polycystin-1 and polycystin-2, respectively, while its 
recessive counterpart, ARPKD, is caused by PKHD1, a gene encoding fibrocystin. Although both 
PKD1 and PKD2 are expressed on the cell surface, they have major differences; polycystin-1 
(PKD1) is a glycoprotein that participates in cell-cell and cell-matrix communications, while 
polycystin-2 (PKD2) forms a cation channel. Even so, both PKD1 and PKD2 localize to the 
primary cilia, and they can act as fluid-sensors and mediate mechanosensation in the primary 
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cilium (Nauli et al. 2003). Another disorder called ADPLD has been linked to PRKCSH, which 
encodes hepatocystin, a protein that helps to process and translocate other proteins in the 
endoplasmic reticulum. Both non-syndromic and syndromic forms, Caroli’s disease and Caroli 
syndrome with additional findings of congenital hepatic fibrosis and hypertension, cause the 
dilatation of intrahepatic bile ducts. Although the genetic component is still obscure, Caroli’s 
disease is a recurrent finding in ARPKD and ADPKD (Torra et al. 1997). Furthermore, genetic 
analysis of a patient with Caroli’s disease detected a heterozygous mutation in PKHD1, a gene 
associated with ARPKD (Sgro et al. 2004). Congenital hepatic fibrosis is another disorder that 
often occurs in families with other cholangiopathies such as ADPKD (Cobben et al. 1990) and 
ARPKD (Kaplan et al. 1988), and it has also be associated with other genetic diseases (Olbrich et 
al. 2003). It hypothesized that hepatic fibrosis is a phenotype altered by variable expressivity, 
although the pathogenesis is still unclear.  
Although most forms of familial cholestasis are not considered cholangiopathies, 
multidrug resistance-3 deficiency can cause many issues in the liver including neonatal 
cholestasis, gall bladder lithiasis, and biliary cirrhosis. Defects in the MDR3 gene impair 
cholangiocytes so they no longer absorb and recirculate bile acids through specific bile acid 
transporters efficiently. Deficiency of the MDR3 protein causes toxic bile acid buildup in the liver, 
and cholangiocytes processing bile and directing bile flow are the most sensitive to this toxicity. 
Multidrug resistance-3 deficiency is estimated to be a contributing factor to progressive familial 
intrahepatic cholestasis type 3 with one-third of patients presenting with homozygous or 
heterozygous mutations in MDR3 (Jacquemin et al. 2001). 
 Genetic susceptibility factors have also been identified for immune-mediated 
cholangiopathies such as primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). 
PBC is an immune-mediated obliteration of the intrahepatic bile ducts that causes chronic 
cholangitis, liver fibrosis, and ultimately requires liver transplantation of the cirrhotic liver. PSC is 
also a chronic cholestatic liver disease characterized by fibrotic tissue formation around the 
38 
intrahepatic and extrahepatic ducts impairing bile flow, and it is frequently associated with 
inflammatory bowel disease, especially ulcerative colitis (7.5%). Although both diseases can lead 
to cirrhosis and end-stage liver disease, they have some differences. For one, PBC is 
predominantly found in females (1:9 male to female ratio) (Liermann Garcia et al. 2001) while 
PSC occurs more frequently in males (2:1) (Worthington and Chapman 2006). Also, the 
pathogenesis of PBC arises from bile duct obstruction necroinflammation affecting only the 
intrahepatic biliary system, whereas PSC is an obstruction of bile flow in both the intrahepatic and 
extrahepatic biliary systems. 
 Three GWA studies have been conducted in populations of European ancestry 
(Hirschfield et al. 2009; Liu et al. 2010; Mells et al. 2011) and a fourth in a Japanese population to 
search for genetic susceptibility loci to PBC (Nakamura et al. 2012). A locus on 17q12 containing 
IKZF3 replicated in all four studies. Four additional loci containing IL12RB2 (1p31.3), IL12A 
(3q25.3), IRF5 (7q32), and the major histocompatibility complex (6p21.3) were significant in the 
three GWA studies in populations of European descent. In addition, there were 15 other loci that 
reached genome-level significance that did not replicated in a separate study. 
 Although PBC and PSC are both immune-mediate cholangiopathies, a GWA study in 
PSC did not uncover any overlapping loci with those found in the four GWA studies of PBC. This 
initial study in 615 European cases and 2,962 controls revealed risk loci for PSC at 2q13 and 
3p21.3. The most significant SNP lies in the intron of a putative coding transcript in 2q13. 
However, the SNP signal in 3p21.3, rs3198999, is a missense mutation (p.Arg703Cys) affecting 
macrophage stimulating 1 or MST1. This gene is highly expressed in the gall bladder epithelium 
and it also confers risk to ulcerative colitis and Crohn’s disease, inflammatory bowel diseases that 
can present in PSC patients (Goyette et al. 2008). 
 Cholangiocarcinoma is also a characterized cholangiopathy, and its risk factors include 
both genetic and acquired pre-existing conditions such as primary sclerosing cholangitis and viral 
hepatitis. In PSC, 8-30% of patients will develop bile duct cancer (Shaib and El-Serag 2004). It is 
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unclear if genetic risk factors exist for cholangiocarcinoma or if it is just a secondary manifestation 
of persistent insults to the bile duct. A candidate gene study of cholestastic genes found a 
significant association of p.Val444Ala in ATP8B1 with cholangiocarcinoma, but this gene is also 
associated with progressive familial intrahepatic cholestasis (Wadsworth et al. 2011). 
1.3 Organization of Dissertation 
The remaining chapters of this dissertation are organized as follows. Chapters 2 and 3 
will address variable expressivity in ALGS. Chapters 4-6 will investigate genetic susceptibility to 
BA. ALGS is a well-characterized genetic disorder that affects multiple organ systems. The 
identification of JAG1 as the primary disease-causing gene revealed that 40% of pathogenic 
mutations in diagnosed probands are inherited (Krantz et al. 1997). Although this disease was 
initially diagnosed based on findings of intrahepatic ductopenia and liver disease in patients that 
exhibit other systemic features (Alagille et al. 1975), clinical features are known to be highly 
variable (Crosnier et al. 2000). The characterization of the ALGS cohort based on their observed 
phenotype and genotype on JAG1 is presented in Chapter 2. The first investigation is for a 
correlation between phenotypic features and the JAG1 mutation (mutation type and transmission). 
The next set of analysis tests correlations between selected phenotypes as well as genotype-
phenotype. In addition, the downstream effects of JAG1 haploinsufficiency are analyzed by gene 
expression analysis of a separated cell populations containing a mosaic deletion of JAG1 in 
fibroblast, induced pluripotent stem cell, and endoderm lines. The progression of liver disease in 
ALGS patients is carefully followed, but some patients still develop severe liver disease and 
require transplantation, while others may have limited or no liver involvement. Chapter 3 explores 
genetic modifiers for the liver phenotype through sib-pair analysis as well as SNP and CNV GWA 
studies. 
A multipronged approach is used to find genetic susceptibility to BA. In Chapter 4, a 
replication study of an association signal localized on chromosome region 10q25.1 is performed 
that included fine-mapping of the region in a cohort with European ancestry. Apart from the 
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10q25.1 association signal, there are have been no other replicable genetic loci identified for 
isolated BA. Chapter 5 investigates 30 exomes of patients with isolated BA, and it aims to directly 
identify disease genes. The exomes are analyzed by first searching for altered genes shared 
across multiple probands. Next, the rare, likely gene-damaging alterations are inspected in 
candidate genes known to cause syndromic BA or biliary abnormalities in model organisms. BA 
patients have been known to have defects in the primary cilia in BECs that line the intrahepatic 
bile ducts (Chu et al. 2012). Furthermore, disruption of planar cell polarity, an important pathway 
that takes place on the cilia, is known to cause biliary abnormalities (Cui et al. 2011a). Thus, a 
pathway-based analysis is performed on genes in the ciliome and that function within the planar 
cell polarity pathway to look for pathogenic alterations. Chapter 6 describes the investigation of 
two familial cases. Family #1 includes a pair of dizygotic twins with isolated BA. In Family #2, the 
proband presented with BA, but both the father and the proband have laterality defects, a 
phenotype regularly associated with BA. The genetic underpinnings of BA in these families were 
investigated using SNP array and next-generation sequencing technologies. 
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CHAPTER 2: ALGS Phenotype and Investigation of its Modifiers 
2.1 Introduction 
In this chapter, we present our work categorizing ALGS patients by their gender, JAG1 
mutation type, mode of mutation inheritance, and clinical features and then looking for 
associations between these categories. The aim of this study was to establish correlations with 
disease phenotypes, so these correlations can be used to aid clinicians in predicting the clinical 
course of the disease and to help patients understand their prognosis. In addition, we will also 
discuss a microarray study we performed as a complementary approach to understanding the 
phenotypic variability in ALGS. To find genes that might be modifiers of the ALGS phenotype, we 
sought to identify genes that act downstream of Jagged-Notch signaling in three different cell 
types, fibroblast cells, induced pluripotent stem cells (iPSCs), and endoderm cells, in populations 
with 1-copy versus 2-copies of JAG1 by observing signature gene expression differences that 
arise from JAG1 haploinsufficiency. 
Like many other autosomal dominant disorders, ALGS demonstrates both incomplete 
penetrance and variable expressivity of the clinical features for each organ system. For example, 
95% of patients have liver manifestations, 94% have cardiovascular manifestations, 40% have 
renal manifestations, and 61% have skeletal anomalies (Kamath et al. 2007). The clinical severity 
of liver and cardiac features can range from insignificant (e.g. mild elevation of liver enzymes or a 
benign cardiac murmur) to life-threatening. If a correlation between the selected systemic defects 
can be established, clinicians may be able to use specific clinical features to help them predict the 
clinical course of other features. 
For decades, it has been known that in some disorders, phenotypic variability can be 
associated with specific disease alleles (McKusick 1973). For example, studies of severe bile salt 
export pump deficiency in families with progressive familial intrahepatic cholestasis found that 
although missense mutations are the most common defect, and patients with protein-truncating 
mutations are at greater risk to develop severe liver disease (Strautnieks et al. 2008). More 
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strikingly, the mutant alleles of the ABCA4 gene responsible for autosomal recessive Stargardt 
disease and other retinopathy has been shown to behave in an allelic series, where the type of 
mutation is associated with the severity of disease (Lewis et al. 1999; Sun et al. 2000). While no 
genotype to phenotype correlation has been demonstrated for JAG1 mutations in ALGS patients, 
there have been reports of isolated cardiovascular anomalies occurring in patients carrying 
specific missense mutations (Bauer et al. 2010; Eldadah et al. 2001; Krantz et al. 1999; Le 
Caignec et al. 2002). 
Modifying effects can also arise from polymorphisms in cis or trans with the disease allele, 
and these polymorphisms can have a regulatory effect on the disease gene expression. For 
example, a polymorphism within an intron of the CFTR gene, the IVS8-5T allele, is a cis-acting 
modifying allele that increases the severity of lung disease in cystic fibrosis patients when found 
together with a p.Arg117His missense mutation (Cuppens et al. 1998; Niksic et al. 1999; Noone 
et al. 2000). In another example, the disease gene PRNP is known to cause autosomal dominant 
familial Creutzfeldt Jakob disease, and families with this disorder also have recurrence of fatal 
familial insomnia. It has been shown that a second mutation on the trans allele of the PRNP gene 
can modify the phenotype and cause fatal familial insomnia (Goldfarb et al. 1992). 
JAG1 mutations in ALGS have been shown to result in one defective allele, either by 
deletion of one copy or production of a truncated or a protein product that does not appear on the 
cell surface where it is normally expressed (Boyer-Di Ponio et al. 2007; Morrissette et al. 2001). 
Therefore, the dosage of this signaling ligand is critical. The modifying effect of cis and trans 
polymorphisms in JAG1 on the severity of ALGS phenotypes has not been previously studied. It 
is unlikely that cis-modifying alleles play a significant role in the severity of ALGS, because more 
than 40% of JAG1 mutations found in clinically affected children are inherited from relatively 
healthy parents who only underwent genetic analysis because they had an affected child 
(Crosnier et al. 2000; Krantz et al. 1997). Variable expressivity of phenotypic features seems to 
be as prevalent within families as it is between families, so the mutated allele is unlikely to be a 
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strong modifying factor (Shulman et al. 1984). In congruency with the concept of allelic series, a 
strong normal allele could mitigate the effects of carrying a defective copy of JAG1. Therefore, we 
hypothesized that there may be an effect of allelic dosage due to trans-modifying alleles, or 
effects from the normal JAG1 allele, which are investigated in this study. There are several 
polymorphisms within the coding sequence of JAG1 including rs35761929 (exon 22), rs1051419 
(exon 26), and rs1051421 (exon 26) that are present in the normal population in substantial 
frequencies (>5%). We tested whether these variants of the normal allele could modify the 
expression of the JAG1 mutation by means of an association study. 
JAG1 is a cell surface ligand that can regulate Notch signaling, a central developmental 
pathway. We hypothesized that comparison of differentially expressed genes via microarray 
analysis, of cells with only a single copy of JAG1 compared to cells with two functional copies, 
might shed light on key downstream targets of Notch signaling. These differentially expressed 
genes may be modifying genes that alter the phenotype arising from deficient Notch signaling. 
Since a heterozygous knockout of JAG1 in mice does not recapitulate many of the ALGS features, 
we used human cell lines with naturally occurring JAG1 mutations as an alterative. This imposes 
a severe limitation on the tissue types we can study, because most of the structural defects occur 
during development and samples from most of the systems affected (e.g. liver, heart, kidney, eye, 
and bone tissue) are impossible to obtain from our subjects.  
In order to examine a cell type that is closer to the tissues involved in ALGS, we initiated 
studies on iPSCs derived from patient cell lines. The establishment and utilization of iPSCs to 
model human disease was first described in 2007 (Takahashi et al. 2007), and disease-specific 
iPSCs has proven to be a powerful model for many genetic disorders (Tiscornia et al. 2011). 
Using this construct, we can study a cell type during early development, when the disease 
phenotype of ALGS first arises. Although robust protocols to derive mature hepatocytes and 
cholangiocytes have yet to be established, differentiating iPSCs into definitive endoderm has 
been fairly successful (Cheng et al. 2012; D'Amour et al. 2005; Touboul et al. 2010). Because 
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endoderm gives rise to hepatoblasts, the progenitor cells of hepatocytes and cholangiocytes, this 
germ layer is a promising cell type to study as it may potentially capture the gene expression 
signatures associated with liver defects in ALGS patients. Thus, the three cell types we 
investigated were fibroblasts established from the skin biopsy, iPSCs, and definitive endoderm.  
When performing microarray analysis, it is important to ensure that the patients used in 
the sample comparison are well-matched for as many characteristics as possible, including 
gender, age, and ethnicity. In our routine screen of parents that have children with ALGS, we 
were able to identify an unaffected mother who was mosaic for a full gene deletion of JAG1, 
confirmed by fluorescence in situ hybridization (Laufer-Cahana et al. 2002). In this subject, the 
cell population without the JAG1 deletion served as a unique normal control for the cell population 
that had a JAG1 deletion, and using the normal population as a matched control for the 
hemizygous JAG1 population would minimize a lot of the expression differences that may arise 
from differences in the genetic background. 
The mosaic subject presented a rare opportunity to establish isogenic cell lines with and 
without a JAG1 deletion. Fibroblasts, iPSCs, and endoderm-derived cells were successfully 
established from both cell populations. For these early experiments, we analyzed the gene 
expression signatures in a homogeneous cell population containing either one or two copies of 
JAG1. We recognized that for this experiment, we are not separately analyzing JAG1-signaling 
and receiving cells. Nevertheless, since both JAG1 and NOTCH2 receptors are expressed in 
these cells, it is relevant to analyze changes in gene expression with JAG1 dosage. Follow-up 
experiments beyond the scope of this thesis will analyze gene expression in NOTCH2 containing 
cells, after exposure to cells with one or two copies of JAG1. In this thesis, we looked for 
significant gene expression differences these matched lines in fibroblast, iPSCs, and endoderm. 
We concentrated on both an analysis of the genes involved in the Notch signaling pathway and 
an analysis of genes involved in liver development to identify candidate genetic modifiers. We 
also performed a pathway enrichment analysis to understand the types of genes that were 
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differentially expressed between the two cell populations. By using these approaches, we hope to 
better understand the genetic defects caused by JAG1 haploinsufficiency and identify candidate 
genes that may have modifying effects on the disease phenotype. 
2.2 Results 
2.2.1 Phenotypic Correlations with Characteristics of ALGS Patients 
The phenotype and genotype information of the entire cohort of patients with JAG1 
mutations is tabulated in Table 2-1, which describes the binary classifications of each 
characteristic interrogated in the subsequent analysis. The available information on each patient 
for each organ system was variable, so each pairwise test was carried out used a different subset 
of the patient cohort. Using the 448 patients with relevant clinical information, the first set of 
statistical analyses investigated any association between the observed phenotypes and gender, 
transmission, or type of JAG1 mutation (Table 2-2). After correcting for multiple testing, neither 
gender, inheritance, nor mutation type was associated with the clinical phenotypes tested. 
2.2.2 Phenotype-Phenotype Correlations 
Liver disease severity and butterfly vertebrae were both significantly associated with 
cardiac anomalies, while the other observed phenotypes did not appear to correlate with one 
another (Table 2-3). The strongest association was between liver disease severity and cardiac 
abnormalities (p = 0.0006). The correlation between these two systems ($ = 0.37) is higher than 
that of any other pairs of observed phenotypes, and patients without cardiac anomalies tend to 
have mild liver disease. The other significant association was between butterfly vertebrae and 
cardiovascular anomalies (p = 0.0024), and these two phenotypes were also modestly correlated 
to each other ($ = 0.27). 
2.2.3 Investigation of the Normal JAG1 Allele for Modifying Effects 
The genotypes of the 3 SNPs on the normal JAG1 allele were individually tested against 
the phenotypic categories for modifying effects in the subset of 210 patients of European descent 
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(Table 2-4). After multiple testing correction, none of the pairwise tests for genotype-phenotype 
association were significant. The SNPs residing on the normal JAG1 allele did not appear to 
modify the five phenotypes that were tested. 
2.3.4 Downstream Effects of JAG1 Haploinsufficiency 
Microarray analysis was performed to investigate gene expression differences between 
isogenic fibroblast, iPSCs, and endoderm lines with and without a JAG1 mutation. The primary 
motivation was to observe gene expression changes that could be a direct result of JAG1 
haploinsufficiency and identify candidate genes relevant to the ALGS phenotype that have altered 
expression. The JAG1 deleted and non-deleted cell line populations were separated via dilution 
cloning from a mosaic fibroblast sample to establish pure fibroblast lines. In addition, the mosaic 
fibroblast sample was also used to established iPSCs, which were re-differentiated into endoderm 
tissue. The differences in JAG1 expression between the non-deleted and the deleted lines are 
nominally significant (p < 0.05) with fold changes of 0.78, 0.53, 0.56 in fibroblast, iPSCs, and 
endoderm, respectively, but none of them were significant after carrying out the requisite multiple 
testing correction (FDR > 0.05). Nevertheless, we believe that the findings of decreased JAG1 
expression in the deleted lines are a positive control for our experimental model. 
In these studies, we analyzed gene expression in homogeneous populations of cells with 
one or two copies of JAG1. The 7 genes in fibroblast, 27 in iPSCs, and 35 in endoderm that were 
significant after multiple testing correction (FDR % 0.05) are listed in Appendix Table A1. 
Intriguingly, all the significant genes in fibroblast were downregulated in the deleted line, half in 
iPSCs were downregulated, and none in the endoderm were downregulated. None of these 
genes overlapped with the Notch signaling pathway gene list or the liver development gene list, 
but protocadherin gamma subfamily A 3 (PCDHGA3), chromosome 18 open reading frame 2 
(C18orf2), and protein kinase inhibitor beta (PKIB) were upregulated in both iPSCs and 
endoderm. Also, it is interesting that endothelin 1 (EDN1) is upregulated in the deleted line of 
47 
endoderm tissue (FDR = 0.3), as studies have shown it to be an inhibitor of JAG1 in the ventral 
domain during early embryogenesis (Zuniga et al. 2010). 
In the pathway enrichment analysis of the top 250 upregulated genes and top 250 
downregulated genes in the deleted cell line, there were no pathways that were significantly 
enriched (FDR < 0.05) in the fibroblast line. However, we observed 7 pathways described in 
Table 2-5 that were significantly enriched for genes upregulated in iPSCs of the deleted line, 3 
pathways with genes upregulated in endoderm of the deleted line, and one pathway with genes 
downregulated in endoderm of the deleted line. The two cellular component ontologies, 
nucleosome (GO:0000786) and protein-DNA complex (GO:0000786), were upregulated in both 
iPSCs and endoderm. Additional biological processes involved in DNA packaging and 
macromolecular complex subunit organization enriched in iPSCs included nucleosome assembly 
(GO:0006334), chromatin assembly (GO:0031497), DNA packaging (GO:0006323), protein-DNA 
complex assembly (GO:0065004), and nucleosome organization (GO:0034728). The genes 
upregulated in the deleted endoderm line were enriched for DNA binding (GO:0003677), a 
molecular function ontology while the genes downregulated in the deleted endoderm line were 
enriched for the extracellular region (GO:0005576) of the cellular component ontology. 
A heat map of the Notch pathway genes with significantly different expression between 
the deleted and non-deleted lines is illustrated in Figure 2-1. The only significantly dysregulated 
gene in the deleted fibroblast line was contactin 1 (CNTN1) with p = 0.0009. CNTN1 is a non-
archetypal Notch ligand that was overexpressed in the deleted line. This gene was also 
prominently upregulated in endoderm tissue and mildly upregulated in iPSCs. In the deleted iPSC 
samples, there were 3 upregulated and 2 downregulated genes that had significant differential 
expression, but the most pronounced was decreased expression of JAG1 (p = 0.001). In the 
endoderm tissue, there were 5 upregulated and 12 downregulated genes including JAG1 and 
HEY2 seen in iPSCs that were differentially expressed. HEY2, a downstream target of the Notch 
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genes, was the most differentially expressed, with a 2.2 times more expression in the non-deleted 
line (p = 0.003), and interestingly, this is the opposite direction as what was observed in iPSCs. 
 Of the liver development genes, there were 8 upregulated and 9 downregulated genes 
that were nominally significant (Figure 2-2). In this gene list, HEY2 is still the gene with the 
greatest expression difference between the deleted and non-deleted lines. Likewise, the gene 
with the smallest FDR (0.09) is hematopoietically expressed homeobox or HHEX (p = 0.03), and 
it was upregulated in the deleted line. In the downregulated genes, targeted homozygous 
deletions of HEY2, CEBPA, and CYS1 in mice have liver anomalies (Eppig et al. 2012). MIR30A 
is a microRNA that is differentially expressed in developing bile ducts (Raynaud et al. 2011), and 
it was also found to be downregulated. Of the upregulated genes, deficiencies of HNF1B 
(Roelandt et al. 2012) and HHEX (Hunter et al. 2007) are known to cause liver defects, but the 
phenotype of these genes when overexpressed is unknown. On the other hand, FOXA1 is an 
important transcription factor in the developing liver, and it was also found to be upregulated in 
the deleted line. Because the aforementioned genes participate in liver development, a critical 
phenotypic feature of ALGS, the observed differential expression may be due to the downstream 
effects of JAG1 haploinsufficiency. Thus, these genes should are candidates for modifying the 
liver disease in ALGS. 
2.3 Discussion 
In this study, we looked for correlation of the clinical features of ALGS with each other to 
determine if the occurrence of one feature could predict the occurrence of others. We also 
investigated the effect of the non-mutated JAG1 allele on the phenotype. The characteristics of a 
JAG1 mutation do not appear to be significantly associated with any given phenotype. Missense 
and loss-of-function mutations did not preferentially segregate with any of the phenotypic 
categories, in concordance with the hypothesis that ALGS results from haploinsufficiency of the 
JAG1 protein rather than a dominant negative effect arising from a mutated protein product. In 
addition, characteristics of the transmission of the JAG1 mutation, inherited or de novo, and the 
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parental origins of an inherited mutation were not significantly associated with any of the 
observed phenotypes. 
From this study, we found two significant phenotypic associations, one between liver 
disease severity and cardiovascular anomalies (p = 0.0006) and the other between 
cardiovascular anomalies and butterfly vertebrae (p = 0.0024). Hofmann et al. have shown that 
JAG1 signaling from the portal vein mesenchyme is responsible for intrahepatic bile duct 
development, and targeted mouse knockouts of JAG1 in these cells causes bile duct paucity and 
liver disease (Hofmann et al. 2010). The correlation between liver disease severity and cardiac 
anomalies in ALGS may be due to lack of JAG1 expression in the mesoderm tissue or its 
derivatives. Alternatively, the physiological sequela from severe cardiac disease might affect the 
liver phenotype in these patients. For example, children with cyanotic heart disease may have 
more severe liver disease due to lower oxygen concentrations in their body. 
The second significant phenotype correlation was between cardiac anomalies and 
butterfly vertebrae. Both heart and bone tissues are derived from mesoderm cells, so these 
systems are derived from the same germ layer. However, we cannot be certain what factors 
influence the formation of either of these anomalies. We recognize that the renal system is also 
derived from mesoderm, yet we did not find a significant correlation between renal disease and 
both cardiac anomalies and the presence of butterfly vertebrae. There could be a weaker 
correlation between these systems and renal involvement that is not detected due to our limited 
sample size, so we would need to test for association in a larger cohort to detect any associations. 
The remaining pairwise correlations between the hepatic, cardiac, renal, ocular, and skeletal 
systems did not achieve significance. 
An allelic series of stronger and weaker alleles for the same gene is a well-studied 
property, and it is thought that a strong normal allele could mollify the effects of haploinsufficient 
genes (Lewis et al. 1999; Sun et al. 2000). We tested for modifying features of the trans-allele 
using three of the most common SNPs of JAG1. None of the SNPs appeared to be associated 
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with phenotype. While not every variant in the coding and intronic regions of JAG1 was tested, it 
is unlikely that the trans-allele produces a significant effect on the phenotype. 
Although this investigation does not examine all phenotypes present in ALGS, it does 
seem to suggest that the cardiac phenotype may be the strongest prognostic factor in 
determining the course of liver disease severity for ALGS patients. We recognize that we cannot 
distinguish a physiological effect of the structural heart defects on the other clinical abnormalities 
from the presence of a genetic predisposition to co-occurrences of multisystem abnormalities. 
Future work determining the cause of these correlations observed with structural cardiac 
abnormalities is underway. 
In addition, we tested the mutation characteristics and three polymorphisms in JAG1 for 
association with clinical phenotypes. We did not discover any modifying effects from the 
characteristics of the mutation or the normal JAG1 allele, suggesting that if there was an effect 
from either, it is likely to be small. Because we could not find an association with JAG1, we 
predict that genetic factors modifying the ALGS phenotype arise not from JAG1, but from genes 
downstream of this Notch ligand or outside the Notch pathway. 
In the microarray experiments observing the differences between the deleted and non-
deleted JAG1 cell lines, there were genes that were significantly altered in the deleted line after 
correcting for multiple testing in the microarray experiment, but none of them were Notch pathway 
or known liver development genes in all three tissue types investigated. Given the small sample 
size of this experiment, the differential expression may not necessarily arise from just the 20p12.2 
JAG1-containing deletion differences. Furthermore, JAG1 is not the only whole-gene copy 
number alteration, and the 3 additional genes deleted on 20p12 as well as the 16 genes 
duplicated on 20p11 could also contribute to these changes. There are three genes upregulated 
in the iPSC and endoderm lines (PCDHGA3, C18orf2, and PKIB), but these genes do not have a 
clear connection with Notch signaling pathway. Craniofacial dysmorphism is one of the most 
penetrant features of ALGS patients with a JAG1 mutation. EDN1 is significantly upregulated in 
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the endoderm line. Zebrafish studies demonstrated that edn1 is an inhibitor of JAG1 in the ventral 
domain, yet edn1 and jag1b interact with grem2 to shape the facial skeleton (Zuniga et al. 2011; 
Zuniga et al. 2010). Correspondingly, it is likely that haploinsufficiency of JAG1 in our deleted line 
led to upregulation of EDN1, although we observe these differences in the endoderm line rather 
than a neural crest cell line responsible for shaping craniofacial features. 
 While there were no pathways that were significantly enriched in the fibroblast lines, it is 
interesting to find enrichment of genes involved in cellular components for DNA packaging and 
macromolecular complex organization upregulated in the deleted iPSC and endoderm lines. Most 
of these upregulated genes enriched in these pathways were part of the histone 1 cluster, 
important components for maintaining higher order chromatin structures (Izzo et al. 2008). In the 
endoderm line, downregulated genes were enriched for cellular components of the extracellular 
region (FDR = 0.009). As JAG1 is also a member of this ontology, and it is interesting that other 
genes encoding proteins expressed at the cell surface were also downregulated. This could 
suggest that cells with a JAG1 deletion may have problems with not only Notch signaling but also 
other cell-to-cell or contact-mediated signaling pathways. 
 Since no Notch pathway genes achieved genome-level significance, we re-investigated 
those that achieved nominal significance (p < 0.05). The Notch ligand, DLL3, was observed to be 
downregulated in addition to JAG1. Curiously, CNTN1 appeared to be upregulated in the 
endoderm and fibroblast lines, and the upregulation of this Notch ligand may be compensating for 
deficient JAG1 signaling. Homozygous mice targeted for a null mutation in CNTN1 have ataxia, 
cerebellum abnormalities, and growth retardation. Furthermore, these mice die prior to weaning. 
Both of these ligands are central to embryogenesis and development, and it would be interesting 
to investigate if there is any redundancy between certain roles of JAG1 and CNTN1. HEY2 is the 
only major downstream target of Notch that is dysregulated, and the largest expression 
differences in the endoderm are observed in this gene. Mice with deficiencies of Hey2 primarily 
die from cardiac defects, but they also exhibit liver congestion (Sakata et al. 2002). This 
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observation suggests that HEY2 or its downstream genes could be potential modifiers for ALGS, 
and further mechanistic are required to confirm that this alteration is a direct result of JAG1 
haploinsufficiency. Phenotypic studies are also necessary to demonstrate that HEY2 expression 
can modify the disease phenotype. 
 In addition to the downregulation of HEY2 in the deleted endoderm line, we also 
observed downregulation of MIR30A, a marker of cholangiocytes, among the genes central to 
liver development. As Notch signaling is necessary for driving hepatoblast differentiation into 
cholangiocytes, this alteration could be reflecting an underlying impairment to form BECs arising 
from the underlying Notch signaling defect. CYS1 was also found to be downregulated in the 
deleted line, and defects in this gene cause polycystic kidney disease (PKD) in mice. Notably, 
renal and hepatic cysts are both symptoms associated with ALGS patients that are also observed 
in PKD. Mice with null targets of the CYS1 homolog, cpk, have hepatic cysts and fibrosis in 
addition to polycystic kidney disease (Ricker et al. 2000). These preliminary studies demonstrate 
that HEY2, MIR30A, and CYS1 may be candidates for modifying liver disease severity in ALGS, 
and further work is needed to extend these studies. 
2.4 Materials and Methods 
Study Cohort 
ALGS patients and parents were enrolled into the study through an IRB-approved 
protocol at the Children’s Hospital of Philadelphia (CHOP). The peripheral blood samples 
obtained from each patient were used to extract DNA and establish lymphoblastoid cell lines 
(LCLs) using standard protocols (Li et al. 1997). All samples were screened for mutations in 
JAG1 and NOTCH2 as part of an ongoing study on ALGS. Of the 582 subjects with a confirmed 
JAG1 mutation, 448 had phenotypic information on any of the five features tested and could be 
used for our statistical analysis. Further exclusions were applied for the genotype-phenotype 
correlation studies looking for an effect of polymorphisms present on the normal allele. In order to 
minimize effects from population stratification, we only selected to test self-reported Caucasian 
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subjects. In addition, family members were excluded from the study in those cases where they 
did not have independent normal alleles (such as biological siblings from the same parents). After 
these selection criteria, the remaining 210 self-reported Caucasians with available DNA were 
genotyped for this analysis. 
The clinical data collected from all patients was reviewed by clinicians to determine the 
absence or presence of phenotypes, such as any hepatic, cardiac, skeletal, ocular, and renal 
anomalies. The severity of the liver disease was graded by several pediatric gastroenterologists 
according to a scale (Table 2-6), with a clear categorical cutoff distinguishing patients with mild 
and severe liver disease. A user-friendly database was designed using FileMaker Pro 10 (Santa 
Clara, CA) to store a summary of the clinical phenotype information (Appendix Figure A1). 
Cardiac and renal involvement were present in a significant subset of our cohort. As 
previously reported, patients with cardiac features primarily had non-structural cardiac anomalies 
including peripheral pulmonary stenosis (PPS) and patent ductus arteriosus (PDA) as well as 
structural cardiac anomalies including ventricular septal defects (VSD), atrial septal defects (ASD), 
and tetralogy of Fallot (TOF) (McElhinney et al. 2002). The range of cardiac anomalies found in 
patients is summarized in Table 2-7. The heart phenotype in ALGS is difficult to classify, because 
each type of structural defect only occurs in a fraction of the patients and the majority present 
with a benign form of isolated PPS. Patients with PPS in our study had symptoms ranging from a 
heart murmur to more significant narrowing of the pulmonary arteries requiring intervention, and it 
was not possible to classify the severity of most patients with isolated PPS based on the available 
information. In addition, only a handful of patients had PDA, an anomaly where the ductus 
arteriosus fails to close after birth, another regularly occurring non-structural cardiac defect 
present in our cohort. Thus, we focused our analysis of cardiovascular anomalies on structural 
defects, and the heart phenotype was analyzed as a binary indicator for the presence or absence 
of structural anomalies.  
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The renal system involvement was also used as a phenotypic indicator rather than 
individual sub-phenotypes of renal disease. Although renal features are not unusual in ALGS, a 
wide variety of renal issues, both structural and functional, have been reported (Kamath et al. 
2013). For example, a subset of renal anomalies such as solitary, small, multicystic, ectopic, or 
hypoplastic kidneys as well as renal dysplasia and ureter anomalies have each been observed in 
less than a handful of patients, but together, 40% of ALGS patients carrying a JAG1 mutation 
present with renal abnormalities (Kamath et al. 2013). The symptoms of patients with renal 
involvement are summarized in Table 2-7. 
Butterfly vertebrae is the most common skeletal feature associated with ALGS, so it was 
the only skeletal anomaly investigated in this report (Alagille et al. 1975). The most prevalent 
ocular anomaly is the presence of posterior embryotoxon, so absence or presence of this 
anomaly was also tested (Krantz et al. 1997). In conclusion, the binary phenotypes in the 
phenotype-phenotype and genotype-phenotype analysis are the following: liver severity 
(mild/severe), cardiovascular system (normal/abnormal), renal involvement (absence/presence), 
butterfly vertebrae (absence/presence), and posterior embryotoxon (absence/presence). 
Phenotypic Analysis 
 We tested whether the phenotypes are correlated with gender, characteristics of the 
JAG1 mutation, such as its transmission (inherited v. de novo as well as maternal v. paternal 
within inherited cases), and the type of mutation (loss-of-function v. missense) using a two-sided 
Fisher’s exact test. Because of the multiple statistical tests performed in this analysis, p = 0.0025 
is the threshold for significance. 
A separate question asked was whether any of the five observed phenotypes of the liver, 
heart, kidneys, eye, and vertebrae are correlated with one another. In addition to computing a p-
value from a two-sided Fisher’s exact test, a Pearson correlation coefficient for categorical 
variables ($) was calculated between pairs of phenotypes. Ten statistical tests were performed to 
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analyze each pairing of the five phenotypes studied. A Bonferroni correction to the Type I error 
rate (0.05) implies p = 0.005 as the significant p-value threshold. 
SNP Genotyping and Allele Phasing 
To analyze genotypes at three selected polymorphisms of the JAG1 gene, sequencing 
was carried out using PCR primer sequences and established experimental protocols for the 
amplification of exons 22 and 26 in mutation-positive ALGS patients and their available parents 
(Warthen et al. 2006). Sanger sequencing for the three SNPs, rs35761929 (exon 22), rs1051419 
(exon 26), and rs1051421 (exon 26), was performed at the NAPCore. 
Phasing of each SNP delineated which nucleotide resided on the disease-causing JAG1 
allele and which one on the normal allele, and this was performed on a case-by-case basis to 
maximize the retention of genotypic information in our cohort. For subjects with a JAG1 deletion, 
the normal allele could be determined directly from the sequencing results. In the case when the 
SNP is homozygous in the patient, the cis and trans alleles are the same. When the SNP is 
heterozygous in a patient with an inherited case of the JAG1 mutation and samples from other 
family members were available, the cis and trans alleles could be logically deduced from pedigree. 
Initial haplotype analysis of pedigrees with available genotypic information was performed using 
MERLIN and the unresolved cases were interpreted manually (Abecasis et al. 2002). 
  SNP association analysis was limited to self-reported Caucasian patients of European 
descent, because the frequencies of the tested polymorphisms varied across different ethnic 
backgrounds. To investigate any evidence of an allelic series due to a common polymorphism on 
the JAG1 allele, we used only the subjects with discernable phase information and tested the 
SNP frequency on the normal alleles against each phenotype using a two-sided Fisher’s exact 
test. 
JAG1 Deletion in a Unique Mosaic Sample 
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Blood samples were obtained from a family trio with a CNV deletion containing JAG1 
enrolled through an IRB-approved protocol. A case report has been published on this family 
(Laufer-Cahana et al. 2002). At 18 months, the proband was first evaluated at CHOP presenting 
with severe cholestasis. The proband was diagnosed with ALGS, and fluorescence in situ 
hybridization (FISH) analysis revealed a full gene deletion of JAG1 on one copy of chromosome 
20. Intriguingly, upon analysis of the parental DNA, this deletion was inherited from her mother 
who was mosaic for this alteration and clinically evaluated to be normal. Depicted in Figure 2-3 is 
the 1 Mb CNV deletion spanning four genes, ANKRD5, SNAP25, MKKS, and JAG1 and the 4 Mb 
CNV duplication spanning 16 genes, GGTLC1, TMEM90B, CST7, ACSS1, VSX1, ENTPD6, 
PYGB, ABHD12, GINS1, NINL, NANP, ZNF337, FAM182B, FAM182A, MIR663, and FRG1B that 
this mosaic mother carried in approximately 40% of her cells and passed on to her child with 
ALGS as calculated using previously established methods (Conlin et al. 2010). 
Blood and skin samples were obtained from the mosaic subject who was enrolled 
through an IRB-approved protocol. Fibroblast cell lines were established and maintained using 
standard protocols from the Clinical CytoGenomics Laboratory at CHOP using tissue collected 
from a biopsy. DNA was extracted from whole blood and as well as the fibroblast cell line using 
the Puregene DNA Genomic Purification System and its recommended protocol (Gentra Systems, 
Minneapolis, MN). Both samples were sent to the Center for Applied Genomics (CAG) at CHOP 
for SNP genotyping using the HumanHap 610 Quad BeadArray (Illumina, San Diego, CA) to 
quantify the percent mosaicism of the cell population containing the JAG1 deletion. 
Generation of iPSCs 
To generate iPSCs, the fibroblast lines were transduced with the four Yamanaka factors, 
OCT4, KLF4, SOX2, and MYC, using a lentiviral construct following the established protocols at 
the iPS Cell Core Facility at CHOP (Mills et al. 2013). The fibroblasts were plated sparsely to 
facilitate the generation of single-cell derived colonies, and this also ensures the separation of the 
two cell populations henceforth referred to as the deleted (1 copy of JAG1) and non-
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deleted/normal (2 copies of JAG1) lines. We selected and expanded 7 colonies from the initial 
induction. These colonies were confirmed to have an integration of a single viral construct using a 
Southern blot by the iPS Cell Core Facility. During the expansion, careful examination of the cell 
morphology in addition to flow cytometry for SSEA3/4 and TRA1-60/81 pluripotency marker 
expressions were performed routinely to check for pluripotency. 
There were 7 iPSC colonies that grew from the initial selection of lentiviral integration. 
After expansion of these colonies for 20 passages, DNA was extracted from these colonies using 
the Qiagen DNeasy (Germantown, MD) kit and sent to the CAG for SNP array genotyping to test 
for structural aberrations, low-level mosaicism, as well as smaller copy number changes. The 
deletion status of JAG1 was characterized using the SNP arrays, and it was confirmed that one 
colony was derived from the non-deleted cell population and 6 colonies were derived from the 
deleted cell population. However, the SNP array data also confirmed that 3 deleted iPSC lines 
carried large chromosomal abnormalities and were subsequently discarded. The CytoGenomics 
Laboratory also performed karyotyping on the non-deleted and deleted lines used for the 
expression analysis to confirm the absence of large inversions and translocations. 
Identification of Cell Populations From a Mosaic Sample 
 This deletion that included JAG1 was characterized by PCR sequencing across the 
breakpoint. From the SNP array data, we were able to resolve the 5’ breakpoint to 3kb of 
uncertainty and the 3’ breakpoint to 31kb of uncertainty. We created three primers in these 
regions spaced 2kb apart to the 3’ breakpoint and two primers just upstream of the deletion on 
the 5’ end (Table 2-8) and performed PCR using Kappa Long Range HotStart Polymerase 
(Woburn, MA) using their recommended protocol on various combinations of these primers. 
Because the deletion was approximately 1Mb, a PCR product can be amplified only in the 
presence of the deletion. The primer sets that successfully captured the deletion breakpoint were 
observed by gel electrophoresis. The smallest PCR product (1.3 kb) was sent to the Nucleic 
Acid/Protein Core Facility (NAPCore) at CHOP for capillary sequencing to resolve the breakpoint 
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to a base pair resolution (Figures 2-4). There is a 7-bp micro-homology flanking this deletion, 
which may have contributed to the formation of this CNV. This deletion is 918kb in size and it 
encompasses the entire coding sequence of ANKRD5 (Raby et al. 2007), SNAP25 (Washbourne 
et al. 2002), MKKS (Stone et al. 2000), and JAG1, but only JAG1 is known to have a phenotype 
in the hemizygous state. 
 While the SNP array is sensitive for mosaicism over 5% (Conlin et al. 2010), we used a 
primer set spanning the deletion breakpoint for PCR to ensure that iPSC lines that appeared non-
deleted did not contain low-level contamination of the deleted population. The PCR primer set 
that amplifies a 600bp product in the presence of the deletion was used as a sensitive assay to 
detect the presence of the deletion cell line and rule out low-level mosaicism. On the 
electropherogram, the relative ratio of a SNP in intron 3 of JAG1, rs2273061, can be used to 
detect mosaicism, because it is heterozygous in the non-deleted line. Table 2-8 summarizes the 
analysis of these two combined PCR tests for pure cell line populations.  
Isolation of Fibroblast Cell Populations From a Mosaic Sample 
 The mosaic fibroblast cell line established from primary tissue was serially diluted to 
establish clonal populations that were each pure for one of the cell populations. This cell cloning 
technique by serial dilution in 96 well plates was performed using established protocols (Ryan 
2008). Gibco® AmnioMax medium by Life Technologies (Grand Island, NY) was used to culture 
and passage these cells. The clonal populations were initially screened by this PCR process 
(Table 2-9) to check for the purity of the cell population. Then, DNA from the 6 pure cell 
population samples (3 deleted and 3 non-deleted) was sent for SNP array genotyping at the CAG 
to check for chromosomal aberrations. However, only 1 non-deleted and 2 deleted lines did not 
carry any chromosomal anomalies. 
Differentiation of Endoderm Cells from iPSCs 
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 After the iPSCs were fully characterized, 3 deleted and non-deleted lines were selected 
to differentiate into definitive endoderm. The differentiation process and characterization was 
performed using established protocols (Cheng et al. 2012). Cell sorting of the final product of this 
5-day protocol isolated the differentiated endoderm population that had CXCR4+ and CD117high 
expression from the few undifferentiated iPSCs. DNA and RNA were extracted from the sorted 
population using the Qiagen DNeasy and RNeasy Kits (Germantown, MD), respectively. 
CNV Analysis of SNP Array Data 
From the SNP array experiments, the Log R ratio and B allele frequency were used by 
PennCNV to call potential regions with copy number changes (Wang et al. 2007). Because the 
samples were run on different SNP array platforms, only the intersecting SNPs were used in this 
analysis. These CNVs were inspected manually to identify inherited versus de novo CNVs within 
the cell lineages from the original mosaic sample. The characterization of the CNVs from the 
original mosaic sample and the subsequent gain of CNVs from the biological replicates used for 
the microarray analysis confirmed the absence of CNVs across other pathogenic genes. The 
CNVs in the biological replicates of the fibroblast line (non-deleted and deleted) used in the 
microarray analysis is summarized in Figure 2-5. Figures 2-6 and 2-7 are a characterization of the 
biological replicates of the deleted and non-deleted iPSC and endoderm lines. Although the DNA 
was extracted from iPSCs, it is unlikely that the brief 5-day differentiation from iPSCs to 
endoderm would introduce cell-line transforming CNVs.  
Microarray Analysis 
The RNA samples were converted to cDNA using the Invitrogen SuperScript® First-
Strand cDNA Synthesis Kit (Carlsbad, CA). Triplicates of each sample were used for the 
microarray experiment on the Affymetrix GeneChip® Human Exon 1.0 ST array (Santa Clara, CA) 
performed by the NAPCore. The subsequent quality control and normalization of the data was 
performed at the Center for Bioinformatics (CBMi) at CHOP. Principle component analysis of the 
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microarray data revealed that the strongest expression signatures reflect the tissue type 
(fibroblast, iPSCs, and endoderm). Within each tissue type, the samples clustered based on the 
cell population (non-deleted or deleted) as expected.  
A standard two-sided t-test and false discovery rate (FDR) calculation from the R 
package of significance analysis of microarrays (R Core Team 2013; Tusher et al. 2001) were 
used to assess expression differences in 19,741 genes probed on the microarray between the 
non-deleted and deleted cell lines. Because of the small sample size, we tried a multipronged 
approach to identify dysregulated genes that may be candidates for phenotypic modification of 
ALGS. We inspected genes with significant differences between the non-deleted and deleted line 
of each tissue type (FDR < 0.05) and performed pathway enrichment analysis of the top 250 
upregulated genes and the top 250 downregulated genes in the deleted line separately using 
DAVID (Huang et al. 2009). 
In addition, we surveyed genes in the Notch signaling pathway for each respective tissue 
type and also genes involved in liver development for the endoderm cell lines, comparing the 
deleted line to the non-deleted line. Since the sample size is small, we examined all genes that 
met nominal significance (p < 0.05) in this part of the analysis. Notch signaling is a central 
developmental pathway that interacts with many other key regulatory pathways, so it is difficult to 
isolate genes central to this pathway using protein-protein interaction data. Instead, a curated list 
of 83 Notch signaling pathway genes was obtained from WikiPathways (Kelder et al. 2012) and 
supplemented with 57 genes implicated in the literature (Chen et al. 2009; Gridley 2010; 
MacGrogan et al. 2010; Weinmaster and Fischer 2011). The 129 liver development genes 
examined were curated from review articles (Gridley 2010; MacGrogan et al. 2010; Raynaud et al. 
2011; Zong and Stanger 2011). 
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Table 2-1. Summary of Features Tested in 582 Subjects with a JAG1 Mutation 
These are the features interrogated and their respective binary classifications. Part I summarizes 
basic characteristics such as gender, inheritance, and the type of mutation. Part II describes the 
five clinical features of ALGS that were investigated. Finally, Part III is the distribution of the trans-
allele in samples that were genotyped. Only self-reported Caucasian patients were genotyped. 
Binary
Classification
Number of
Subjects
I. Characteristics
Gender male / female 298 / 277
Origin inherited / de novo 152 / 170
Inheritance paternal / maternal 59 / 93
Mutation Classification LOF / missense 346 / 91
II. Phenotypes
Liver Severity mild / severe 118 / 83
Cardiovascular System normal / abnormal 26 / 176
Renal Involvement absence / presence 155 / 102
Butterfly Vertebrae absence / presence 162 / 151
Posterior Embryotoxon absence / presence 107 / 212
III. SNPs on Trans-Allele
rs35761929 C / G 181 / 12
rs1051419 T / C 49 / 101
rs1051421 C / T 111 / 32
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Table 2-2. Characteristics of Subjects 
The binary classifications for Group 1 and Group 2 represented here can be found in the previous 
table. This table includes the categories for the Fisher's exact test, the corresponding p-value and 
also the odds ratio (OR) for each pairwise test. The corrected p-value threshold for significance is 
p = 0.0025.
Binary
Classification p OR (95% CI)
I. Gender Male Female
Liver Severity mild / severe 60 / 44 58 / 39 0.78 0.92 (0.50, 1.67)
Cardiovascular System normal / abnormal 17 / 92 9 / 82 0.29 1.68 (0.66, 4.52)
Renal Involvement absence / presence 75 / 60 78 / 42 0.16 0.67 (0.39, 1.15)
Butterfly Vertebrae absence / presence 86 / 78 75 / 71 0.91 1.04 (0.65, 1.67)
Posterior Embryotoxon absence / presence 58 / 115 48 / 97 1.00 1.02 (0.62, 1.67)
II. Inheritance Inherited De Novo
Liver Severity mild / severe 32 / 25 25 / 30 0.68 1.53 (0.68, 3.46)
Cardiovascular System normal / abnormal 7 / 42 2 / 72 0.03 5.91 (1.06, 60.94)
Renal Involvement absence / presence 40 / 20 64 / 36 0.86 1.12 (0.55, 2.35)
Butterfly Vertebrae absence / presence 40 / 38 60 / 64 0.61 1.12 (0.61, 2.06)
Posterior Embryotoxon absence / presence 34 / 54 30 / 81 0.89 1.70 (0.89, 3.24)
Paternal Maternal
Liver Severity mild / severe 14 / 11 18 / 14 0.30 0.99 (0.30, 3.24)
Cardiovascular System normal / abnormal 4 / 22 3 / 20 1.00 1.21 (0.18, 9.28)
Renal Involvement absence / presence 20 / 6 20 / 14 0.17 2.30 (0.66, 8.87)
Butterfly Vertebrae absence / presence 15 / 23 25 / 15 0.14 0.40 (0.14, 1.07)
Posterior Embryotoxon absence / presence 12 / 27 22 / 27 0.20 0.55 (0.20, 1.43)
III. Mutation Type LOF Missense
Liver Severity mild / severe 62 / 54 18 / 5 0.04 0.32 (0.09, 0.98)
Cardiovascular System normal / abnormal 13 / 108 5/ 27 0.54 0.65 (0.20, 2.54)
Renal Involvement absence / presence 93 / 66 23 / 10 0.25 0.61 (0.24, 1.45)
Butterfly Vertebrae absence / presence 90 / 96 22 / 15 0.28 0.64 (0.29, 1.38)
Posterior Embryotoxon absence / presence 55 / 125 20 / 30 0.23 0.66 (0.33, 1.34)
Number of Subjects
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Table 2-3. Pairwise Phenotype Correlations     
A Fisher’s exact test was conducted in a pairwise fashion for the five phenotypic categories. The 
p-value threshold for significance is 0.005 after Bonferroni correction. The pairwise tests that pass 
this threshold for significance is in bold, and there is significant association between 
cardiovascular anomalies and liver disease severity as well as cardiovascular anomalies and 
butterfly vertebrae. 
Binary
Classification p ! (95% CI)
A. Liver Severity mild severe
Cardiovascular System normal / abnormal 16 / 33 1 / 35 0.0006  0.37 (0.17, 0.54)
Renal Involvement absence / presence 37 / 14 28 / 25 0.0445  2.34 (0.97, 5.83)
Butterfly Vertebrae absence / presence 42 / 30 30 / 29 0.4805  0.07 (-0.10, 0.24)
Posterior Embryotoxon absence / presence 25 / 62 24 / 43 0.3857 -0.08 (-0.23, 0.08)
B. Cardiovascular System normal abnormal
Renal Involvement absence / presence 12 / 3 63 / 43 0.1606  2.71 (0.68, 15.85)
Butterfly Vertebrae absence / presence 13 / 3 49 / 75 0.0024  0.27 (0.11, 0.41)
Posterior Embryotoxon absence / presence 6 / 13 38 / 80 1.0000  0.00 (-0.17, 0.16)
C. Renal System normal abnormal
Butterfly Vertebrae absence / presence 69 / 56 33 / 43 0.1121  1.60 (0.87, 2.97)
Posterior Embryotoxon absence / presence 43 / 78 24 / 47 0.8759  1.08 (0.56, 2.11)
D. Butterfly Vertebrae absence presence
Posterior Embryotoxon absence / presence 57 / 81 31 / 80 0.0330  0.14 (0.02, 0.26)
Number of Subjects
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Table 2-4. Phenotype-Genotype Correlations in Caucasians 
To minimize effects of varying allele frequencies across ethnic groups, only the Caucasian 
subjects were genotyped and tested for phenotype-genotype correlations. The p-value threshold 
for significance after Bonferroni correction is 0.0034, and none of these pairwise comparisons 
exceeded this threshold. N/A denotes uncalculated odds ratios due to the presence of an 
unobserved category.  
Binary
Classification p OR (95% CI)
rs35761929 C G
Liver Severity mild / severe 56 / 27 4 / 5 0.27 2.56 (0.51, 14.02)
Cardiovascular System normal / abnormal 9 / 62 0 / 5 1.00 N/A
Renal Involvement absence / presence 54 / 40 2 / 3 0.65 2.01 (0.22, 25.13)
Butterfly Vertebrae absence / presence 58 / 58 3 / 7 0.33 2.32 (0.50, 14.57)
Posterior Embryotoxon absence / presence 37 / 84 2 / 8 0.72 1.76 (0.33, 17.76)
rs1051419 T C
Liver Severity mild / severe 16 / 5 37 / 20 0.42 1.72 (0.50, 6.90)
Cardiovascular System normal / abnormal 4 / 17 5 / 37 0.47 1.73 (0.30, 9.18)
Renal Involvement absence / presence 19 / 6 22 / 27 0.01 3.81 (1.2, 13.78)
Butterfly Vertebrae absence / presence 14 / 17 32 / 35 0.83 0.90 (0.35, 2.30)
Posterior Embryotoxon absence / presence 9 / 27 19 / 47 0.82 0.83 (0.29, 2.25)
rs1051421 C T
Liver Severity mild / severe 38 / 16 12 / 8 0.41 1.57 (0.46, 5.18)
Cardiovascular System normal / abnormal 6 / 41 3 / 7 0.18 0.35 (0.06, 2.66)
Renal Involvement absence / presence 27 / 25 10 / 7 0.78 0.76 (0.21, 2.61)
Butterfly Vertebrae absence / presence 33 / 38 12 / 9 0.46 0.65 (0.21, 1.94)
Posterior Embryotoxon absence / presence 25 / 51 6 / 15 0.80 1.22 (0.39, 4.33)
Number of Subjects
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Table 2-5. Pathway Enrichment Analysis of Top Differentially Expressed Genes in the Deleted 
JAG1 Line. 
The fold change between the deleted and the non-deleted line was used to calculate the top 250 
genes that were upregulated or 250 genes that were downregulated in the deleted line. Then, 
pathway enrichment for these genes was performed for each respective gene list and cell type. In 
fibroblast, the differentially expressed genes were not enriched in any observed GO pathway. In 
iPSCs, the 7 pathways enriched for upregulated genes all contained histone cluster 1 genes. 
Furthermore, 2 of these pathways were also enriched in the deleted endoderm line. In endoderm, 
there was also significant downregulation of genes that localize to the extracellular region, 
including JAG1, as well as genes that participate in DNA binding. 
Top 250 List Ontology GO ID GO Term Count % inSet
Fold
Change p-val FDR Genes
I. Fibroblast
none
II. iPSC
upregulated CC GO:0000786 nucleosome 9 3.6 11.6 9.5E-07 0.001 CENPA, HIST1H1D, HIST1H1A, HIST1H2AJ, HIST1H2BG,HIST1H2BL, HIST1H3E, HIST1H4A, HIST1H4F, HIST3H2A
upregulated CC GO:0032993 protein-DNA complex 9 3.6 8.5 1.0E-05 0.013 CENPA, HIST1H1D, HIST1H1A, HIST1H2AJ, HIST1H2BG,HIST1H2BL, HIST1H3E, HIST1H4A, HIST1H4F, HIST3H2A
upregulated BP GO:0006334 nucleosome assembly 9 3.6 8.4 1.1E-05 0.017 CENPA, HIST1H1D, HIST1H1A, HIST1H2AJ, HIST1H2BG,HIST1H2BL, HIST1H3E, HIST1H4A, HIST1H4F, HIST3H2A
upregulated BP GO:0031497 chromatin assembly 9 3.6 8.1 1.4E-05 0.023 CENPA, HIST1H1D, HIST1H1A, HIST1H2AJ, HIST1H2BG,HIST1H2BL, HIST1H3E, HIST1H4A, HIST1H4F, HIST3H2A
upregulated BP GO:0006323 DNA packaging 10 4.0 6.7 1.7E-05 0.028 CENPA, HIST1H1D, HIST1H1A, NAA10, HIST1H2AJ, HIST1H2BG,HIST1H2BL, HIST1H3E, HIST1H4A, HIST1H4F, HIST3H2A
upregulated BP GO:0065004 protein-DNA complex assembly 9 3.6 7.8 1.9E-05 0.032 CENPA, HIST1H1D, HIST1H1A, HIST1H2AJ, HIST1H2BG,HIST1H2BL, HIST1H3E, HIST1H4A, HIST1H4F, HIST3H2A
upregulated BP GO:0034728 nucleosome organization 9 3.6 7.6 2.3E-05 0.037 CENPA, HIST1H1D, HIST1H1A, HIST1H2AJ, HIST1H2BG,HIST1H2BL, HIST1H3E, HIST1H4A, HIST1H4F, HIST3H2A
III. Endoderm
upregulated MF GO:0003677 DNA binding 54 22.0 1.9 2.0E-06 0.003
BRCA1, HIST1H1B, HIST1H2AE, HIST1H1A, RARB, RXRG, STAT4,
TNFAIP3, ZNF37A, ZNF229, ZNF232, HIST1H2AI, HIST1H2AL,
HIST1H2BG, HIST1H2BL, HIST1H3E, HIST1H3H, HIST1H4L,
BCLAF1, ZNF443, TBX22, POLR3B, ZNF302, ZNF253, TBX20,
ZNF630, CLSPN, DSCC1, ZNF614, MIXL1, BRIP1, ZNF528, ZNF559,
ZNF594, ZNF502, ZNF300, FOXQ1, ZNF560, ZNF542, ZNF583,
ZNF681, ESCO2, ZNF836, ZNF780B, ZNF676, ZNF718, ZNF326,
ZNF660, ZNF677, ZNF429, ZNF470, ZNF749, ZNF793, ZNF724P,
ZNF732, ZNF605
upregulated CC GO:0000786 nucleosome 8 3.3 12.6 3.0E-06 0.004 HIST1H1B, HIST1H2AE, HIST1H1A, HIST1H2AI, HIST1H2AL,HIST1H2BG, HIST1H2BL, HIST1H3E, HIST1H3H, HIST1H4L
upregulated CC GO:0032993 protein-DNA complex 8 3.3 9.2 2.4E-05 0.030 HIST1H1B, HIST1H2AE, HIST1H1A, HIST1H2AI, HIST1H2AL,HIST1H2BG, HIST1H2BL, HIST1H3E, HIST1H3H, HIST1H4L
downregulated CC GO:0005576 extracellular region 48 19.5 1.9 7.2E-06 0.009
JAG1, C2, COL1A2, COL5A2, HAPLN1, GPX7, HSPG2, ICAM1,
IGFBP2, IGFBP6, IGHM, IGLL1, LOX, KITLG, MMP9, NCAM1, NTS,
PCSK2, PECAM1, PGA5, PRB1, PRB3, PROS1, PTPRZ1, SFRP2,
PMEL, TFF1, PLA2G7, TFPI2, TNFSF12, APLN, GDF15, EDIL3,
LASS1, CHL1, SULF1, SRPX2, WNT4, HHIP, LYNX1, PCYOX1L,
FAM108A1, COL25A1, CTHRC1, LIPH, IL28A, LOC643797,
LOC728715
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Table 2-6. Stratification Categories for Liver Disease Severity 
The criteria listed were reviewed and approved by the clinicians performing the stratification of 
liver disease severity. Patients were initially stratified using the letter categories, but due to the 
limited sample size of some of these categories, a binary classification (mild/severe) of liver 
disease severity was used for the analysis.  
 
Liver Disease
Severity Category Clinical Features
A No known hepatic involvement. Normal liver tests
B Biochemical abnormalities (serum aminotransferases
greater than the upper limit of normal for the laboratory,
but normal bilirubin)
C1 Biochemical cholestasis without overt clinical
manifestations: Elevated conjugated bilirubin ( >15% of
total bilirubin or > 2mg/dL) or elevated cholesterol, bile
salts, or gammaglutamyl transferase above the upper
limit of normal for the laboratory
severe C2 Cholestasis (as above) with clinical manifestations
including severe pruritus, xanthomata, bone fractures
Any of the following:
- Died under age of 5
- Liver transplant under age of 5
- Biliary diversion under age of 5
- History of Kasai procedure
N/A Not enough clinical data or currently under 5 years of age
mild
undeterminable
X
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Table 2-7. Summary of Non-Structural and Structural Cardiovascular Anomalies. 
All the patients with notable heart anomalies were summarized in (a). There were 221 patients 
that exhibited only non-structural anomalies including peripheral pulmonary stenosis (PPS) and 
patent ductus arteriosus (PDA). In addition, there were 176 patients with structural anomalies 
including tetralogy of Fallot (TOF), valvar pulmonary stenosis (VPS), pulmonary atresia (PA), 
atrial septal defect (ASD), and ventricular septal defect (VSD). Some of these patients with 
structural cardiac anomalies also presented with PPS and PDA. Every ALGS patient was only 
counted once by his or her primary cardiac defect. Patients with renal involvement were 
summarized in (b) by their primary renal issue. 
 
Cardiovascular Findings Total 
Non-Structural Anomalies  
Isolated PPS 205 
Isolated PDA 15 
PPS and PDA 1 
  
Right-Sided Anomalies  
TOF 41 
VPS 24 
PA 12 
Other! 1 
  
Left-Sided Anomalies  
Anomalies of the aortic valve, aortic arch, 
and coarctation of aorta 28 
Hypoplastic left heart syndrome 2 
Other" 7 
  
Other Structural Anomalies  
ASD 23 
VSD 24 
ASD and VSD 7 
Total anomalous pulmonary venous 
return 2 
Vascular Anomalies 4 
Tricuspid regurgitation 1 
! One patient was found to have left pulmonary vein hypoplasia and a bicuspid 
pulmonic valve. 
" These patients have aortic anomalies, but they also presented with ASD or VSD. 
!"#$%&'"()*+,-&."'&)/+"+(0(-1.(.2"3&-,++/'4".01)5&"6(-)&42"5+13&',+10/$%42"
)&0%'1+($%(/.(."7892"0'1$&(),'(/"7892"/)-"/*,$&"6(-)&4"():,'4;"
Renal Defects Patients 
Hypoplastic/Dysplastic Kidneys 35 
Renal Cysts 19 
Renal Tubular Acidosis 10 
Vesicoureteric Reflux 10 
Obstruction 7 
Chronic Kidney Disease 6 
Renal Anomalies 5 
Vascular 2 
Other! 8 
 
7/9? 7<9?
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(b) 
 
Table 2-8. PCR Primer Design for Characterization of the Mosaic JAG1 deletion. 
The primer designs for long-range PCR screening of the deletion breakpoint sequence are 
summarized in (a). The two forward primers are paired with each of the reverse primer sets. The 
two primer sets in (b) are used to screen the cell line samples to identify populations that are pure 
deleted and non-deleted lines as well as those that are still mosaic. 
# Primer Name Type
Reference to
Breakpoint 5' to 3' Sequence
1 for1   forward upstream AGATCTCAGCATACCTGGGAAAGGG
2 for2   forward upstream CTAGGTGGAGGACCATACATTGGGC
3 rev2kb1 reverse downstream GACAGATCAACACAGCACATCGCTC
4 rev4kb1 reverse downstream GTCTGCTAGGTAGTAGGTGCTCTG
5 rev6kb1 reverse downstream TCTCCACACAAGTCCCTAGATGCC
# Primer Name Type 5' to 3' Sequence
1 del_F forward GTGGAGGACCATACATTGGGCA
2 del_R reverse CCCTCATGTGTTTCCTTCTGTC
3 snp_F forward GGTGCCATTCTGGTCACAGGCA
4 snp_R reverse TGCACGGACTCTGATTCAGCAC
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Table 2-9. Identification of Cell Population by PCR Screening. 
The clonal populations derived from the mosaic sample can be characterized using the PCR 
primer pairs described in Table 2-7 along with this table. Two PCR experiments are performed in 
this screen, one for a PCR product across the breakpoint that can only exist in the presence of a 
deletion and the other for a heterozygous SNP in the deletion, rs2273061, which is hemizygous in 
a pure deleted line. This PCR-based assay is very sensitive, and it can detect low-level 
mosaicism, where both the PCR breakpoint and two alleles of rs2273061 are observed. 
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Figure 2-1. Expression Profile of Notch Signaling Genes in Three Cell Types. 
The 21 genes listed above are the only ones with a p<0.05 using SAM, and the expression levels 
with p>0.05 are not reported. Although saturation of this graph is at 1.5 fold change, HEY2 is 2.2 
times more significantly expressed in non-deleted endoderm. HEY2 and JAG1 are the only two 
overlaps between the iPSC and endoderm lines, and interestingly, HEY2 is differentially 
upregulated in iPSCs but downregulated in endoderm. There are no overlaps between the iPSC 
and fibroblast lines. CNTN1 is the only Notch signaling gene differentially regulated in both the 
fibroblast and endoderm. 
c1 c2 c3
JAG1
HEY2
FHL1
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Figure 2-2. Expression Profile of Liver Development in Definitive Endoderm. 
There are 17 liver development genes that were differentially expressed in the deleted endoderm 
line (p<0.05). HEY2, which also appears in the Notch signaling gene list, is still the most 
prominently underexpressed gene in the deleted endoderm line. 
 
 
fibro endo ipsc
FGF7
ALDH1A3
MIR15A
ATP8B1
OPN5
EFNB2
FOXA1
GATA4
FGF8
HNF1B
NRP1
CFTR
VPS18
ERBB2
MIR30A
ERBB4
LHX2
OPN3
F2R
TBX2
FOXC2
HEY2
-1.5 -1 -0.5 0 0.5 1 1.5
!"#$#%&'(
72 
(a) 
 
(b) 
 
Figure 2-3. Mosaic Deletion and Duplication CNVs in a Unique Patient Sample. 
From the SNP array, we have detected that these two CNVs, (a) a deletion on 20p and (b) a 
centromeric duplication around chromosome 20, are mosaic in our unique patient sample. 
Approximately 40% of her cell contained these two CNVs while the other 60% of her cells do not 
contain these CNVs. There are 4 genes in (a) that are deleted and 16 genes in (b) that are 
duplicated. 
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Figure 2-4. Characterization of the Deletion CNV Breakpoint. 
The PCR product that is sequenced is described in (a), where primers are designed around a 
region of the reference sequence that was deleted, and the long-range PCR product was 1.2 kb 
in size. In (b) we were able to use capillary sequencing to determine the exact sequence of the 
deleted allele (middle row) and compare it with the sequence upstream (top row) and 
downstream (bottom row) of the breakpoint. We observed 7 bases of microhomology at the 
breakpoint, which may have significance in the formation of this CNV. Additionally, the lines and 
arrows indicate the presence and direction of repetitive elements on the reference sequence just 
upstream or downstream of the deletion. 
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Figure 2-5. CNV Characterization of Fibroblast Cell Lines. 
This Circos plot depicts all the CNVs with more than 10 SNPs in the fibroblast lines. The outer 
most ring annotates the genes in the CNV region. Then, (1) is the skin biopsy sample, which is 
mosaic for the duplication and deletion and contains one other duplication on chromosome 10. 
The normal fibroblast line (2) carries only the duplication on chromosome 10, while the two 
deletion lines (3) and (4) contain the two CNVs on chromosome 20 in addition to this duplication.
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Figure 2-6.CNV Characterization of Non-Deleted iPSC Lines. 
This Circos plot captures the CNV diversity and accumulation of new CNVs through the 
passaging of the non-deleted iPSC line. The skin sample used to establish the iPSC line is 
depicted in (1). Then, the iPSC lines were propagated from one transfected cell and the CNV 
analysis of an early passage of this colony is depicted in (2). The inner three rings (3), (4), and (5), 
are the iPSC colonies used for the microarray studies, and these CNVs are assumed to be the 
same ones present in the endoderm lines, which is a 5-day differentiation from this time of DNA 
sampling.
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Figure 2-7. CNV Characterization of Deleted iPSC Lines. 
This Circos plot captures the CNV diversity in the deleted iPSC line. In (1), the three CNVs 
present in the reference skin sample used to establish these iPSC cells. In (2), the early passage 
establishment of this clonal deleted line shows two novel deletions, one on chromosome 1 and 
the other on chromosome 19, which are fixed in the later passages (3), (4) and (5). In addition, 
these late-passage lines also have additional deletions and duplications, but upon examination of 
the genes in these regions, it is unlikely that these changes play a significant role in the alteration 
of gene expression.  
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CHAPTER 3: Genetic Modifiers of Liver Disease Severity in ALGS 
3.1 Introduction 
The liver disease seen in patients with ALGS ranges from sub-clinical to severe, and the 
factors influencing liver disease severity are unknown. In this chapter, we report our studies 
investigating the possible genetic components of liver disease severity, starting with studies to 
analyze JAG1 (both the mutated and non-mutated alleles) to hypothesis-neutral genome-wide 
approaches. ALGS patients are primarily diagnosed by gastroenterologists, because many 
experience neonatal jaundice and poor growth at a young age, approximately 85% of ALGS 
patients present with bile duct paucity, and the gastroenterological issues tend to require the most 
clinical intervention over the course of most patients’ lives (Emerick et al. 1999). Early symptoms 
may resolve and never develop into severe liver disease, yet 20% to 30% of ALGS patients will 
eventually require liver transplantation (Emerick et al. 1999; Hoffenberg et al. 1995; Lykavieris et 
al. 2001; Quiros-Tejeira et al. 1999). Unlike the cardiac defects, where severe forms of cardiac 
disease can be categorized by its initial presentation, liver disease severity cannot be predicted 
based on the presence of bile duct paucity alone. It has also been observed that liver disease in 
children under 5 years of age is not a stable predictor of long term liver transplantation (Kamath 
et al. 2010). Furthermore, there is presently no reliable biomarker to predict the development of 
end-stage liver disease in these children. We hypothesize that there is a genetic component to 
liver disease severity, such that some children will progress to end-stage liver disease due to their 
genetic risk. The rationale for understanding this component of the disorder is to better diagnose 
and monitor children at risk for liver failure. 
The phenotypic variation in ALGS patients has been observed since its diagnosis 
(Alagille et al. 1975). Even before mutations in the JAG1 gene were found to be the principle 
cause of ALGS, examination of recurrent cases implicated extreme phenotypic variability among 
family members (Dhorne-Pollet et al. 1994; Elmslie et al. 1995; Shulman et al. 1984). We suspect 
that this phenotypic variability, including the liver disease severity, has a genetic modifier 
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component. Although there could be an environmental factor that modifies liver disease severity, 
no such factor has been identified so far. Furthermore, the observation of three monozygotic twin 
pairs in our study who are all concordant for liver disease severity suggests a genetic component. 
We have carried out several experiments to look for genetic factors that may modify liver 
disease severity. To control for genetic heterogeneity, we only studied ALGS probands and 
relatives who have a confirmed JAG1 mutation. Using the stratification criteria for liver disease 
severity described in Chapter 2, we first tested for characteristics of JAG1 mutations with liver 
disease severity. Then, we used two hypothesis-neutral approaches, SNP and CNV GWA studies, 
to identify loci that may confer genetic susceptibility to liver disease severity in ALGS patients. 
Standard statistical tests are designed to test association in cohorts of unrelated 
individuals, but this rare disease does not lend to such statistical tests. Instead, we used a 
variance component model that accounts for population structure of related individuals and 
measures the deviation from a linear regression rather than performing a standard allelic test. 
Only the unrelated individuals were used in the CNV association study, and the Fisher’s exact 
test was used to test for association. From these two association studies, we were able to identify 
several loci and candidate genes that may modify liver disease severity in ALGS patients with a 
JAG1 mutation. 
3.2 Results 
3.2.1 Investigation of Modifying Effects from JAG1 
 We examined the type and location of the JAG1 mutations in our patients with both mild 
and severe liver disease. The frequency distribution by exonic location was similar between the 
mild and severe liver disease patients (Figure 3-1). JAG1 mutations in most exons have been 
observed in patients with both mild and severe liver disease except exon 8 (4 patients with mild 
liver disease) and exon 15 (1 patient with mild liver disease), as there were no severe liver 
disease patients with mutations in these two exons. Of the stratified patients with a full gene 
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deletion, half of them had mild liver disease (9% of mild patients) and the other half had severe 
liver disease (6% of severe patients). 
 The frequencies of the four main mutation types were summarized for both mild and 
severe liver disease (Figure 3-2). There was no significant association between the mutation 
types and liver disease severity (p = 0.148) based on a two-sided !2 test with 3 degrees of 
freedom, even though missense mutations were more frequent in mild liver disease patients than 
severe liver disease patients (17% versus 7%). 
Next, we turned our attention to the normal JAG1 allele, hypothesizing that its 
characteristics could influence absolute JAG1 dosage and consequently the clinical phenotype. 
We used sib-pairs to investigate the transmission of the non-mutated alleles in affected sibs 
concordant and discordant for liver disease severity. We classified 26 sib-pairs into 4 groups 
based on concordance or discordance of their phenotype and genotype, and this is tabulated in 
Table 3-1. There were 5 sib-pairs concordant for liver disease severity and JAG1 allele genotype, 
6 discordant for liver disease severity but with concordant JAG1 genotypes, 4 with concordant 
liver disease severity but discordant JAG1 genotypes, and 11 with discordant liver disease 
severity and JAG1 genotypes. We were unable to achieve significance for an association for 
concordance of liver disease severity and the normal JAG1 alleles (p = 0.28) using a one-sided 
Fisher’s exact test for these 26 sib-pairs. The calculated OR was 2.2, which measures the 
likelihood of observing the same severity of liver disease given concordance of genotype with a 
large 95% confidence interval range (0.43, Inf).  
In power calculation plotted in Figure 3-3, we only had power (1-" > 0.8) to detect an 
effect of the normal allele on liver disease severity if OR > 3 when testing only 26 sib-pairs. Next, 
we performed simulation studies on 12 OR values between 1.2 and 3.5 as a measure of the 
magnitude of the effect we can expect to observe given our sample size and these simulations 
are plotted in Figure 3-4. Assuming that the true effect size on liver disease severity from 
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concordant JAG1 genotypes is around OR = 2, then we would need to at least 60 samples to 
achieve enough power to detect an association. 
3.2.2 SNP Association Analysis 
Since there was no evidence that the JAG1 gene itself affected liver disease severity, we 
carried out a GWA study to look for regions influencing this phenotype. Figure 3-5 is a Manhattan 
plot of the p-values from all the SNP markers tested using EMMAX. None of the markers passed 
our p-value threshold cutoff for genome-wide significance (p < 5x10-8). However, there were one 
marker in 6q27 (rs7382539 with p = 1.8x10-6) and two markers in 9q33.2 (rs944961 with 
p = 2.3x10-6 and rs2900162 with p = 8.5x10-6) that reached the suggestive p-value threshold 
cutoff (p < 1x10-5). 
The marker with the lowest p-value, rs7382539, was located at 6q27 just upstream (14kb) 
of thrombospondin 2 (THBS2). This marker is in linkage disequilibrium (LD) (0.2 < r2 % 1) with 
SNPs in the region approximately 2kb upstream of THBS2 in the 1000 Genomes European (EUR) 
reference superpopulation, and this LD region is indicated in blue in Figure 3-6. A regional 
association plot of the genotyped and imputed SNPs in and around this region is shown in Figure 
3-7 with p-values calculated from an additive linear model. SNP rs4078087 is in perfect 
correlation with rs7382539 (r2 = 1), and is the strongest SNP signal in the region after imputation. 
A second imputed SNP (rs7451470) appears to have the same magnitude of significance as the 
most significant genotyped SNP in the region. These three SNPs are strongly correlated with 
each other and have a stronger association with liver disease severity than other SNPs in the 
region. Upon closer inspection of the ENCODE histone modification peaks in this marker region 
(ENCODE Project Consortium 2012), we observed histone marks that may be indicative of 
enhancer activity (Creyghton et al. 2010), peaks for both acetylated histone H3 lysine 27 
(H3K27Ac) and monomethylated histone H3 lysine 4 (H3K4Me1) as depicted in Figure 3-6. 
The second and third ranking markers were located on 9q33.2, almost 500kb away from 
the proximal flanking genes, deleted in bladder cancer protein 1 (DBC1) and CDK5 Regulatory 
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Subunit-Associated Protein 2 (CDK5RAP2). The extent of LD around these markers does not 
extend to these genes. The regions tagged by these markers did not have any histone 
modification peaks (H3K27Ac, H3K4Me1, and H3K4Me3) and were not in any DNase I 
hypersensitivity clusters (ENCODE Project Consortium 2012). Figure 3-8 is a regional association 
plot of the genotyped and imputed SNPs in this region. Even though imputed markers were also 
tested, the top SNP signal in this region is still the genotyped SNP (rs944961). 
3.2.3 CNV Association Analysis 
In addition to the association study using SNPs, we also investigated association with 
CNVs. There were 11 CNV regions (CNVRs) that were associated with liver disease severity of 
ALGS patients, based on a nominal p-value (p % 0.05), and these CNVRs are tabulated in Table 
3-2. Three were copy number losses enriched in ALGS patients with severe liver disease, 2 were 
copy number gains enriched in patients with severe liver disease, and 6 were copy number gains 
enriched in patients with mild liver disease. There were no copy number losses that were 
enriched in patients with mild liver disease. 
Nine of the 11 CNVRs have parts of or an entire gene duplicated or deleted. Altogether, 
13 genes were affected, including a partial gene deletion of CYP2A6, partial gene duplications of 
GOLPH3, PDZD2, TM4SF20, ARHGEF10, ABO, PWWP2B, PQLC1, ADRM1, and LAMA5, and 
whole gene duplications of KCNG2 and MIR4758. We cannot be certain if there is a partial or 
whole gene duplication of KCNG2 and ULK1 reported in these CNVRs, because the nearest 
flanking SNP marker not in the CNVR is outside the gene. There were two CNVRs that affected 
two genes and one that affected three genes. 
The CNVRs that achieved the smallest p-values (p = 0.01) were at 8p23.3 and at 9q34.2. 
The 8p23.3 CNVR duplicated an entire exon of Rho Guanine Nucleotide Exchange Factor 10 
(ARHGEF10), while the 9q34.2 CNVR duplicated the first exon of histo-blood group ABO system 
transferase (ABO). The largest CNVR (63.3kb) was at 10q26.3, containing a duplication of 
possibly the entire PWWP Domain-Containing Protein 2B (PWWP2B) gene, as the first non-
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deleted SNP marker was 10kb upstream of the start of PWWP2B. The second largest CNVR was 
at 5p13.3 and it contained the most SNP markers (n = 25). This CNVR partially duplicated golgi 
phosphoprotein 3 (GOLPH3) and PDZ domain containing 2 (PDZD2). There was only one CNVR 
(p = 0.02) containing a gene deletion, and this CNVR disrupts cytochrome P450 2A6 (CYP2A6). 
3.3 Discussion 
The position of the JAG1 mutation does not appear to be associated with liver disease 
severity, as mutations are equally distributed throughout the different domains of the protein in 
both mild and severe liver disease patients. More compellingly, the frequency of full gene 
deletions was found to be similar between mild (9%) and severe (6%) liver disease patients. 
JAG1 mutations are predicted to cause haploinsufficiency, because even full gene deletions, 
which clearly have complete loss of one allele, appeared evenly distributed between the mild (9%) 
and severe (6%) liver disease patients. Upon investigation of the four major mutation types, 
protein truncating, splice site alteration, missense, and full gene deletions, there were no 
significant differences in their frequencies between mild liver disease and severe liver disease 
patients. A previous report has found that there was no phenotypic difference between the 
severity of JAG1 deletions and intragenic JAG1 mutations (Krantz et al. 1998). Consistently, the 
JAG1 deletions screened in our cohort were not significantly associated with mild or severe liver 
disease. 
There are very few sib-pairs that both inherit a mutated JAG1 allele, since ALGS is a rare, 
autosomal dominant disorder, with over half of the patients carrying a de novo mutation. With only 
26 affected sib-pairs, we would only be able to detect an association if the effect size of the 
normal allele was OR > 3. Moreover, to detect an association of the JAG1 normal allele with liver 
disease severity with a reasonable effect size (1.3 < OR < 1.8), we would need at least 100 
affected sib-pairs, and it will take many more years to enroll that many samples. Although we 
failed to detect a significant association, we can conclude that there is unlikely to be a strong 
modifier effect on liver disease severity coming from the normal JAG1 allele. 
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In the context of modifiers of liver disease severity given JAG1 haploinsufficiency, 
obvious gene candidates include genes that regulate JAG1 expression, genes that potentiate or 
compete with Jagged1 for binding with the Notch receptor, and downstream Notch signaling 
genes that are expressed in the liver or bile ducts. THBS2, the first gene implicated by the SNP 
association analysis, is a good candidate modifier gene of ALGS. THBS2 is known to enhance 
JAG-NOTCH binding and help to activate the Notch signaling pathway. THBS2 was found to bind 
directly with the JAG1-NOTCH3 complex. Furthermore, THBS2, but not THBS1, another protein 
in the thrombospondin family, enhances Notch signaling (Meng et al. 2009).  
In the 6q27 regional association plot, the SNPs yielding the three strongest signals were 
in strong LD with each other (r2 > 0.8). Moreover, these markers were two orders of magnitude 
more significant than the other SNP markers in the region. There appears to be a recombination 
site just upstream of THBS2, which is in agreement with our observation of an LD region around 
rs7382539 ending just upstream of the gene. Although the causal marker may not be in the 
coding sequence of THBS2, it can still potentially play a role in regulating this gene especially 
since there are marks of a poised enhancer in this region.  
Not much is known about the role of DBC1 and CDK5RAP2, the other two genes 
possibly implicated by the SNP association analysis, with respect to Notch signaling. DBC1 is 
thought to be a tumor suppressor gene, and its disruption has been associated with bladder 
cancer as well as non-small cell lung cancer (Edwards et al. 2002; Izumi et al. 2005). CDK5RAP2 
is highly expressed in the brain, and it plays an important role in centrosome cohesion (Bond et al. 
2005; Graser et al. 2007). Neither gene has been associated with the Notch signaling pathway. 
Variants located in the intergenic region between these two genes may still be important in 
conferring risk to ALGS liver disease severity, but we do not believe the association signal we 
detected is due to DBC1 or CDK5RAP2. Curiously, the p-values depicted in the regional 
association plot of 9q33.2 (Figure 3-8) do not seem to correlate as well with the top SNP signal in 
the region. 
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As these two loci only pass the threshold of a suggestive signal, the results should be 
interpreted with caution. It is possible that one or both of these signals are false positives, given 
that one false positive is expected when using this relaxed significance threshold. Because the 
top signal near THBS2 seems to be more biologically relevant, we are more confident about this 
association signal. Further investigation of this gene as a potential modifier of ALGS liver disease 
severity is warranted using reporter constructs or animal models. 
In the CNV association study, we also do not expect all the regions listed in Table 3-2 to 
be biologically relevant, but we believe this is a good candidate approach to identify regions and 
genes that may confer susceptibility to liver disease severity for experimental validation. Deletion 
CNVs can be easier to interpret than duplication CNVs; when they contain genes, the deletion 
results in premature termination or loss of one copy of a gene, and the effects of 
haploinsufficiency of many genes is well known from the cytogenetic and molecular genetics of 
disease literature. In the case of a homozygous deletion CNV, both copies of the gene are 
disrupted or lost. A duplication CNV that contains part or all of a gene can function in various 
ways. Its effect may derive from the region of the genome the duplication is inserted into rather 
than the duplication itself. A functional, whole gene duplication may also be problematic, 
especially for genes highly sensitive to dosage. A duplication can be benign, especially if the 
extra DNA sequence and the region it inserts into do not have a functional role. Thus, the effects 
of a duplicated CNVR cannot be predicted with just the array data alone, and they must be more 
carefully investigated in an experimental model. 
Of the three deletions enriched in patients with severe liver disease, only one contained a 
gene. The deletion CNVR of 19q13.2 spans CYP2A6 (p = 0.02), a gene involved in metabolizing 
xenobiotics. Cytochrome P450 genes such as CYP2A6 play an important role in drug metabolism 
and the clearance of toxic compounds (Johnson and Stout 2005). We can therefore hypothesize 
that disrupting one copy of CYP2A6 may impede toxin clearance and further damage a liver 
already suffering from toxic bile buildup due to bile duct paucity. 
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The two duplications enriched in patients with severe liver disease partially duplicated 3 
genes, GOLPH3 and PDZD2 on 5p13.3 and TM4SF20 on 2p36.3. Because these genes appear 
to only be partially duplicated, it is unlikely that this duplicated content is functional. Rather, if 
these CNVRs were to play a role, it would likely be due to a gene disruption caused by the 
inserted sequence or regulatory anomalies due to the inserted sequence containing a regulatory 
element. Tandem duplications are common because of the proximity of the site, but if inserted in 
an inverted orientation, they may disrupt these partially duplicated genes. GOLPH3 is a Golgi 
protein that is responsible for proper trafficking of vacuolar proteases (Dippold et al. 2009). This 
may be an important mechanism may modify the ALGS phenotype by reducing the cellular load 
by trafficking vacuolar proteases to break down mutated copies of JAG1 that do not properly 
signal. PDZD2 is a ubiquitously expressed protein on the endoplasmic reticulum. In addition, this 
protein can be transported into the nucleus and secreted by the cell. Although the function of this 
protein is unclear, PDZ domains often facilitate signaling, establish cell polarity, and direct protein 
trafficking. Both GOLPH3 and PDZD2 are interesting modifier candidates that can have a clear 
biological association with liver disease severity of ALGS. 
There were more duplications enriched in patients with mild liver disease than either 
deletion or duplication CNVRs enriched in patients with severe liver disease. The top two 
duplication CNVRs among the mild liver disease patients partially duplicate ARHGEF10 and ABO. 
ARHGEF10 is known to play a role in the formation of the mitotic spindle (Aoki et al. 2009), and 
ABO determines an individual’s ABO blood group (Ferguson-Smith et al. 1976). There is no 
obvious role for either of these genes in the determination of liver disease severity. The next 
duplication CNVR is in 10q26.3, but it is unclear whether the PWWP2B gene was completely or 
partially duplicated. Not much is known about this gene, but the PWWP domains are involved in 
DNA methylation, DNA repair, and transcription regulation (Qiu et al. 2002). In 18q23, PQLC1, 
Proline and Glutamine Loop Repeat-Containing Protein 1, was partially duplicated, and KCNG2, 
a potassium channel subunit (Pongs 1999), was entirely duplicated. Aside from its expression in 
mammalian liver, little is known about the role of PQLC1 in the liver (Yang et al. 2010b), and 
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potassium channels are more central to the nervous system than the hepatic system. Thus, the 
genes in the 18q23 duplication CNVR do not seem to have an established role in the liver. ULK1 
is entirely duplicated, and this gene is involved in the initial process of autophagy (Ganley et al. 
2009). In 20q13.33, the partial duplications of ADRM1, a proteasome-associated factor, 
(Jorgensen et al. 2006) and LAMA5, a heterotrimeric extracellular glycoprotein (Malinda and 
Kleinman 1996), do not appear as relevant as the whole duplication of MIR4758, a functional 
microRNA with a potentially relevant role in gene regulation (Persson et al. 2011). Because the 
inserted duplicated segment cannot be identified, it is difficult to interpret the function and 
significance of these duplications. Additional experimental work mapping the duplication and 
functional studies would need to be performed to understand the impact of these duplications. 
The data reported in Database of Genomic Variants (DGV), a catalog of CNV cohorts 
reported in the literature, indicates copy number duplications or deletions spanning the Notch 
ligands and receptors (Iafrate et al. 2004). The dosage changes in these genes could modify the 
effects of JAG1 haploinsufficiency. However, we did not observe any significant CNV association 
in any of the receptors or ligands. The CNV analysis provided several interesting genetic modifier 
candidates for liver disease severity including CYP2A6, GOLPH3, and PDZD2 to examine further 
in experimental studies. 
3.4 Materials and Methods 
Sample Cohort and Liver Disease Severity Stratification 
 The samples described in Chapter 2 were used in this investigation of genetic modifiers 
of liver disease severity in ALGS. Additionally, samples were enrolled from the Childhood Liver 
Disease Research Education Network (ChiLDREN) Consortium, a NIDDK-funded research 
network involving 16 pediatric centers across North America, including CHOP. Because we 
received de-identified samples from ChiLDREN, we had to address concerns of dual enrollment 
during the quality control of SNP array data. The DNA samples from ALGS patients enrolled in 
ChiLDREN were provided to us by the Rutgers University NIDDK biorepository. The clinical data 
87 
used for liver disease stratification was provided by the ChiLDREN data collection center at 
University of Michigan. 
The same criteria for liver disease stratification described in Table 2-6 used to stratify our 
internal cohort was used to stratify the ChiLDREN samples into categories of mild and severe 
liver disease. As before, only subjects with a confirmed JAG1 mutation were used for this study. 
The liver disease severity, mild and severe, was used as a binary classifier of phenotype. Due to 
the aforementioned conditions, investigation of liver disease severity was limited only to ALGS 
patients older than 5 years of age. The stratification criteria were carefully determined by a group 
of hepatologists treating children with ALGS. 
Analysis of the JAG1 Mutation 
 We tallied the number of patients with stratified liver disease severity based on the exonic 
location of the mutation. The patients with translocations, partial gene deletions, and partial gene 
duplications were omitted. We used a standard !2 test with three degrees of freedom to examine 
association between the type of JAG1 mutation and the mild and severe liver disease patients 
using the four major categories of mutations, which include a full gene deletion, mutations altering 
splice sites, mutations that prematurely truncate the protein, and missense mutations. 
Sib-Pair Analysis 
There were 26 quartets in our cohort with enough clinical data and available DNA sample 
to include in our affected sib-pair analysis. In these families, the siblings inherited the JAG1 
mutation from an affected parent. Patients were stratified based on their liver disease severity, 
and expert clinicians evaluated concordance or discordance of phenotype in these sib-pairs. 
 Nine coding SNPs, rs1051415, rs1801138, rs1131695, rs1051419, rs1051421, 
rs10485741, rs1801140, rs114048678, rs35761929, present in these subjects were used to 
identify the normal JAG1 allele from the unaffected parent. Sequencing was carried out using 
PCR primer sequences and established experimental protocols on all members of the quartet 
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(Warthen et al. 2006). Siblings with concordant genotypes shared the same paternal and 
maternal JAG1 alleles, whereas siblings with discordant genotypes only shared the same 
mutated JAG1 allele. These sib-pairs were grouped into four categories based on this binary 
classification of genotype and phenotype. 
 A one-sided Fisher’s exact test for significance was employed to test genotype-
phenotype correlation between normal JAG1 allele and degree of liver disease severity. We 
simulated 10,000 datasets to calculate power at sample sizes ranging from 5 to 100 sib-pairs by 
increments of 5 at a range of OR between 1.2 and 3.5. Similarly, we also used this dataset to 
investigate the minimum effect size to detect an association given our sample size along with the 
number of sib-pairs needed to detect various effect sizes. 
Sample Preparation and Quality Control 
In total, we genotyped 259 ALGS patients with a liver disease phenotype using the 
Omni1 and OmniExpress SNP arrays (Illumina, San Diego, CA). The use of two genotyping 
platforms could not be avoided, because the vendor abruptly discontinued production of the 
Omni1 SNP array halfway into our study. Thus, DNA from 138 samples were genotyped on the 
Omni1 array and 121 remaining samples were genotyped on the OmniExpress array using 
services provided by the CAG. 
Samples from both platforms were merged together into one dataset, keeping only the 
705,132 markers that are present on both platforms. We followed standard quality control 
procedures to select samples and SNPs for the association test. SNPs with a minor allele 
frequency (MAF) < 0.05, with a missing rate > 0.05, or that did not follow Hardy-Weinberg 
equilibrium in mild or severe patients (Phwe < 0.00001) were removed. The remaining 579,677 
SNP markers were used to test for association. Individuals with a call rate < 0.95 were also 
removed. Analysis of heterozygosity rate on chromosome X found no gender discrepancies in our 
sample cohort. 
89 
Because of concerns of population stratification, we chose to focus on Caucasian 
subjects, our largest ethnic population, for this association study. We inferred European ancestry 
using Multi-Dimensional Scaling (MDS) implemented in the PLINK software (Purcell et al. 2007). 
MDS was performed on our samples and existing HapMap dataset of 4 populations, Utah 
residents with ancestry from northern and western Europe (CEU), Han Chinese in Beijing, China 
(CHB), Japanese in Tokyo, Japan (JPT), and Yoruba in Ibadan, Nigeria (YRI) (International 
HapMap Consortium 2003). As expected, our self-reported Caucasian subjects cluster closely 
with the CEU and our self-reported Asian samples clustered closely with CHB and JPT. This 
result is shown in Figure 3-9. From the first two components, C1 and C2, we selected individuals 
with -0.0525 < C1 < -0.04 and -0.04 < C2 < -0.03 as our cohort of patients with European 
ancestry.  
 Since samples came from two sources, our internal CHOP cohort and the ChiLDREN 
consortium, there could be patients enrolled in both cohorts. To identify identical and related 
individuals, we calculated genome-wide identity-by-state (IBS) estimates for all pairwise 
comparisons among all patients. We were able to detect individuals that shared a significant 
portion of their genome by the " value, estimated frequency of identity by descent, in these 
pairwise calculations. Due to the rarity of this disorder, to maximize the power of our analysis we 
included related individuals into this study. We found 11 samples that were enrolled twice into this 
study, once in the CHOP cohort and once in ChiLDREN (" = 1.0). The remaining subject pairs 
with " > 0.15 were accounted for by our existing knowledge of their relationships, except one pair. 
We suspect that in this pair with " = 0.52 and Z1 = 0.95 indicating that most of the genome has 
one shared allele between the two individuals, the de-identified ChiLDREN proband is the child of 
the sample we collected in our internal cohort. In this pedigree, we were unable to obtain DNA on 
the affected proband through our internal cohort. There were three pairs of monozygotic twins 
with concordant liver disease severity, and one proband from each pair was removed for 
subsequent analysis. 
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We checked for additional biases by plotting a quantile-quantile (Q-Q) plot in Figure 3-10 
of the p-values from the !2 distribution using the standard allelic test. The genomic inflation factor, 
calculated using the method described (Devlin and Roeder 1999), was # = 1.013, which does not 
appear to be significantly inflated. 
SNP Association Analysis 
After sample quality control, 97 mild liver disease and 64 severe liver disease patients 
remained for our association study. Because this includes related individuals, we could not use 
the standard !2 allelic test for association that requires samples to be independent. Instead, we 
used EMMAX, an efficient implementation of the variance component approach that accounts for 
sample structure (Kang et al. 2010). We did not observe any genomic inflation in the Q-Q plot 
(Figure 3-10) of the observed p-values against the expected p-values from a uniform distribution 
(# = 1.005). 
 The standard accepted genome-level threshold for significance is 5x10-8. Using a 
Bonferroni correction for the number of SNPs we tested, a 0.05 Type I error rate requires a 
threshold of 8.6x10-8. We considered SNPs that reached the suggestive threshold of 1x10-5, a 
threshold in which Duggal et al, calculated would yield one false positive association per GWAS 
for populations of European ancestry (Duggal et al. 2008). 
Imputation 
 For a finer resolution of the genome, we used genotyped SNP markers to impute SNPs 
that were not genotyped using IMPUTE2 (Howie et al. 2009). Reference haplotypes were 
provided from the 1000 Genomes Phase I dataset that is comprised of 1,092 individuals (1000 
Genomes Project Consortium 2012). Testing only biallelic markers, the output from imputation 
gives a probability score for each of the three possible genotypes. Following the software 
recommendations, SNPs with INFO < 0.8 were removed from subsequent analysis. 
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 The imputed dataset could not be analyzed using EMMAX, because the statistical 
analysis of imputed data requires that uncertainty in the imputed genotypes is taken into account 
with weights proportional to their probabilities. Instead, we utilized SNPTEST and performed our 
test for association using an additive linear model (Marchini et al. 2007). Only the top loci were 
reanalyzed using imputed data for a finer resolution of the region. Plots of each loci were 
generated using LocusZoom (Pruim et al. 2010). 
CNV Association Analysis 
 As in the SNP association study, only samples of European ancestry (call rate > 0.95) 
from the SNP array data were used for the CNV association study. Because our association 
approach for this analysis requires independent observations, we also removed one sample from 
all pairs of related individuals. We chose to keep only the proband whenever possible, because 
we have the greatest information on this patient for phenotype stratification. In this study, we 
examined 69 mild and 64 severe liver disease patients for CNV association to liver disease 
severity in ALGS. 
From the SNP genotyping data, we extracted the intensity and allele frequency data in 
the form of a log R ratio (LRR) and B allele frequency (BAF) for markers found on both arrays. 
Using these two data values with respect to the marker position, we implemented a hidden 
Markov model (HMM) approach to CNV detection through the PennCNV software (Wang et al. 
2007). 
We performed Fisher’s exact test for association of liver disease severity and copy 
number variation, analyzing copy number gains and copy number losses separately. The tests for 
association was initially performed on the smallest unit of a CNV as previously described by 
Glessner et al. to overcome the poor breakpoint resolution of CNVs identified by the CNV-calling 
algorithm (Glessner et al. 2009). The CNVs were broken down to 2-marker regions. However, 
these fragments do not represent independent regions. After performing tests for significance, we 
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stitched up these observations in regions with nominally significant p-values (p < 0.05) into 
CNVRs, keeping only the CNVRs comprised of 5 or more SNPs.  
Even though CNVs are a genome-wide occurrence, their prevalence and larger size 
leads to fewer observations than SNPs of many orders of magnitude. We chose not to correct for 
multiple testing because of the relatively few occurrences of common CNVs and the lack of 
observations of rare and even sometimes common CNVs in most individuals. Furthermore, our 
sample size is modest and we do not expect to find many significant CNVRs. We reviewed each 
nominally significant CNVR and evaluated them based on the biological significance of their 
presence. 
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Table 3-1. Association Test for 26 Sib-Pairs. 
The number of sib-pairs with liver phenotype information and JAG1 genotype information are 
tallied above. Of the 5 concordant phenotype and genotype sib-pairs, only one pair had severe 
liver disease. For a 1-sided Fisher’s exact test on the observations tabulated above, there is no 
significant association between the normal JAG1 allele and liver disease severity (p=0.28). 
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Table 3-2. CNVRs Associated with Liver Disease Severity in ALGS Patients. 
This table depicts all the CNV regions with p % 0.05 that are associated with liver disease severity 
in ALGS patients. I-IV breaks down the results into deletion CNVRs enriched in patients with 
severe liver disease, duplication CNVRs enriched in patients with severe liver disease, deletion 
CNVRs enriched in patients with mild liver disease, and duplication CNVRs enriched in patients 
with mild liver disease, respectively. 
Mild Severe Mild Severe
19:41350895-
41356751 19q13.2 5 5.9 0 5 69 59 0.02
cannot be
calculated CYP2A6
Involved in xenobiotic
metabolism
8:5599399-
5602637 8p23.2 7 3.2 4 12 65 52 0.03
3.7
(1.0-16.7) none
2:195979780-
195982450 2q32.3 5 2.7 2 8 67 56 0.05
4.7
(0-47.5) none
Mild Severe Mild Severe
5:32107381-
32159517 5p13.3 25 52.1 0 5 69 59 0.02
cannot be
calculated
GOLPH3
PDZD2
Golgi protein; PDZ domain
containing protein
2:228243905-
228258288 2q36.3 7 14.4 1 7 68 57 0.03
8.2
(1.0-381.1) TM4SF20
Transmembrane protein in
gut epithelial cells
none
Mild Severe Mild Severe
8:1784859-
1806229 8p23.3 10 21.4 14 3 55 61 0.01
5.1
(1.3-29.3) ARHGEF10
Involved in mitotic spindle
formation
9:136131002-
136131905 9q34.2 8 0.9 10 1 59 63 0.01
10.5
(1.4-469.5) ABO
Histo-blood group ABO
system transferase
10:134213897-
134277154 10q26.3 16 63.3 13 3 56 61 0.02
4.7
(1.2-26.9) PWWP2B
PWWP Domain-Containing
Protein 2B
18:77607884-
77648218 18q23 12 40.3 13 3 56 61 0.02
4.7
(1.2-26.9)
KCNG2
PQLC1
Potassium channel subunit;
Proline and Glutamine Loop
Repeat-Containing Protein 1
12:132381920-
132400309 12q24.33 7 18.4 10 2 59 62 0.03
5.2
(1.0-50.7) ULK1
Involved in initial process of
autophagy
20:60880653-
60909518 20q13.33 19 28.9 17 7 52 57 0.05
2.6
(0.9-8.2)
ADRM1
LAMA5
MIR4758
Proteasome-associated
factor; Developmental
protein; miroRNA
Gene(s) in
CNVR
Description
Description
Description of Genes in
CNVR
II. Duplications Enriched in Patients with Severe Liver Disease
IV. Duplications Enriched in Patients with Mild Liver Disease
III. Deletions Enriched in Patients with Mild Liver Disease
P value
OR
(95% CI)
CNVR
CNVR
Samples with
Duplication(s)
Diploid
Samples
I. Deletions Enriched in Patients with Severe Liver Disease
P value
OR
(95% CI)
Band
No. of
SNPs
Size
(kb)
Samples with
Deletion(s)
Diploid
Samples
Samples with
Duplication(s)
Diploid
Samples
Gene in CNVR
Gene(s) in
CNVR
P value
OR
(95% CI)
Band
No. of
SNPs
Size
(kb)
No. of
SNPs
Size
(kb)BandCNVR
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Figure 3-1. Distribution of JAG1 Mutations and Liver Disease Severity. 
The protein domains of JAG1 and the respective exons are depicted above. There are mutations 
in every domain of the JAG1 protein. There are 201 ALGS patients with JAG1 mutations and a 
classified liver phenotype (mild or severe liver disease) in the chart above. A few mutation types 
such as translocations, splice site alterations, cryptic splice sites, partial gene deletions, and 
partial gene duplications were not represented in this graph. 
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Figure 3-2. Distribution of Liver Disease Severity and JAG1 Mutation Types. 
The classification of JAG1 mutation types for mild and severe liver disease is pictured above. 
There were 103 patients with mild liver disease and 73 with severe liver disease whose mutations 
could be classified into the four categories listed above. The most notable difference is the 
increased number of missense mutations in the mild liver disease category (65 v. 55 patients). 
However, there was still no significant difference observed between the 4 mutation types and liver 
disease severity. 
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Figure 3-3. Power Analysis of Sib-Pairs at Different Effect Sizes. 
Power was calculated for each condition, number of sib-pairs and odds ratio, using simulated 
data (n=10,000). Given only 26 sib-pairs, there was no power to observe a reasonable effect size 
(OR < 3) of the normal allele on liver disease severity. Furthermore, more than 100 sib-pairs are 
needed to capture biologically relevant effect sizes, and this is beyond the scope of this study.
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Figure 3-4. Average P-Values for Different Simulated Conditions of Sib-Pairs and Effect Sizes. 
Each sample size and odds ratio was simulated 10,000 times to calculate the expected p-value at 
the given conditions. From this, we observe that with 26 sib-pairs, we would expect to a p=0.28 if 
the underlying effect size was small or negligible (OR<1.5). Furthermore, we are likely to require 
at least 100 sib-pairs to achieve a significant p-value for this small effect size. 
20 40 60 80 100
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Simulated Data n=1000
Number of Sib-Pairs
p-
va
lu
e
Odds Ratio
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2
2.5
3
3.5
99 
 
Figure 3-5. Manhattan Plot of Association of Liver Disease Severity in ALGS Patients. 
In this plot, the red line indicates a standard genome-level significance threshold (p=5x10-8) and 
the blue line indicates the suggestive p-value threshold (p=1x10-5) for samples of European 
ancestry. The three SNPs that passed the suggestive p-value threshold were rs7382539 
(p=1.8x10-6) on chromosome 6, and rs944961 (p=2.3x10-6) and rs2900162 (p=8.5x10-6) on 
chromosome 9. 
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Figure 3-6. Top SNP signal and the proximal THBS2 gene. 
In this figure, a red arrow indicates the site of the top signal from the SNP association study, 14kb 
upstream of the transcription start site of THBS2. This region is also marked by H3K27Ac and 
H3K4Me1 peaks, which indicate a potential enhancer site. The solid blue bar depicts the LD 
region of all SNP markers with r2 > 0.2 with rs7382539. 
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Figure 3-7. Regional Association Plot of 6q27. 
This regional plot depicts the p-values obtained from an additive linear test on the genotyped 
(circle) and imputed (square) markers in the region. The recombination rate is calculated from the 
1000 Genomes Phase I dataset of subjects with European ancestry. The top three markers are in 
strong LD with each other, and LD around them taper off just upstream of the THBS2 gene.
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Figure 3-8. Regional Association Plot of 9q33.2. 
This is a regional plot of genotyped (circle) and imputed (square) markers in the 9q33.2 region, 
the region that contains the second and third most significant SNP markers from the variance 
component analysis. Interestingly, the two genotyped markers that reached suggestive genome-
level significance appear to be weakly correlated. Furthermore, there are many SNP markers with 
little correlation to the top signal in this region, but similar p-values as those exhibiting modest 
correlation with it. 
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Figure 3-9. MDS Plot of ALGS Patients with Mild and Severe Liver Disease. 
This plot depicts the ALGS patients with mild and severe liver disease plotted on top of the 
original 4 HapMap populations. As expected from the self-reported ethnicities, the majority of our 
cohort is Caucasian. We selected the individuals inside the boxed region as our cohort of patients 
with European ancestry.  
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Figure 3-10. Q-Q Plot of Association Study. 
In (a), the Q-Q plot is from the data from the observed p-values in the standard allelic association 
test. In (b), the Q-Q plot is from the observed p-values from our variance component model. 
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CHAPTER 4: Investigation of a 10q25.1 Association Signal in BA 
4.1 Introduction 
Biliary atresia (BA) is a disease of the liver and bile ducts affecting neonates in the first 
months of life. BA is a progressive idiopathic, necroinflammatory process initially limited to the 
extrahepatic biliary tree, but the progressive obliteration of the extrahepatic bile duct lumen leads 
to obstruction of bile flow resulting in cholestasis and chronic liver damage. If left uncorrected, the 
mortality rate is 100%. BA is the most common indication for liver transplantation in children. Fifty 
percent of affected individuals undergo transplantation by two years of age and 80% undergo 
transplantation by twenty years of age (Erlichman et al. 2009; Mack and Sokol 2005; Shneider et 
al. 2006). 
The incidence rate of BA varies across ethnic groups. It is more commonly found in Asian 
populations including those living in Asia as well as those living in the United States. The 
incidence rate is 0.6, 1.0, 1.7, 2.0, and 3.0 per 10,000 live births for the respective Caucasian, 
Japanese, Taiwanese, Filipinos in Hawaii, and Chinese in Hawaii populations (Muraji et al. 2009). 
While the etiology of BA is unknown, it is proposed to be multi-factorial, with infectious, 
inflammatory, and genetic risk factors (Shneider et al. 2006). 
A previous GWA study of Chinese individuals (324 BA cases, 481 controls) identified a 
region on chromosome 10q as a potential susceptibility locus. The most significant finding was 
association with SNP rs17095355 (p = 6.94x10-9) on chromosome 10 at position 111735750 
(hg19) (Garcia-Barcelo et al. 2010). This SNP is located upstream of two genes expressed in the 
hepatobiliary system, XPNPEP1, encoding X-Prolyl Aminopeptidase 1, and ADD3, encoding an 
F-actin binding protein called adducin 3 (Citterio et al. 2003; Ersahin et al. 2005). Association with 
the same SNP was replicated in a Thai cohort (p < 0.003) of 124 BA cases compared against 114 
controls (Kaewkiattiyot et al. 2011). Both of these investigations were conducted on Asian 
subjects and there has been no report of this association in other ethnic groups. We investigated 
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this region in our data from an ongoing GWAS study in a Caucasian cohort to test if this locus 
affects risk of BA in a non-Asian population. 
4.2 Results 
4.2.1 Association Study of 10q25.1 From Genotyped Data 
In order to test for the effects of population stratification, we calculated a genomic 
inflation factor (&) based on the genome-wide association tests. The value of & was estimated to 
be 1.01, and therefore no strong evidence for substructure was detected in our sample. A Q-Q 
plot of the observed p-values did not indicate significant deviation from the expected values 
(Figure 4-1).  
Looking at association test results for the SNPs genotyped on the array in our Caucasian 
cohort, we searched for a signal at the 10q25.1 locus previously reported to be associated with 
BA in a Chinese study. We found no SNPs that achieved genome-wide significance at this locus 
(Figure 4-2A). The significance of rs17095355 was unknown because it was not present on the 
array platform used to genotype our samples. However, SNPs strongly correlated with it based on 
the HapMap 3 samples of Chinese descent (CHB + CHD) (r2 = 0.99) achieved nominal 
significance (p < 0.03) (Table 4-1).  
4.2.2 Fine-mapping of the 10q25.1 Region Following Imputation 
An exploratory analysis of the candidate region haplotype structures in HapMap 3 
Chinese and Caucasian data was performed to better understand variability at this locus. The LD 
plots generated from the genotypes of the Han Chinese in Beijing, China (CHB) (Figure 4-3A) 
and of the United States residents of western and northern European ancestry from Utah and 
Tuscans in Italy (CEU+TSI) (Figure 4-3B) depict the diversity of this region between ethnic 
groups. The bars above the LD plots represent haplotype blocks defined according to the default 
algorithm in Haploview (Gabriel et al. 2002). In the Chinese population studied, the LD block 
containing rs17095355 is strongly correlated with a neighboring LD block (r2 = 0.91). Together, 
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these two blocks partially encompass both XPNPEP1 and ADD3. To extensively cover the 
biologically relevant regions of these genes, we performed subsequent analysis on all SNPs 
included in the genomic region from 5kb downstream of XPNPEP1 to 5kb downstream of ADD3 
(chr10:111619000-111901000 in hg19 coordinates).  
Following SNP imputation, we performed an association test on 333 SNPs in the 
candidate region correcting for the first two MDS components. Results for the most significant 
imputed (rs7099604) and genotyped (rs12569425 and rs7069128) SNPs are listed in Table 4-1. 
Also, rs17095355 and the genotyped SNPs most highly correlated with it (rs921348 and 
rs7906904) are included. While rs17095355 was nominally significant (p = 0.026), it was not the 
most significant SNP in this region. The strongest signal came from rs7099604 (p = 0.002), a 
SNP that lies in the first intronic region of ADD3 (Table 4-1). This SNP was not reported in the 
published association study (Garcia-Barcelo et al. 2010), and it is only moderately correlated with 
rs17095355 (r2 = 0.49 in 197 1000G Phase I CHB + CHD samples). The SNPs most strongly 
correlated with rs7099604 in the 1000G Phase I CHB + CHD samples showed p-values of around 
10-4 in the Chinese BA GWAS (Garcia-Barcelo et al. 2010).  
 Most markers achieving marginal significance (p % 0.05) were highly correlated (r2 > 0.6) 
with rs7099604 but a handful had low correlation (r2 < 0.2). To explore if multiple independent 
SNPs in this region may be associated with BA, we performed additional association tests 
conditional on the genotype at rs7099604. The results are reported in Figure 4-2B. Overall the 
association was less significant for the SNPs in the intergenic region, including rs17095355 
(conditional association p = 0.917), and in ADD3. Curiously, a few markers in XPNPEP1 that did 
not reach nominal significance or were barely significant (p = 0.04) have an increased 
significance with the conditional association test. Conversely, we also performed an association 
test of this region conditional on rs17095355 and found that rs7099604 remains borderline 
significant (conditional association test p = 0.053). 
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4.2.3 Confirmation of Imputation Results 
 We determined the genotype at rs7099604 of 58 patients with confidently imputed 
genotypes. These genotypes were determined by Sanger sequencing, and 5 of 5 GG, 28 of 29 
AG, and 20 of 24 AA genotypes were correctly imputed. The 4 incorrectly predicted AA 
genotypes were determined to be either AG (n = 3) or GG (n = 1). The incorrectly predicted AG 
genotype was confirmed to be GG. The genotypes in 4 of 8 patients genotyped on the older 
HumanHap 550v3 SNP arrays and experimentally checked via Sanger sequencing did not 
validate. However, only one of the 49 patients genotyped on the HumanHap 610 SNP array and 
experimentally checked was imputed incorrectly (2% error rate). These experimental findings also 
show that the imputation algorithm was conservative when predicting a deviation from the major 
allele, as the error in genotypes underestimated the prevalence of the risk allele, G. From the 
experimental validation, we believe the imputed data is reliable and suitable for downstream 
analysis. 
4.3.4 Localization of XPNPEP1 and ADD3 
The function of X-prolyl aminopeptidases is to breakdown bradykinin, a peptide that participates 
in regulating blood pressure and this aminopeptidase can be inhibited by apstatin (Li et al. 2011b). 
XPNPEP1 is ubiquitously expressed throughout the body, with the most expression found in the 
small intestine. The role of XPNPEP1 in the liver and hepatobiliary tract has not been established, 
although an increased expression of serum leucine aminopeptidase has been associated with 
several hepatobiliary diseases affecting intrahepatic or extrahepatic bile ducts (Kowlessar et al. 
1961). From the immunohistochemistry stains of liver sample tissue, we showed that XPNPEP1 
is present in both hepatocytes as well as the biliary epithelium in normal and diseased livers 
(Figure 4-4A). Moreover, protein expression of XPNPEP1 was also present in the extrahepatic 
biliary epithelium, but not in the surrounding fibrous tissue. 
The adducin gene family has an established association with hypertension (Cusi et al. 
1997). Although adducin proteins are known to be ubiquitously expressed membrane-skeletal 
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proteins, the presence of ADD3 in the hepatobiliary system has not been described. By 
immunohistochemistry, we found evidence of ADD3 expression in the biliary epithelium (Figure 4-
4B), but there seemed to be little or no expression of ADD3 in the surrounding hepatic cells. 
ADD3 was also present in the extrahepatic biliary epithelium (Figure 4-4B). 
4.2.5 Expression of XPNPEP1 and ADD3 
The expression of XPNPEP1 and ADD3 was measured in the liver of normal control (NC), 
diseased control (DC) and BA subjects by qPCR. There did not seem to be any apparent 
differences in XPNPEP1 expression between the three groups of patients (Figure 4-5A). However 
there was a significant difference in the level of expression of ADD3 between BA and normal 
control subjects (p < 0.001) (Figure 4-5B). No significant difference was observed between the 
diseased control group and the normal controls as well as the BA group. We also investigated the 
possibility of the expression of these two genes being linked to the underlying genotype at the 
significantly associated SNP rs7099604 (Figure 4-6). Although the sample size is small, there did 
not seem to be any correlation of rs7099604 genotype with expression of XPNPEP1 (p = 0.34) 
and ADD3 (p = 0.61). 
4.2.6 ADD3 Gene Sequencing 
We looked for coding changes in ADD3 by sequencing 60 patients. Sanger sequencing was 
carried out in a diverse representation of patients with rs7099604 genotypes (14 AA, 43 AG, 3 
GG), but we did not identify any deviation from the human reference genome. 
4.3 Discussion 
Findings in 10q25.1 
Two independent studies in Asian patients showed an association of 10q25.1 variants 
with BA (Garcia-Barcelo et al. 2010; Kaewkiattiyot et al. 2011). Our investigation of genotyped 
and imputed SNPs in this region indicates that the association to BA at this locus is also present 
in Caucasians. However, we find that while rs17095355, the most significant SNP in Asian 
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samples, is also nominally significant in our cohort, rs7099604 in the first intron of ADD3 has a 
stronger signal in our Caucasian cohort. These differences may be attributed to regional 
differences in haplotype structure (Figure 4-3) as well as variation in the minor allele frequency of 
these SNPs between the two ethnic groups. The dbSNP data on the frequency distribution of 
rs17095355, the candidate BA SNP reported in two Asian cohorts, show a large disparity in allele 
frequencies between Asians and Caucasians as well as within Caucasians (Figure 4-7). The 
lower level of LD in this region combined with decreased prevalence of the polymorphism at 
rs17095355 in Caucasians may have decreased our power to detect an association with BA. 
Even so, the marginally significant p-value from a conditional association test on rs17095355 
indicates a residual association at rs7099604 that is not accounted for by the previously reported 
SNP. Our data suggests that while rs17095355 could be a good marker of the true signal in 
10q25.1 in the Asian population, it may not necessarily be the best marker of the underlying 
signal in the European population. We propose rs7099604 as a better marker of the true 
association at 10q25.1 than rs17095355 in a Caucasian cohort, and its intronic location indicates 
ADD3 as the more relevant gene to the etiology of BA. 
The negative findings from ADD3 exon sequencing in 60 BA patients suggest that the 
association signal is not from a direct change in its coding sequence. It is possible that the causal 
variant responsible for the association signal could alter the function of a regulatory element. The 
top two associated SNPs are intronic to ADD3, but the third most significant SNP, rs7067604, lies 
33kb upstream of ADD3. This SNP lies in a strong enhancer region in the HepG2 cell line from 
the ENCODE data (Rosenbloom et al. 2013). 
Implication of ADD3 in BA 
As the LD block containing the association signal on 10q25.1 spans XPNPEP1 and 
ADD3, it has been difficult to conclude where the signal arises. Both genes are expressed in the 
biliary epithelium and are downstream of the previously reported associated SNP. Interestingly, 
ADD3 seems to stain more specifically for the bile ducts, whereas XPNPEP1 seems to be more 
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ubiquitously expressed in the liver. Our most significant signal is an intronic polymorphism in 
ADD3, although the genotype at this SNP does not seem to directly correlate with the expression 
of ADD3. Examination of the intrahepatic biliary tree revealed that zebrafish with a gene 
knockdown of xpnpep1 exhibited little or no biliary abnormalities, but biliary defects were present 
in the add3a knockdown construct (R.P. Matthews, personal communication). These results 
seem to correspond well with the gene expression data, indicating no difference between 
XPNPEP1 expression in BA and the control cohorts and a significant difference between ADD3 
expression in BA and the normal control cohort. More recently, a publication by Cheng et al. also 
reported ADD3 as a likely candidate gene for BA. They found that the Chinese BA patients with 
the risk haplotype had significantly lower expression of ADD3 suggesting that the risk haplotype 
can contribute to BA by decreasing ADD3 expression (Cheng et al. 2013).  
In conclusion, we demonstrated that the 10q25.1 region reported in Asian populations is 
also significantly associated with BA in the Caucasian population. While the original association 
signal lies upstream of XPNPEP1 and ADD3, SNP imputation in this region suggests a stronger 
association signal intronic to ADD3 and supports its role as a BA susceptibility gene.  
4.4 Materials and Methods 
Sample Collection 
The BA patients in this studied were enrolled through two studies. The majority of the BA 
patients (n = 240) were enrolled under IRB-approved protocols in the ChiLDREN. The remaining 
BA patients (n = 51) were followed at CHOP and directly enrolled into an IRB-approved study at 
this institution. These patients had a diagnosis of BA made by clinical presentation, liver histology, 
and intra-operative cholangiogram. Most patients also had the diagnosis confirmed by 
examination of the biliary remnant from a Roux-en-Y hepatic portoenterostomy (Kasai operation). 
The DNA samples from patients enrolled in ChiLDREN were provided by the Rutgers University 
NIDDK biorepository (Shneider et al. 2012). The DNA samples of patients enrolled at CHOP were 
extracted from peripheral blood using the 5Prime DNA extraction kit or from lymphoblastoid cell 
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lines transformed from peripheral blood. The genotypes of 3,000 healthy controls were supplied 
by the CAG. These healthy individuals were enrolled from several different primary care clinics in 
the Greater Philadelphia region through an IRB approved protocol (Shaikh et al. 2009). All 
samples were genotyped by the CAG on the HumanHap 610 Quad SNP BeadArray (Illumina, 
San Diego, CA), with the exception of 11 BA patients genotyped on the HumanHap 550v3 SNP 
BeadArray for a previous study (Cui et al. 2013; Leyva-Vega et al. 2010). 
The liver biopsies and clinical data for the samples used in the qPCR expression assays 
were obtained from infants with cholestasis enrolled into a prospective study of the ChiLDREN or 
from infants evaluated at Cincinnati Children’s Hospital Medical Center through the participating 
institution’s IRB-approved protocols. For subjects with BA, liver biopsies were obtained from 64 
infants during the preoperative workup or at the time of intraoperative cholangiogram (age: 66.1 ± 
26.6 days). Subjects with intrahepatic cholestasis served as diseased controls (DC). Liver biopsy 
samples were obtained percutaneously or intraoperatively from 14 infants at the time of 
diagnostic evaluation (age: 77.1 ± 48.7 days). This group consisted of children diagnosed with 
Alagille syndrome (n = 1), ABCB4 deficiency (n = 2), alpha-1-antitrypsin deficiency (n = 2), and 
cholestasis with unknown etiology (n = 9). A separate group of normal controls (NC) consisted of 
liver biopsy samples obtained from deceased-donor children aged 22-42 months (n = 7) as 
described previously (Li et al. 2011a). All samples were obtained after informed consent from 
patients' parents or legal guardians. 
SNP Array Quality Control 
The genotypes from the HumanHap 550v3 and 610 Quad BeadArrays were merged 
together. The markers unique to the 550v3 were excluded from further analysis and the markers 
unique to the 610 Quad were set to missing in the 11 samples genotyped on the 550v3 array. 
There were 551,044 markers that passed quality control filtering criteria (Figure 4-8). 
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A genetically matched set of cases and controls was identified from the SNP array data 
(Figure 4-9 for detailed selection criteria). Of the 229 BA patients with self-reported ethnicity, 169 
(74%) were self-reported Caucasian, 33 (14%) were African American, 31 (14%) were Hispanic, 
7 (3%) were Asian, 1 was American Indian or Alaska Native, 1 was Native Hawaiian or Other 
Pacific Islander, and the remaining reported an unlisted ethnicity. For our analysis, we chose to 
focus on Caucasians because they were the largest ethnic group in our cohort. We clustered all 
the subjects using MDS algorithm in PLINK (Purcell et al. 2007). The MDS plot (Figures 4-10) 
depicts the ethnic diversity of our patient and in-house control populations as compared with the 
HapMap 3 reference population (International HapMap 3 Consortium 2010). We controlled for the 
population structure of our cohort by first isolating individuals who were within the range of self-
identified Caucasians for the first and second MDS components, and then by filtering for only 
individuals who had these two components within two standard deviations of the mean of this 
subpopulation (Figure 4-10). After quality control and filtering, the remaining 171 cases and 1,630 
controls were used for our association study. We performed a second MDS analysis on this 
smaller cohort to look for finer population substructure and accounted for this by adjusting for the 
first two components in the association tests.  
Linkage Disequilibrium in 10q25.1  
We investigated the LD structure around rs17095355 on 10q24.2 (now referred to as 
10q25.1 in hg19) in the HapMap 3 Release 2 Chinese and Caucasian SNP data. It is important to 
understand the population structure differences in this region between Chinese and Caucasians 
because the SNP association was detected in a Chinese cohort whereas we tested a Caucasian 
cohort. The confidence interval method in Haploview was used to define haplotype blocks (Barrett 
et al. 2005; Gabriel et al. 2002). Also, this method was used to calculate the r2 correlation 
between these blocks.  
Imputation and Association Study 
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The logistic regression test adjusted for the first two MDS components was performed 
using PLINK on genome-wide genotyped SNPs to estimate the genomic inflation factor (Purcell et 
al. 2007). Results of this test were plotted as a Q-Q plot in R (R Core Team 2013) to check for 
deviation from the expected distribution of p-values.  
Imputation of SNP genotypes was performed at and around rs17095355 to look for the 
strongest signal of association in this candidate region. We had 339 SNPs in the 2Mb region 
around rs17095355 genotyped by the SNP array. We used these genotypes for imputation using 
IMPUTE2 (Howie et al. 2009). The low coverage WGS data from 1,092 individuals of diverse 
ethnic backgrounds in Phase I of the 1000 Genomes Project (1000G) served as our imputation 
reference panel (1000 Genomes Project Consortium 2012). SNPs that were imputed with low 
confidence (info < 0.8), that were rare in our cases and controls (MAF < 0.01), as well as those 
that appeared to be non-unique in hg19 were removed. The imputation procedure is summarized 
in Figure 4-11. Association test of the imputed data adjusting for the first two MDS components 
was performed using SNPTEST (Marchini et al. 2007) on 333 SNPs that passed our quality 
control criteria in the region that spanned the Chinese LD block around rs17095355 and 
encompassed the two flanking genes, including a 5kb region downstream of each gene 
(chr10:111619000-111901000 in hg19 coordinates) by logistic regression under an additive 
model. Using SNPTEST, we also performed an association test of the same SNPs conditional on 
rs17095355 and rs7099604 by logistic regression analysis under a standard additive model. 
Confirmation of Imputation Results 
From imputation, a probability score was assigned to each of the three possible 
genotypes of a biallelic SNP. A confidently imputed genotype is considered one where the 
probability of the most likely genotype is greater or equal to 90% (Marchini et al. 2007). Sanger 
sequencing confirmed the genotype at rs7099604 in 57 BA patients with confidently imputed 
genotypes. Sequencing was performed using a primer set consisting of 5'-TGG GCA TAA GTG 
CCT TGG ATG A -3' (forward) and 5'- ACA AGC AGA CAG TTG TGG AGA -3' (reverse). The 
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primers were designed using PrimerQuest and ordered through Integrated DNA Technologies 
(Coralville, IA). 
Immunohistochemistry 
A control liver sample from an autopsied infant with no known liver disease and a BA 
sample (liver tissue from a wedge biopsy and biliary remnant from a Kasai operation) were 
provided by the Pathology Department at CHOP. These samples had been fixed by routine 
methods in 10% buffered formalin and paraffin-embedded. The existing autopsy sample was 
obtained from a 2-month old infant. The samples from the BA patient were collected at 1.5 
months of age. Immunohistochemistry for P1/XPNPEP1 monoclonal antibody (R&D Systems, 
Minneapolis, MN) at a dilution of 1:400, and Adducin-gamma rabbit polyclonal antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:100, was done on the Leica Bond-Max 
Autostainer using the Bond Polymer Refine Detection System (Leica Microsystems, Buffalo 
Grove, IL). Paraffin sections were cut onto charged glass slides at 5µm and dried overnight at 
45°C. Deparaffinization, epitope retrieval with ER2 buffer (pH 9) for 20 minutes for ADD3 and 
ER1 buffer (pH 6) for XPNPEP1, and detection were all performed on the Leica Bond-III stainer. 
The detection reagents include a horseradish peroxidase-linked polymer, which works for mouse 
and rabbit antibodies, and DAB chromagen. The sections were counterstained with Gill’s 
hematoxylin, washed, dehydrated with graded concentrations of ethanol, cleared in xylene, 
mounted, and examined microscopically. 
Expression Analysis 
 The qPCR experiments were performed on the Mx3005P qPCR System (Agilent 
Technologies, Santa Clara, CA) using the Brilliant III Ultra-Fast SYBR Green QPCR Master Mix 
as previously reported (Shivakumar et al. 2004). The mRNA expression of target genes was 
normalized to the endogenous reference GAPDH gene. PCR primers used in the study are listed 
in the Table 4-2. 
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The Kruskal-Wallis test was performed to test for a difference among the 3 groups (NC, 
DC, and BA). Then, pairwise Dunn’s multiple comparison tests were performed to determine the 
source of the difference. Statistical analysis was done using Prism 5.0c (GraphPad Software, San 
Diego, CA), and p < 0.05 was regarded as statistically significant. The correlation between gene 
expression and SNP genotype was tested by fitting a linear regression with the genotype 
expressed as number of minor alleles (0, 1, or 2) as a predictor of the expression. 
Sanger sequencing of ADD3 
The coding exons of ADD3 were sequenced in 60 patients to look for novel or rare 
mutations. Primers were designed to sequence all 14 coding exons of ADD3 (Table 4-2). PCR 
was performed with AmpliTaq Gold DNA polymerase (Life Technologies, Carlsbad, CA) using the 
optimized annealing conditions for each primer set. The quality of the PCR product was 
confirmed by running 5µl on a 1.5% agarose gel at 120V for 45 min. The unincorporated primers 
and dNTPs were removed from each sample using 2µl of Exonuclease 1 and 4µl of Fast 
Thermosensitive Alkaline Phosphatase. Capillary electrophoresis was performed at the NAPCore. 
The sequences were aligned to the hg19 reference of ADD3 to identify variants. 
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Table 4-1. Regional Genotyped and Imputed SNPs Achieving the Highest Significance. 
The most significant genotyped and imputed SNPs as well as the relevant SNPs from the 
Chinese study are included. The imputed SNPs are italicized. The most significant SNP 
(rs7099604) in this region is in boldface. The r2 correlation between the SNPs listed and 
rs17095355 as well as rs7099604 are listed separately. Linkage disequilibrium was determined 
with respect to two populations of 1000G data, the subjects of Chinese descent (CHB and CHD) 
and of European descent (EUR, comprised of CEU, FIN, GBR, IBS, TSI). 
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Table 4-2. Primer Sequences for XPNPEP1 and ADD3. 
The primers used for qPCR analysis of XPNPEP1 and ADD3 are listed in (a). The primer sets 
used to sequence the 14 coding exons of ADD3 are listed in (b). All primer sequences were listed 
from 5’ to 3’. 
Gene Forward Sequence Reverse Sequence
ADD3 TTG AGT TTG AAG GGC TTA TGA GG TTG CTG GGA TTT CCA CAT CAC
XPNPEP1 TCA TTG ATG GTG ACC GCA TAG CTC GCT CAG GAT GGA CTT GTA G
Exon Forward Sequence Reverse Sequence
1 TGC ACC TGT TAA CTC TGA GGG CAA AAG ACT GGA AGC AAC TGG TCA C
2 TCT TGC TGC TTC TTG CAG TGC T ACT CCT GGG CTC AAG CAT TTC T
3 CCA GTG GTG TGA GCC TTT GAT A TGA CCT CCT CTA TCT TCC TTG CCT
4 TGA CCC TAA ATA ACC TTA GAG CCC AGT GCT TGG ATT ACA GGC GTG A
5 AAT TGC AGC AGA GGC CCA CAA A TTG CAG CCC ACT TCC CAC TTT A
6 TGG GCT GCA ATG GTG AAA CAC A TCC AAG TGC AAC CAC ACC ATG A
7 TAA AGT GGG AAG TGG GCT GCA A AGG CCC TTA GAT TGT GTG TGA G
8 GGC AGC AGA ATT CCG TGG CTT AAA TGA TTG TGT CAC GGC ACT CCA A
9 ATG TGG TGT TTG GAA GGA TGC C AGT GGA CAA GAA CTG GGC TCA A
10 TGC CAT CTT CAT CTG ACT GCT G AGC AGG GTT CTC TAA CGC AGA A
11 TTC TGC GTT AGA GAA CCC TGC T ACA GAA AGT TGC TGC ACC TGG A
12 AGG GCA TCA ATC TTA CAA GAG CA GCT TTC TAT CAT CCA ACG TGA GG
13 CAT GCT CAG CTC ACT GCT GAA CTT AAG AAC TGC GGG TTG CCA
14 CTC CCA ATC AGC AGC ATG AAA TAC TTC ATG AGG GCA GAG CTA A
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Figure 4-1. Q-Q Plot of the Genotyped SNP Association Test. 
In this Q-Q plot, the observed p-values are from the logistic regression association test adjusted 
for MDS components 1 and 2. There is no evidence of genomic inflation; most of the markers do 
not deviate from their expected values and the genomic inflation factor is close to 1 (&=1.01). The 
SNPs with p < 1e-5 in order of increasing p-value are rs2345662 (7p22.1), rs12683683 (9q33.3), 
rs1867896 (2q21.2), rs9359428 (6q14.1), rs1612815 (18q23), rs3779312 (7q21.11), rs481777 
(6q14.1), rs2287595 (7p22.1), rs946442 (1p32.3), rs11069817 (13q33.3), rs4702142 (5p15.1), 
rs7452665 (6q12) and rs11057354 (12q24.31).  
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Figure 4-2. Regional Association Plot of 10q25.1. 
The most significant SNP in this region, rs7099604, is depicted as a purple diamond. The 
remaining colors correspond to each SNP’s r2 correlation to rs7099604 in the European 
population of the 1000 Genomes Phase I data. The circles represent the markers that were 
genotyped using the SNP array and the squares represent the imputed markers. (a) The regional 
association plot of the p-values from the additive genetic model. (b) The regional association plot 
of the p-values conditional on rs7099604. 
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Figure 4-3. Linkage Disequilibrium Plots of the Region Surrounding XPNPEP1 and ADD3.  
LD plots of the region chr10:111,600,000-112,000,000 (hg18) of HapMap 3 Release 2 
populations were generated in Haploview. The linkage disequilibrium block in the Chinese of Han 
descent in Beijing (CHB) is pictured in (a). The linkage disequilibrium block in the Caucasians of 
European ancestry in Utah (CEU) and Tuscans in Italy (TSI) is pictured in (b). The black bars 
above the graph represent the haplotype blocks as calculated by the default algorithm in 
Haploview. The values above these bars in red represent the correlation between neighboring 
blocks. The yellow arrow points to rs17095355. 
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Figure 4-4. XPNPEP1 and ADD3 are Expressed in Intra- and Extrahepatic Bile Ducts by 
Immunohistochemistry. 
The black arrows refer to a representation of bile ducts present in the figure. (A) The staining of 
XPNPEP1 is present in the intrahepatic as well as the extrahepatic bile ducts. It seems that 
XPNPEP1 is ubiquitously expressed, as it also stains the hepatocytes. (B) ADD3 seems to be 
only expressed in the intra- and extrahepatic bile ducts as it faintly stains the hepatocytes and 
surrounding tissues.  
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Figure 4-5. Relative Expression of ADD3 and XPNPEP1. 
The expression levels of XPNPEP1 and ADD3 were measured in normal controls (NC), disease 
controls (DC), and BA patients (BA). The comparisons between these groups were not significant 
(NS) for XPNPEP1. A significant difference was detected (*** P<0.001) between the NC and BA 
for ADD3. 
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Figure 4-6. Expression Levels of Candidate Genes by the Genotype of rs7099604. 
Data from 30 BA patients with available genotypes (4 GG, 7 AG, and 19 AA) were plotted with 
their corresponding expression levels. There is no correlation of XPNPEP1 (p=0.34) and ADD3 
(p=0.61) expression with the underlying patient genotype. 
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Figure 4-7. Population Diversity of rs17095355 in HapMap 3. 
This table of allele frequencies for rs17095355 in the HapMap populations was retrieved from 
dbSNP. The T allele of this C/T SNP varies from 8-44% in different populations. The populations 
are sorted in descending order of minor allele frequencies. Interestingly, most of the Asian 
populations have a higher minor allele frequency than the Caucasian populations. The CEU and 
MEX populations have reported minor allele frequency less than 10%, while other populations 
have a reported value more than 20%. 
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Figure 4-8. SNP Selection Flowchart. 
SNPs that were only present on the 550v3 were removed. Standard thresholds were set and 
SNPs that did not meet these thresholds were removed from the association test. 
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Figure 4-9. Sample Selection Flowchart. 
The entire cohort of available BA DNA samples was genotyped, but only the samples identified 
as Caucasian from the genotype data were used for the association test. The 171 BA cases and 
1,630 healthy controls passed the sample quality control and were used in our association study. 
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Figure 4-10. MDS Plot of BA Patients and Controls  
The distribution of the 13 HapMap 3 populations are plotted in (a) for comparison with the BA 
case and control samples. In (b), the MDS plot of the first two components in the BA case and 
control samples overlie the 11 HapMap 3 populations. As expected from the self-reported 
ethnicities, most of the BA cases should be of European descent, and they overlie the CEU and 
TSI Caucasian populations. The MDS components 1 and 2 for all the 291 BA samples and 3,000 
healthy controls are plotted in (c). The samples inside the box are within two standard deviations 
from the means of the self-reported Caucasian samples cohort and are used in the association 
study. 
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Figure 4-11. Imputation and Association Test Flowchart. 
Regional imputation was performed in the 2Mb interval surrounding the reported SNP association 
signal. Only the imputed SNPs with a high information score and a minor allele frequency greater 
than 1% were used for our association test. Furthermore, SNPs outside the Chinese haplotype 
block were excluded. 
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CHAPTER 5: Using Whole Exome Sequencing to Uncover Genetic Variants in BA 
5.1 Introduction 
The etiology of BA is not clear, but there is evidence for genetic susceptibility based on 
familial recurrence, identified mutations syndromic BA patients, and association studies. In 
addition, missense mutations in JAG1 have been found in 9 of 109 of severe BA cases (Kohsaka 
et al. 2002), but they do not explain a majority of cases of isolated BA. A genome-wide study 
carried out in 324 Chinese patients with perinatal BA identified a SNP associated with BA 
upstream of the genes XPNPEP1 and ADD3 on chromosome 10q24.2 (Garcia-Barcelo et al. 
2010), and this association has been confirmed in both a Thai (Kaewkiattiyot et al. 2011) and a 
European-American cohort (Chapter 4). A copy number variation association study found that a 
deletion of the GPC1 gene confers risk for the development of BA (Leyva-Vega et al. 2010). A 
zebrafish model confirmed that suppressing GPC1 expression gives rise to biliary defects (Cui et 
al. 2013). 
We hypothesize that genes identified in human and animal studies as well as genes that 
participate in cilia and polarity genes may cause isolated biliary atresia. To investigate this, we 
examined if the isolated BA exomes had any disruptions in candidate genes from literature 
reports and from the cilia and polarity pathways. To date, there have been 9 genes implicated in 
BA from patient studies: one is based on severe form of isolated BA, 3 are based on confirmed 
genetic alterations found in syndromic forms of BA, 3 are implicated from association studies, and 
one is a liver transcription factor gene that has been associated with renal anomalies similar to 
the findings in BA patients. Additionally, there are 8 genes found to cause a BA-like phenotype in 
mice and 5 additional genes implicated in BA etiology based on zebrafish models. These 
candidate genes are summarized in Table 5-1. We propose that genes involved in the structure 
and function of cilia, as well as those involved in the establishment of cell polarity may be 
associated with biliary atresia. It has been hypothesized that defective cilia could contribute to BA, 
as BA patients exhibit paucity of immotile cilia in their intrahepatic ducts (Chu et al. 2012). In 
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zebrafish models, it was observed that disrupting planar cell polarity could also result in biliary 
defects (Cui et al. 2011a). 
The utility of exome sequencing for disease gene identification has been established as a 
successful tool for uncovering the underlying genes for Mendelian diseases (Ng et al. 2010b). 
The application of exome sequencing to solve complex disorders requires large sample sizes 
(Neale et al. 2012; O'Roak et al. 2012; Zaidi et al. 2013). 
In this study, we performed exome sequencing on 30 patients with isolated BA using 
several models for the interpretation of the variants identified. We utilized public databases to 
filter for variants that could potentially disrupt protein function. First, we interrogated the possibility 
of isolated BA as a monogenic, Mendelian disorder by looking for a common gene altered in the 
majority of our BA patients. Next, we examined a list of candidate genes that have been 
associated with BA. Finally, we performed a pathway-based approach to look for genes disrupted 
in the cilia and planar cell polarity pathways using a new approach that selected genes shown to 
be sensitive to variation.  
5.2 Results 
 There were 17 male and 13 female probands sequenced from DNA extracted from whole 
blood or lymphoblastoid cell lines. This includes a pair of dizygotic male twins, but the other 28 
probands were unrelated. Table 5-2 lists each proband sample used for exome sequencing and 
selected variant findings. One-third of the probands have findings identified by the following 
analyses. Table 5-3 is a summary description of the exome sequencing data. 
5.2.1 Whole Exome Analysis 
 The gene count summary including only loss-of-function (LOF) variants as well as both 
LOF and missense variants is tabulated in Table 5-4. As expected, there are a disproportionate 
number of genes with one alteration occurring in one proband. Every gene altered in the vast 
majority of the cohort (more than 25 patients) was observed to have two or more variants in at 
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least one exome. There are 324 genes with at least one LOF variant and 725 genes with at least 
one LOF or missense variant observed in at least one exome. 
We did not observe any gene containing only one variant shared by all the BA patients. 
However, we observed 5 genes, CD207, OR4X1, KLRF1, MAPK8IP2, and PLCD3, shared by the 
30 samples with two LOF variants each. Of these, MAPK8IP2, a JNK-interacting protein, also 
contained additional missense mutations and no longer appeared as one of the genes in the 2 
variants list. Langerin or CD207 is expressed in Langerhans cells, a type of immune cell found in 
the skin and mucosa, and critical for their function in the body’s defense against bacterial and 
viral pathogens (Valladeau et al. 2002). OR4X1 is an olfactory receptor gene, a family of highly 
polymorphic genes (Malnic et al. 2004). KLRF1 is a transmembrane glycoprotein that has multiple 
isoforms and is also expressed in the liver. It participates in the natural killer-mediated cytolysis of 
phytohemagglutinin-induced lymphoblasts (Roda-Navarro et al. 2000). Mouse knockout 
constructs of mitogen-activated protein kinase 8 interacting protein 2 (MAPK8IP2) are known to 
be smaller in size and males have infertility (Kennedy et al. 2007). Phospholipase C, Delta 3 
(PLCD3) is part of a family of phospholipases that are expressed in endothelial cells that regulate 
cell growth and immunity, and they are also responsible for the regulation of the inflammation 
cascade (Lo Vasco et al. 2013). The high frequency of likely-gene damaging alterations in our 
cases may be due to the polymorphic nature of these genes. 
5.2.2 Candidate Gene Analysis 
In order to target our analysis on genes we felt had a high likelihood to be involved in BA, 
we curated a list of likely candidate genes (Table 5-1). We turned to the analysis of rare variants 
in our list of candidate genes. The CFC1 gene on our candidate gene list was the only gene that 
was not targeted in the exome capture kit, so variants in this gene could not be detected by 
exome sequencing. There were 340 variants observed in the targeted regions of the candidate 
genes, which included parts of the intronic regions and the untranslated regions. Only 77 of these 
variants were in the coding regions, of which 24 were protein-altering variants. No coding variants 
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were observed in 3 genes (FOXF1, SOX17 and HES1). Only synonymous mutations were 
observed in the coding regions of FOXH1, HHEX, PRICKLE1, XPNPEP1, and VANGL2. Fifteen 
genes have non-synonymous or LOF variants found in frequencies in the normal populations 
ranging from not detected to 85%. 
The variants in exonic regions with MAF % 0.01 in reference cohorts are reported in Table 
5-5. There were nine rare, protein-altering mutations found in nine candidate genes. Two of these 
mutations were found in the same patient (maternally inherited p.Arg248His variant in PRICKLE3 
and p.Ala55dup polyalanine extension in ZIC3 as shown in Figure 5-1). The p.Arg248His 
missense mutation in PRICKLE3 was predicted to be damaging and had never been observed in 
the reference population. We could not make a prediction for the polyalanine expansion in ZIC3 
due to insufficient data to support or negate functional consequences arising from this protein 
alteration (Albrecht and Mundlos 2005). 
A non-synonymous variant (p.Ala92Val) was identified in ANKRD6, an important gene in 
the establishment and regulation of planar cell polarity. One proband possessed a heterozygous 
alteration of this missense variant, which has never been observed in the Caucasian population 
of both 1000 Genomes (1000G) and the Exome Sequencing Project (ESP). The same patient 
also had an non-synonymous variant (p.Asp269Gly) in ADD3, a gene proximal to the genome-
wide association signal identified in a Chinese BA study and confirmed in our work (see Chapter 
4). The PolyPhen-2 prediction for both of these variants is predicted to be possibly damaging.  
The remaining 5 variants were also heterozygous changes, all in different patients. The 
non-synonymous variants in ZEB2 (p.Pro494Ser), PRICKLE2 (p.Val209Ile), and HNF1B 
(p.Asp82Asn) were predicted to be benign by PolyPhen-2. A probably-damaging LGR4 variant 
(p.Gly363Cys) was observed in 1% of the normal population and once in our cohort. 
Interestingly, there is a missense variant (p.Ser242Leu) within INVS, a gene that has 
been previously shown to cause left-right axis formation defects in conjunction with biliary 
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abnormalities (Morgan et al. 1998). This mutation was found at a frequency around 1% in the 
normal population, but PolyPhen-2 predicted it to be probably damaging. In a previous publication, 
Schon et al. have reported several damaging mutations in INVS that are implicated in a range of 
disorders linked with laterality and biliary defects (Schon et al. 2002). 
The inheritance of the variants was well studied following parental DNA sequencing for 
each proband with a variant, and every variant was inherited from a parent without a history of BA 
(Figure 5-1). Given that all parents were unaffected, these rare variants may contribute to the risk 
of developing BA, there must be other factors that also play a role in the disease etiology. 
5.2.3 Pathway Enrichment Analysis 
In our final analysis, we investigated genes that establish and maintain the cilium and 
planar cell polarity. The disruption of either of these two cellular properties causes biliary 
abnormalities (Chu et al. 2012; Cui et al. 2011a). To prioritize the genes in these pathways that 
may cause greater damage when disrupted, we elected to only concentrate on rare variants in 
genes with a residual variant intolerance score (RVIS) ranking in the top 25 percentile of genic 
intolerance (see Materials and Methods) (Petrovski et al. 2013). The frequency of the variants 
analyzed ranged from never observed to observed in <1% of the general population. Variations of 
these analyses are described in the methods, performed separately (Categories 1-4), and 
summarized in Table 5-6. 
Starting from the most stringent filter, Category 1 includes variants that were not 
observed in the reference databases, 1000G and ESP, and have a definite LOF effect. There 
were four variants in this category that were observed in different individuals on genes 
participating in cell polarity, DCHS1, SMAD9, VPS13C, and FBF1. One variant disrupts a splice 
acceptor site in SMAD9, while the other three variants led to an early truncation of their 
respective protein products. Dachsous 1, or Dchs1, is a ligand that binds to the Protocadherin Fat 
4 (Fat4) receptor, and murine studies have shown that this ligand-receptor pair plays a critical 
role in the regulation of planar cell polarity (Mao et al. 2011). SMAD9 mutations have been 
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associated with an inherited form of pulmonary arterial hypertension (Shintani et al. 2009). BA 
patients can also have complications of pulmonary arterial hypertension (Schuijtvlot et al. 1995; 
Soh et al. 1999), although whether this is caused by an underlying structural defect or is a 
symptom of their liver disease is unclear. It is interesting that a heterozygous, previously 
unobserved, disruptive change in SMAD9 was found in a BA patient. There is a nonsense variant 
in VPS13C, one of four orthologs of the Vps13 protein in yeast. Like the other members of this 
protein family, this vacuolar sorting protein appears to be ubiquitously expressed in the body 
(Velayos-Baeza et al. 2004). The last variant in Category 1 is a protein truncating alteration in 
FBF1 (Fas Binding Factor 1). This protein is required for epithelial cell polarization and interacts 
with polarity protein PARD3 to organize the apical junction complex (Sugimoto et al. 2008). 
The parameters were relaxed for Category 2, and this category includes missense 
variants that were not observed in the reference databases. However, at least two of these types 
of variants must be found in the same gene to be reported in this category. The Category 2 
alterations include two missense mutations in DCHS1 in another patient. These missense 
variants that have never been reported in the reference databases. 
Category 3 relaxes the filter of missense and LOF variants that were analyzed by also 
including observed, rare variants (<1%) and at least two of these alterations in the same proband. 
The patient in Category 2 was also the only one with observed variants in Category 3. This 
patient carried two missense variants on DNAH3, a gene that encodes for the axonemal dynein 
heavy chain of the cilium (Maiti et al. 2000). No patients were observed to carry any variants in 
Category 4, which includes any LOF variants unobserved in the reference population and in 
genes without a calculated RVIS. 
5.3 Discussion 
 From variant analysis based on genes reported in the literature as well as cilia and 
polarity genes with a high RVIS, we were able to identify variants in 14 of these candidate genes 
across 10 of the 30 patients (Table 5-2). All of these variants were confirmed in the patient DNA 
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via Sanger sequencing and also found to be inherited. The patients with multiple gene alterations 
have one or more missense variants, which may not be protein-damaging. Further confirmation of 
the impact of the missense variants is necessary to discriminate benign and protein-damaging 
changes. 
Exome sequencing is a powerful tool with which to identify genetic changes that 
contribute to or cause disease and has successfully identified disease-causing mutations for 
many disorders. Most successful cases have been for disorders suspected to follow Mendelian 
inheritance, although in a number of cases a search for mutations in unrelated individuals 
observed in concordance with the presence (transmitted) or absence (de novo) of family history 
has resulted in discovery of pathogenic changes believed to be disease-causing (Ng et al. 2010a). 
There is no clear understanding of the basis of genetic susceptibility in BA, and it is unlikely to be 
inherited in a Mendelian fashion. Nevertheless, we hypothesize that there is a genetic 
susceptibility, and in this study, we set out to identify these risk factors.  
We have reported exome sequencing of 30 patients with biliary atresia. There are three 
genes that are altered in these 30 patients when we observed both LOF and missense variants. 
All of these genes, CD207, KLRF1, and PLCD3, are part of the immune response to pathogens, 
and PLCD3 also functions in the inflammation cascade. Due to the nature of their function, genes 
in the immune response pathway are known to be highly polymorphic. However, the immune 
system has been hypothesized to contribute towards pathogenesis of BA. The high level of 
polymorphisms in these genes makes it difficult to access the significance of these changes for 
the pathogenesis of BA. Furthermore, we believe that any contributions from these alterations 
would be very small. 
For part of our analysis, we examined likely gene-damaging variants found in 21 
candidate genes reported in the literature. We identified 9 rare variants including 1 frameshift and 
8 missense variants in genes that are likely to play a role in the disease etiology of BA. Although 
all of these variants are inherited, three of them altering ANKRD6, PRICKLE3, and ZIC3 were 
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never observed in the reference population. We suspect they are likely to contribute to disease 
phenotype. 
Of the rare variants, two are found in genes from the PRICKLE family, which encode for 
planar cell polarity proteins. They have been described to co-localize at the cell surface and 
participates in the polarization of epithelial cells. PRICKLE1 has been well-studied, and it has 
been hypothesized to negatively regulate the Wnt/beta-catenin signaling (Chan et al. 2006). A 
knockdown of the PRICKLE1 homolog leads to biliary abnormalities in the development of 
zebrafish (Cui et al. 2011a). In our study, missense variants in PRICKLE2 (p.Val209Ile) and in 
PRICKLE3 (p.Arg248His) were found once each in the sequenced exomes. While the precise 
role of PRICKLE2 has not been delineated, it is a functional gene as pathogenic mutations in both 
PRICKLE1 and PRICKLE2 have been identified in drosophila, mice, and humans to cause 
epilepsy (Tao et al. 2011). Although PRICKLE3 only contains the LIM domain, it should not be 
disregarded as this cysteine-rich domain is the critical protein-binding interface for protein-protein 
interactions.  
 ZIC3 has been associated with heterotaxy syndrome as well as cardiac malformations 
and situs abnormality (Casey 1998). Located on the X chromosome, pathogenic mutations in 
ZIC3 cause VACTERL association, a severe disorder that primarily affects male patients 
presenting with heterotaxy and sometimes BA (Wessels et al. 2010). Although none of the 
patients sequenced had syndromic BA, there was an interesting duplication in ZIC3 (p.Ala55dup) 
that extends the polyalanine repeat from 10 to 11 in a patient with isolated BA. While a 10 to 12 
polyalanine expansion has been reported in a male patient with VACTERL association (Wessels 
et al. 2010), the pathogenicity of the variant found in this report is less clear, especially since it 
was observed in a female patient. 
 ZEB2 has been described in a case report of a Mowat-Wilson syndrome patient with BA 
(Cui et al. 2011b). It is another candidate gene we considered for BA, and a variant observed in 
less than 0.5% of the normal Caucasian population. The knockdown of the ZEB2 homolog in 
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zebrafish exhibits biliary defects. The dramatic change in the amino acid side change caused by 
the missense variant (p.Pro494Ser) may have phenotypic consequences. 
 In a GWAS performed in a Chinese cohort, there was a significant signal 51kb upstream 
of ADD3 associated with susceptibility to BA. Subsequent studies have implicated ADD3 in the 
etiology of BA and patients with the risk haplotype had a significantly lower expression of ADD3 
(Cheng et al. 2013). We do not know the role of this missense variant in ADD3, but it may 
decrease the function of ADD3 and confer risk to BA. Interestingly, this patient also inherited a 
non-synonymous mutation of ANKRD6 that has never been observed in the normal reference 
populations. Both variants were maternally inherited. Although the mother is unaffected, rare 
variants are likely to only serve as a risk factor. 
Three of the remaining candidate genes with potentially interesting variants are INVS, 
LGR6, and HNF1B. All three genes had missense variants observed at a low frequency in the 
general population (MAF ! 0.01) and were considered a rare variant in our analysis. Mice lacking 
LGR6 have a striking feature and present with absence of the gall bladder and the cystic duct 
(Yamashita et al. 2009). The p.Ser242Leu variant in INVS and p.Gly363Cys variant in LGR6 were 
identified once in the cohort, and they were observed in different probands. These variants were 
predicted by PolyPhen-2 to be damaging, but their biological effects cannot be determined from 
the identification the sequence change alone. Future work includes observing the pathogenicity of 
these alterations in other BA patients or a biliary phenotype from a comparable defect of this 
gene in animal models. In addition, a p.Asp82Asn variant in HNF1B was observed in a separate 
proband. HNF1B is an important liver transcription factor, and heterozygous mutations in this 
gene cause renal anomalies including renal cysts. Curiously, renal cysts are also a reoccurring 
anomaly in BA patients (Ulinski et al. 2006). This HNF1B variant was not predicted to affect the 
function of the protein product, but this cannot be confirmed without performing the appropriate 
experimental studies. Although missense mutations have been reported in patients with isolated 
renal abnormalities, the p.Asp82Asn variant has never been reported.  
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In the pathway-based analysis of intolerant genes that participate in cilia and planar cell 
polarity pathways, we observed alterations in five probands of this cohort. Ranked by the RVIS, 
we found variants in DNAH3, DCHS1, VPS13C, SMAD9, and FBF1 with RVIS percentiles of 3.7, 
4.4, 12.1, 12.9, and 14.7, respectively, with lower percentiles representing genes that are the 
least invariant. Two probands had alterations in DCHS1, one with a heterozygous LOF alteration 
and another with two missense variants. The proband with two DCHS1 variants also had two 
missense alterations in DNAH3. In combination with the previous analysis, this patient was 
observed to have a maternally-inherited missense variant in HNF1B. Although it is unlikely all five 
of these are pathogenic variants, the pathogenicity of each variant cannot be determined without 
functional experiments on their impact in gene function and the gene function in BA. In addition, 
functional follow-up studies using animal models should also be pursued. 
The four genes uncovered in Category 1 of the cilia and PCP pathway analysis can 
potentially be new and interesting BA gene candidates, because they are unobserved gene-
damaging alterations acting in the relevant pathways and intolerant to gene-damaging variation. 
Because of the recurrence of rare and possibly damaging variants in DCHS1, this is the primary 
novel gene we suspect that may be involved in the pathogenesis of BA. In addition, we propose 
the heterozygous LOF variants in VPS13C, SMAD9, and FBF1 of three separate probands as 
candidate mutations for their disease etiology. However, further confirmation of these genes is 
necessary to understand how a disrupted copy of the gene can contribute to the disease etiology. 
5.4 Materials and Methods 
Sample Cohort 
Our cohort includes 28 subjects with isolated BA who were enrolled in ChiLDREN under 
their IRB-approved protocol. In addition, a set of concordant dizygotic twins was consented into 
an approved IRB study at Children’s Memorial Hospital (Chicago, IL). These twins were also 
reanalyzed in a familial setting (Family #1 in Chapter 6). Parental samples were available for all 
probands. The confirmed diagnosis of BA was made by clinical presentation, liver histology, and 
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an intraoperative cholangiogram. Most patients also had BA confirmed by examination of the 
biliary remnant from a Roux-en-Y choledochojejunostomy or Kasai operation. All subjects were 
self-reported as Caucasians and their ethnic background was further confirmed upon MDS 
analysis of SNP genotype data from the Illumina HumanHap 610 SNP BeadArray. This analysis 
was described in Chapter 4 as part of a larger study to investigate the risk locus at 10q25.1. The 
de-identified DNA samples received were extracted from whole blood or lymphoblastoid cell lines. 
Sample Preparation 
Genomic DNA (3-5 ug) was supplied to PerkinElmer, Inc. (Waltham, MA) for whole 
exome sequencing. The DNA was amplified and enriched using the Agilent SureSelect V4+UTR 
71MB All Exon Capture Kit. This kit captures all the coding exons of the selected candidate BA 
genes except CFC1, which was not captured by this assay. Exome sequencing was performed 
on the Illumina HiSeq 2000. The unaligned FASTQ reads were returned to us for read analysis 
and downstream processing. 
Variant Calling 
  An outline of the variant calling process is depicted in Figure 5-2. Briefly, the reads were 
mapped to the GrCH37 reference genome using BWA (Li and Durbin 2009). The depth of 
coverage was calculated using SAMtools (Li et al. 2009a). The variant calling workflow, DRAW, 
was used to efficiently standardize the variant calling process (Lin et al. 2013). Variant calling was 
performed jointly across the 30 exomes using the Genome Analysis Toolkit (GATK) developed at 
the Broad Institute following the software program recommendations as well as the Best Practice 
Variant Detection procedures (DePristo et al. 2011). 
The candidate gene analysis focused on non-synonymous or LOF mutations in genes 
identified from literature reports, because the biliary phenotype reproduced in model organisms 
are recapitulated from defects in this gene list. Thus, only variants that are likely to be gene 
damaging such as nonsense, frameshift, insertion or deletion (indel), splice site alteration, and 
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missense variants were kept for the subsequent analysis. We utilized snpEff to perform gene 
annotation of the variants identified by exome sequencing (Cingolani et al. 2012) and ANNOVAR 
to perform additional MAF annotation against public datasets such as 1000 Genomes Phase I 
European population data (1000G_EUR), dbSNP, and European American population of the 
NHBLI Exome Sequencing Project (ESP_EA) (1000 Genomes Project Consortium 2012; Sherry 
et al. 2001; Tennessen et al. 2012; Wang et al. 2010b). Variants that appeared in dbSNP build 
137 were also annotated with their respective refSNP numbers (Sherry et al. 1999). 
Variant Analysis of the BA Cohort 
 We first hypothesized that BA is monogenic and investigated genes enriched for 
alterations in the probands with BA. For this portion of the analysis, all observed variants in public 
databases, including dbSNP, 1000G, and ESP were excluded. The genes disrupted by the 
remaining variants were summarized for each proband by the number of variants found in the 
gene. We predicted that genes with 3 or more private alterations were likely to be polymorphic 
genes, and variants in these genes do not contribute to the disease phenotype. Moreover, 
because the mode of inheritance of BA is not confirmed, we investigated the possibility of a 
dominant (genes with one alteration) and recessive (genes with two alterations) separately. We 
prioritized our search for only LOF variants, but also extended the analysis of candidate genes to 
genes with both LOF and missense variants. 
Variant Analysis of Candidate Genes 
The variants were further filtered, keeping only those considered rare with MAF !"0.01 in 
1000G_EUR (1000 Genomes Project Consortium 2012) and ESP_EA (Fu et al. 2013). An 
additional prediction of the function of missense mutations was performed using PolyPhen-2 
(Adzhubei et al. 2010). We utilized snpEff to annotate these variants’ effect on the ENSEMBL 
genes (build 37.66) in the nearby region (Cingolani et al. 2012). For each gene, we tallied the 
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number of probands that carry one or multiple variants. Additionally, we also tabulated a list of 
rare or novel variants observed in the curated list of candidate genes (Table 5-1). 
PCR confirmation was only performed on variants in genes that appear in Table 5-7 and 
that were rare in the European population (MAF !"0.01). Primers were designed around every 
rare variant called by the variant analysis pipeline. PCR was performed with AmpliTaq Gold DNA 
polymerase (Life Technologies, Carlsbad, CA) following its recommended protocol. Capillary 
electrophoresis was performed to confirm the presence of these variants in the genomic DNA. 
Parental samples were also sequenced for the variant for determination of inheritance. 
Variant Analysis of Genes in the Cilia and Planar Cell Polarity Pathways 
A list of genes that are known to be a part of either functional group was curated from 
public sources. The Gene Ontology (GO) project annotates genes against GO terms, a lexicon of 
gene product characteristics. Each GO term has a corresponding ID for rapid access to 
compilations of genes grouped by their functional characteristics (Reference Genome Group of 
the Gene Ontology Consortium 2009). We used the GO terms, Cilium (GO0005929) and 
Establishment Or Maintenance Of Cell Polarity (GO00000132) as our primary sources for 
compiling the lists of known human genes that are involved in cilia and the regulation of cell 
polarity. These lists were supplemented with two manually curated sources. Cilia pathway genes 
were supplemented by the Ciliome Database (Inglis et al. 2006), and the PCP pathway genes 
were supplemented by a curated list of genes known to be involved in PCP from zebrafish studies 
(Cui et al. 2013). In total, we considered 291 cilia genes and 280 PCP genes for subsequent 
investigation. 
Because there may be many genes associated with BA, we devised a method to 
prioritize genes and variants that are likely to cause a phenotype. Gene prioritization was 
achieved by comparing each gene’s residual variant intolerance score (RVIS), a value defined in 
a previous report (Petrovski et al. 2013). This score is calculated for each gene based on the 
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residual from a linear regression of the total number of variants versus the number of likely-
damaging variants (i.e. protein-truncating, splicing, or missense variants) observed in the ESP 
dataset. A high residual score would be indicative of a gene with few likely-damaging variants 
compared to the total variation observed in the gene. Following the recommended standards for 
using this score to identify causal variants from the original report, we concentrated our analysis 
on genes with a high RVIS score, those scoring in the first quartile. We prioritized variants of the 
genes with a high RVIS into four categories. Category 1 variants were not observed in the public 
databases (1000G and ESP) and had a LOF effect. Category 2 variants were not observed in the 
public databases, were LOF or missense variants, and had at least two hits on the same gene. 
Category 3 variants were observed in low frequencies (<1% in all normal ethnic populations in the 
public databases), were LOF or missense variants, and had at least two hits on the same gene. 
Genes without a calculated RVIS score were analyzed separately. The final category, Category 4, 
contained variants that were not observed in the public databases and had a LOF effect from 
genes without a calculated RVIS. 
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Table 5-1. Candidate Genes Associated with BA. 
The candidate genes associated to BA from previously published literature reports are listed in 
the above. Part I summarizes genes associated to BA observed in human subjects. Part II 
summarizes genes implicated in BA from abnormal biliary findings in animal studies.  
 
Gene Association with Biliary Atresia Primary Reference
I. Observations from Human Studies
JAG1 Missense mutations observed in 11 probands Kohsaka (2002) Hepatology 36, 904
GPC1 Deletion CNVs of GPC1 enriched in BA Cui (2013) Gastroenterology 144, 1107
XPNPEP1 Proximal gene to GWAS signal Garcia-Barcelo (2010) Hum Mol Genet, 19, 2917
ADD3 Proximal gene to GWAS signal Garcia-Barcelo (2010) Hum Mol Genet, 19, 2917
ZIC3 Mutations found in probands with BA and laterality issues Casey (1998) Hum Mol Genetc, 7, 1565
CFC1 Mutations found in probands with BA and laterality issues Jacquemin (2002) J Pediatr Gastroenterol Nutr 34, 326
ZEB2 Case report of proband with Mowat-Wilson syndrome and BA Cui (2011) J Pediatr Gastroenterol Nutr 52, 339
HNF1B Liver transcription factor that can cause renal anomalies Ulinski (2006) J Am Soc Nephrol 17, 497
II. Observations from Animal Studies
INVS Mouse model has lateriality defects and BA Shimadera (2007) J Pediatr Surg 42,1555
SOX17 Mouse model has BA Uemura (2013) Development 140,639
FOXF1 Mouse model has absence of gallbladder and cystic duct Kalinichenko (2002) JBC 277,12369
FOXM1 Mouse model has agenesis of the intrahepatic bile ducts Krupczak-Hollis (2004) Dev Biol 276, 74
HES1 Mouse model has hypoplasia of the extrahepatic bile ducts Sumazaki (2004) Nat Genet 36, 83
HHEX Conditional mouse knockout has absence of extrahepatic bile ducts Hunter (2007) Dev. Biol. 308, 355.
LGR4 Hypomorphic mice have defective gallblader and cystic duct Yamashita (2009) Dev. Dyn. 238, 993
ONECUT1 Mouse model has abnormal extrahepatic bile ducts Balistreri (2005) Hepatology 42, 222
PRICKLE1-4 Disrupted planar cell polarity leads to biliary defects Cui (2011) Dev Biol 351, 229
ANKRD6 Disrupted planar cell polarity leads to biliary defects Cui (2011) Dev Biol 351, 229
DNMT1 Zebrafish model with hypomethlyation Matthews (2011) Hepatology 53, 905
FOXH1 Mutations in zebrafish disrupts left-right symmetry Long (2003) Development
VANGL2 Disrupted planar cell polarity leads to biliary defects Cui (2011) Dev Biol 351, 229
145 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-2. Summary of Probands and Genes with Findings. 
The thirty probands sequenced are listed above. DNA from whole blood (WB) was used when 
available, but most patients were sequenced using DNA from a lymphoblastoid cell line (LCL). 
Notable gene alterations in each proband were recorded. Italicized genes represent ones with 
two interesting variant findings, and boldface represented genes with heterozygous frameshift 
variants. 
# Proband ID Gender 
DNA 
Source 
Genes with Findings of 
Interest 
1 25047 M LCL DCHS1, DNAH3, HNF1B 
2 25058 M LCL SMAD9 
3 67016 M LCL  
4 35176 M LCL  
5 27032 M LCL  
6 97024 M LCL  
7 35206 M WB  
8 75031 F LCL INVS 
9 37116 M LCL  
10 25133 M LCL ANKRD6, ADD3 
11 25025 F LCL  
12 37161 F LCL  
13 35217 F LCL  
14 35228 M LCL  
15 37343 M LCL  
16 37398 F LCL DCHS1 
17 35198 F LCL  
18 97091 M LCL  
19 35154 F LCL  
20 35251 F LCL PRICKLE2 
21 27225 F WB LGR4 
22 37451 F LCL FBF1 
23 67265 F WB  
24 45197 M LCL  
25 97187 F LCL PRICKLE3, ZIC3 
26 37503 M LCL VPS13C, ZEB2 
27 47193 M WB  
28 27173 F WB  
29 NA087p1 M WB  
30 NA087p2 M WB  
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Table 5-3. Summary of Exome Sequencing Data 
This exome summary data captures the total mapped reads, captured targeted region, and 
identified variants. 
Statistic Total Average Range
Samples 30
Total raw bases (Gb) 579 16.7 (10.4, 67.4)
Total mapped bases, no duplicates (Gb) 343 11.4 (7.7, 16.3)
Target region statistic Total Average Range
Mean mapped depth on target(X) 108.96 89.12 - 169.3
TiTv ratio 2.55 2.49 2.46 - 2.51
No. of SNPs (% novel) 171,402  (10.0%) 57,833   (1.3%) 56,852 - 59,036
No. of indels (% novel) 11,804    (33.3%) 4,017   (12.1%) 3,787 - 4,332
% target coverage !10X 98.6% 97% - 99%
% target coverage ! 20X 95.0% 91% - 98%
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(a)      (b) 
  
Table 5-4. Gene Count Summary Table. 
In (a), only LOF variants that were not observed in public databases (dbSNP, 1000G, and ESP) 
were used in this summary table. This table counts the number of genes containing variants only 
observed in one proband or shared between 2-30 probands. These genes were further classified 
depending on the maximum number of variants that were observed in each exome. For example, 
a gene could be counted in 3+ variants if there was at least one exome containing 3 or more 
variants in that gene. A similar summary of gene-altering variants that includes missense variants 
along with the LOF variants in (a) is summarized in (b). 
 
No. of
Probands
1
variant
2
variants
3+
variants
30 0 5 1
29 0 1 1
28 0 1 1
27 0 3 0
26 0 2 0
21-25 1 2 0
16-20 0 3 0
11-15 1 6 0
6-10 1 2 0
5 1 0 0
4 2 0 0
3 2 0 0
2 12 0 0
1 270 6 0
No. of
Probands
1
variant
2
variants
3+
variants
30 0 3 3
29 0 0 2
28 0 1 1
27 0 3 0
26 0 2 1
21-25 2 2 0
16-20 0 2 1
11-15 1 4 2
6-10 2 3 0
5 2 0 0
4 10 1 0
3 41 10 1
2 323 14 1
1 2243 44 0
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Table 5-5. Rare Variants in Candidate Genes. 
Nine variants in different genes were observed in the 30 exomes. These variants were rare 
(MAF%0.01) or unobserved in the 1000G European population (1000G_EUR) or European 
American cohort of the ESP cohort (ESP_EA). All of the changes were heterozygous alterations 
in the proband designated by their ID. No probands shared the same variant and only one variant 
(MAF=0.017) was found for each gene. 
Chr
Base
Position Gene Name
Ref
Allele
Alt
Allele
Protein
Alteration
1000G_EUR
MAF
ESP_EA
MAF Polyphen-2
2 145157274 ZEB2 G A p.Pro494Ser 0.004 0.004 benign
3 64142981 PRICKLE2 C T p.Val209Ile 0.003 0.001 benign
6 90312803 ANKRD6 C T p.Ala92Val 0.000 0.000 possibly-damaging
9 103002451 INVS C T p.Ser242Leu 0.010 0.006 probably-damaging
10 111879027 ADD3 A G p.Asp259Gly 0.001 0.002 possibly-damaging
11 27398727 LGR4 C A p.Gly363Cys 0.010 0.009 probably-damaging
17 36104632 HNF1B C T p.Asp82Asn 0.000 0.001 benign
X 49034646 PRICKLE3 C T p.Arg248His 0.000 0.000 probably-damaging
X 136648984 ZIC3 A ACGC p.Ala45dup 0.000 0.000 N/A
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Table 5-6. Pathway-Based Analysis of Rare Variants. 
The rare or unobserved variants in cilia and PCP pathway genes with an RVIS in the top 25 
percentile of genic intolerance were tabulated above with their respective categories in 
decreasing order of constraint. Category 1 lists all genes and the respective LOF variants that 
were not observed in the public databases. Category 2 includes genes with at least two LOF or 
missense variants observed in the same proband. Category 3 relaxes the constraint, including all 
genes with at least two LOF or missense variants in the same proband observed in less than 1% 
of the general population (1000G and ESP). Because not every gene identified in our pathways 
has a calculated RVIS, the remaining genes were included in Category 4 to capture all LOF 
variants in these genes that were unobserved in the general population. Two probands had 
alterations in DCHS1, the only recurring gene in this table. We also observed that proband 25047 
had two variants in each gene, DCHS1 and DNAH3. 
 
Pathway
PCP
PCP
PCP
PCP
PCP
PCP
Cilia
Cilia
I. Category 1
none
II. Category 2
IV. Category 4
III. Category 3
Chr Position
11 6653428
13 37427813
15 62325676
17 73924229
11 6648524
11 6651839
16 20948167
16 21048162
Ref
Allele
Alt
Allele
CA C
C T
G A
TAG T
C T
A G
T C
T C
GeneName
DCHS1
SMAD9
VPS13C
FBF1
DCHS1
DCHS1
DNAH3
DNAH3
Protein Alteration
p.Leu1105Cysfs*11
splice site alteration
p.Arg117Term
p.Ser94Term
p.Ala1916Thr
p.Phe1396Leu
p.Lys3888Arg
p.Ile1653Met
1000G_EUR
MAF
ESP_EA
MAF PolyPhen-2
0 0 N/A
0 0 N/A
0 0 N/A
0 0 N/A
0 0 benign
0 0 possibly-damaging
0.003 0.001 benign
0.004 0.005 probably-damaging
Proband
ID
37398
25058
37503
37451
25047
25047
25047
25047
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Table 5-7. Primer Sets for Sanger Sequencing Confirmation of Variants. 
The primer sets listed above used to confirm the rare variants, with the position listed, in the 
candidate genes associated with BA. These primers were used to sequence the proband with the 
observed variant and both parents to check the mode of inheritance. 
Gene Variant Position Forward Primer (5' to 3') Reverse Primer (5' to 3')
1 ZEB2 chr2:145157274 ACC GCC TTG ATC TCT TCA TTC ATT CAG CCA TTA CCC AGT TAA GA
2 PRICKLE2 chr3:64142981 TAC AGA AAC TGC CTT CCC AAC TCC TCA TTC TCC CAA TGA CTT TC
3 ANKRD6 chr6:90312803 CAG CGT GCG TTG TCT ACT AA GCT GGG ATA CCA GAT AGT GTT TC
6 INVS chr9:103002451 GTA TGT CTG AAG TCT CTG GTT CC GGG AGT AAA CAG TGG AAG GG
4 ADD3 chr10:111879027 TGG GCT GCA ATG GTG AAA CAC A TCC AAG TGC AAC CAC ACC ATG A
5 LGR4 chr11:27398727 CAC AGG ACA TGA TGG GAA CTG TGA GAA GCT GAC AAG TCT TAG G
7 HNF1B chr17:36104632 GGA CTT CTC TGG TGG GAA AC GCT CCA GCA AGA ACT CCT GA
8 PRICKLE3 chrX:49034646 TGT CCA TCC ATC CCT CTG T TGA GCA GGG TCA GTC TCT AA
9 ZIC3 chrX:136648984 CCG GTA CCC TCT CTC ACT T TCG CGC GTT GAG TTG AA
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Figure 5-1. Transmission of Rare Variants in Candidate Genes. 
All of the rare variants of the candidate genes identified in the literature were confirmed to be 
transmitted by an unaffected parent. Two probands each had two heterozygous variants in two 
different genes. Proband 25133 had a heterozygous variant in ANKRD6 on chromosome 6 and 
one in ADD3 on chromosome 10. Proband 97187 had one variant in PRICKLE3 and one in ZIC3 
inherited on the chromosome X from the mother. 
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Figure 5-2. Overview of Variant Calling Pipeline. 
This flowchart is an outline of the variant calling process. It handles unmapped reads in FASTQ 
format, aligns them to the reference genome, performs the necessary quality control, and calls 
the variants for downstream processing. 
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CHAPTER 6: Genomic Analysis of Families with BA 
6.1 Introduction 
 Familial recurrence of BA is not commonly observed, due to a combination of a rare 
incidence, the fatality of the disease if not diagnosed and treated in a timely manner, and possibly 
the incomplete penetrance of genetic susceptibility. Although there are dozens of documented 
pairs of affected siblings, there is only one report of transmission from parent to child (Kobayashi 
et al. 2008). The lack of parent to child transmission of the disease may be owing to the fact that 
BA was a fatal childhood disease prior to the establishment of the corrective Kasai procedure. 
Thus, families have been underutilized in the genetic analysis of BA because they are very rare 
and difficult to obtain. 
 In this chapter, we perform genetic analysis on two unique families to uncover their 
genetic predisposition to BA. Family #1 includes a set of dizygotic twins with isolated BA. The 
proband in Family #2 presented with BA and heterotaxy, and her father has heterotaxy but not BA. 
(Figure 6-1). Family #1 did not receive any prior genetic screening, because there are no 
candidate genes for isolated BA. This is an interesting case, because out of the 32 reported 
cases of twins, only 2 in addition to this case, were concordant for BA. This is also the only set of 
affected siblings with isolated BA available to us. 
In Family #2, the proband was screened for mutations in genes on a panel of heterotaxy-
associated genes at the Children’s Hospital of Pittsburgh. This panel included CFC1, FOXH1, 
NODAL, and ZIC3, but no coding mutations were found that could explain the heterotaxy. 
However, the proband was heterozygous for a SNP (rs1904589) within the NODAL gene. This 
variant has been observed in approximately 50% frequency in Caucasians, and is therefore 
unlikely to be involved in the disease. In our study, we investigated genetic changes on a 
structural level down to those at a single base-pair level, and we hope this comprehensive 
approach can uncover some variants that may explain the pathogenesis of BA in the two families. 
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6.2 Results 
6.2.1 Family #1: Affected Dizygotic Twins 
Structural Variants 
WGS was carried out on DNA from these twins, and we did not identify any large 
structural changes due to inter-chromosomal rearrangements as summarized in Figure 6-2. 
Proband 1 had 7 structural variants and Proband 2 had 3 structural variants. The 2 structural 
variants shared between Probands 1 and 2 did not appear to disrupt any genes. 
The CNVs shared by the two probands were observed in one or both parents as reported 
in Table 6-1. Of the 19 shared CNVs, 5 CNVs contained genes, but these CNVs appeared to be 
highly polymorphic, as they were observed in many controls found in DGV (Iafrate et al. 2004). In 
this CNV analysis, there were no candidates that appeared to confer risk to BA. 
Analysis of NGS Variants 
The genomic regions shared identify-by-descent (IBD) 1 or 2 by the two affected twins 
were depicted in Figure 6-3. The twins shared both alleles (IBD = 2) at the 10q25.1 BA 
associated locus, although no exonic variants were found in ADD3 or XPNPEP1. The twins were 
heterozygous for the risk allele (G) of rs7099604 described in Chapter 4.  
WGS did not reveal coding exon variants in any of the previously implicated genes (Table 
5-1) or suspicious variants from cilia and polarity genes. From the WES data, we found 34 LOF 
and missense variants that appeared in both twins but not in the parental exomes. However, the 
target regions for these variants were not well covered in one or both parental exomes, so it is 
likely that most or all of these putative de novo variants in the twins’ DNA sample sequenced may 
be present in the parental samples. There were 5 variants (Table 6-2) that were not observed in 
any reference databases, including dbSNP. From the WGS data from the probands, we also 
looked for variants shared between the probands that were never observed in any reference 
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databases. We only had exome data on the parents, so we also used the parental exome data to 
filter observed variants in the WGS variants found in the probands. There were 25 variants across 
different genes identified in this analysis (Table 6-2). Only one variant was identified via both 
WGS and WES technologies, and this variant on fibulin 1 (FBLN1) was also the most biologically 
relevant finding. FBLN1 is a secreted glycoprotein that is incorporated into fibronectin-containing 
matrix fibers, and this protein is important in cell adhesion and migration (Kostka et al. 2001). 
Defects in FBLN1 are homozygous lethal in mice, and they suffer from massive hemorrhages in 
several tissues during mid-gestation. FBLN1 has also been observed to correlate with liver injury, 
and this gene is upregulated in acute and chronic liver disease (Piscaglia et al. 2009). Re-
sequencing of this region via Sanger sequencing in the quartet validated the presence of this 
variant in both probands, but revealed that this variant was also present in the father. Thus, this 
inherited mutation was not a result of a germline mutation. Although it could still potentially be 
interesting in the disease etiology, we do not have compelling evidence to support such a claim. 
 We also examined IBD = 2 regions for multiple (' 2) loss-of-function alterations in the 
same gene to look for recessive mutations. We were unable to find any shared variants in these 
regions that were inherited in a recessive manner that are likely to contribute to the disease 
phenotype. We searched the IBD ' 1 regions for a single loss-of-function alteration in genes 
directly involved in liver development, virus or toxin response (cell surface receptors), or the 
process of inflammation. We were able to identify a TGTT insertion (rs144060127) causing a 
frameshift in a type I interferon gene, interferon-( (IFNK). This c.31_34dup alteration causes an 
early truncation of the protein (p.Trp13Phefs*4). The implications of a defective IFNK allele may 
be potentially relevant, since studies have shown that certain viruses silence IFNK during 
infection (Reiser et al. 2011). 
We confirmed the presence of this frameshift in IFNK via Sanger sequencing as a 
heterozygous variant in both probands. This variant appears in the raw dataset of called variants 
in the 1000 Genomes Phase I dataset, but it was filtered out of the final variant file because it did 
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not meet quality control metrics. This could be due to the presence of c.1dupA upstream of this 
exonic variant in a polyadenine repeat in the 5’ UTR that we find also inherited in both probands. 
The complex DNA architecture at this region could have caused these variants to be under 
annotated in the final 1000 Genomes Phase I release data. From the pre-filtered 1000 Genomes 
Phase I data and the preliminary Phase II data, we estimate that the TGTT insertion has a minor 
allele frequency of 2% of the European population, similar to the 3% observed frequency in the 
Exome Variant Server database. 
5.2.2 Family #2: Father with Atypical Features and an Affected Child 
Survey of CNVs Identified from SNP Array 
There were 152 CNVs computationally predicted for the affected proband, 53 deletions 
and 99 duplications. Of these, 8 CNVs were not observed in either parent (de novo), 27 CNVs 
appeared paternally inherited, 30 CNVs appeared maternally inherited, 9 CNVs inherited from 
both parents, and 78 CNVs were observed in both parents. Table 6-3 lists the de novo and 
paternally-inherited CNVs as well as the CNVs inherited from both parents. 
 Only three of the de novo CNVs contained genes. One of them contained a deletion of 
CEACAM22P, pseudogene for the Carcinoembryonic Antigen-Related Cell Adhesion Molecule. 
The other CNV contained a deletion of PCDH11X or the protocadherin 11 X-linked gene, which is 
predicted to be a calcium-dependent cell-adhesion protein. Neither gene appears to play a critical 
role in development or in the proper function of the biliary system. In the duplication, 6 genes are 
altered, including a partial duplication of ATPase, H+ Transporting, Lysosomal Accessory Protein 
1 (ATP6AP1). Deficiencies in this vacuolar H+-ATPase subunit are known to cause biliary defects 
(EauClaire et al. 2012), but the effect of this duplication on the gene expression of ATP6AP1 is 
unknown. Other genes duplicated include FAM3A and FAM50A responsible for defense against 
fungal microbes, GDP dissociation inhibitor (GDI1), L antigen family, member 3 (LAG3), Plexin 
A3 (PLXNA3), Solute Carrier Family 10 Member 3 (SLC10A3), and ubiquitin-like 4A (UBL4A), but 
they also do not appear to have a significant phenotype when duplicated. 
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 Of the 27 CNVs inherited paternally, 2 deletions and 5 duplications included altered 
genes. The most striking alteration is a deletion CNV on 20p11 inherited from the father that 
spans almost 300 SNP markers but only encompassed one gene (Figures 6-4 and 6-5). The 
deleted gene, forkhead box A2 (FOXA2) is an important transcription factor, and targeted 
knockouts of the mouse homolog result in embryonic lethality. During development, it was 
demonstrated in mice that Foxa2, also known as Hnf3!, interacts with Nodal, a critical gene for 
LR axis formation and responsible for heterotaxy in patients, and also, it is asymmetrically 
expressed on the left side of the embryo during left-right patterning (Collignon et al. 1996). 
Moreover, FOXA2 is also critically expressed in endoderm-derived tissues including the liver 
(Carlsson and Mahlapuu 2002). FOXA2 is known to upregulate HNF-1! and HNF-4!, two genes 
implicated in maturity onset diabetes of the young (MODY), as well as their downstream targets 
(Duncan et al. 1998). One heterozygous mutation in FOXA2 has been observed in a patient with 
MODY (Yamada et al. 2000), and two other mutations have been observed in patients with 
impaired glucose homeostasis (Navas et al. 2000). A study in mice with increased susceptibility 
to maternal diabetes observed interstrain differences in susceptibility to situs abnormalities 
(Maeyama et al. 2001). Screening of LR axis determining genes in these mouse strains revealed 
alterations in the promoter sequence or coding sequence of Hnf3!, while the other genes 
screened, Nodal, Lefty1, Zic3, Smad2, and Acvr2b, did not have alterations that segregated with 
these observations. 
 We also studied CNVs that were inherited in a recessive manner, and found that there 
were 8 CNVs shared between the twins that were inherited from both parents. These CNVs were 
also regularly observed in healthy individuals (Iafrate et al. 2004). Four of these polymorphic 
regions had homozygous deletions of AMY2A, SH3GL3, SDK1, and SNTG1, which do not appear 
to have an associated clinical phenotype. In addition, one alteration of a CNV region contained 
four full copies of NKX6-2, ATP5D, and STK11. Of these, NKX6-2 expression is the only one with 
a clear connection to liver development. During endodermal development, NKX6 genes are 
expressed alongside PDX1 to mark the pancreatic endoderm and distinguish it from the 
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developing liver (Pedersen et al. 2005). Overexpression of NKX6-2 during this developmental 
period may have ramifications such as a disproportional part of the endoderm adopting a 
pancreatic rather than a hepatic cell fate. However, such studies of ectopic NKX6-2 expression 
have not yet been reported. Instead, the NKX6 transcription factors are a known to be critical for 
!- and "-cell development in the pancreas (Henseleit et al. 2005). 
Validation of 20p11.21 Deletion CNV 
 From the SNP array, a 277kb deletion in 20p11.21 that spans the entire FOXA2 gene 
was observed in the father and proband of Family #2. Digital droplet PCR confirmed that only one 
copy of FOXA2 was present the proband and the father while two copies of this gene were 
present in the mother. These quantitative results are plotted in Figure 6-6. 
6.3 Discussion 
6.3.1 Family #1: Affected Dizygotic Twins  
Investigation of the genomes of a set of dizygotic twins identified two shared variants that 
may be responsible for the development of isolated BA. These variants include a risk allele at 
rs7099604 and a protein-truncating variant in IFNK. Utilization of genome-wide SNP array data in 
combination with WGS provides a robust methodology to identify disease susceptibility regions in 
affected family members. CNV analysis of the SNP array data did not uncover any pathogenic 
alterations. However we identified a shared risk allele of rs7099604 in 10q25.1 in the affected 
probands from the WGS data, and this region was shared IBD = 2, suggesting that both affected 
probands inherited the same parental alleles. We suspect that these alleles could have conferred 
risk to BA. 
The most relevant variant predicted to be de novo caused a heterozygous missense 
change (p.Arg466Trp) in FBLN1 turned out to be an inherited variant that was not called in the 
parental exome due to lack of coverage at that target site. We did not experimentally confirm the 
transmission of the remaining variants, because the relevance of these genes to BA was obscure. 
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From our results, we suspect that a shared a germline mutation is unlikely the model for the 
disease etiology in this family. 
 In our analysis of rare variants inherited by both twins, we observed a protein-truncating 
mutation in IFNK caused by an early frameshift, and this variant implicated IFNK as a potential 
disease susceptibility gene. Literature references for this Type I interferon gene is scant, although 
it has been reported that certain viruses, including human papillomavirus, silence this gene upon 
infection to prevent the activation of its pathogen recognition receptor (Reiser et al. 2011). This 
gene is located on 9p21, as part of the Type I interferon cluster, and this region was shared 
IBD = 2 between the affected twins. We hypothesize that lack of immunity due to this defect in 
pathogen recognition, could make patients more vulnerable to pathogenic insults to the liver and 
result in BA. 
From our preliminary exome sequencing data of 28 unrelated BA cases (Chapter 5), we 
have found the same heterozygous rs144060127 variant in IFNK in two other isolated BA 
probands. In unrelated BA probands, the variant allele is 2.8 times more frequent than in the 1000 
Genomes population (5.2% versus 1.8%), although they are all inherited. In addition, another 
inherited and rare IFNK variant (<0.1% in reference populations) causing a p.Lys133Glu change 
(rs700785) in the protein was observed in a separate proband. Although we do not have the 
sample size to test for a significant association, this notable observation may suggest a role for 
immunity genes conferring risk to BA. 
6.3.2 Family #2: Father with Atypical Features and an Affected Child 
 FOXA2 has been implicated in diabetes, with mutations found in one patient with MODY 
(Yamada et al. 2000) and two patients with impaired glucose homeostasis (Navas et al. 2000). In 
addition, situs abnormalities have been observed in mice with alterations promoter and coding 
sequence of FOXA2 (Maeyama et al. 2001). It is a transcription factor regulating critical 
developmental processes including the development of the liver bud, and we believe that 
alterations in this gene are responsible for the abnormalities identified in the father and proband. 
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FOXA2 is co-expressed with NODAL and it is known to act as an upstream activator of NODAL at 
the node during development. A binding site for FOXA2 has been found in an important node 
enhancer element (Brennan et al. 2002). Like NODAL, FOXA2 was also found to be upregulated 
on the left side of the embryo from murine experiments on LF axis formation (Collignon et al. 
1996), an important developmental step that can be responsible for heterotaxy when it is 
disrupted. Moreover, the initiation of liver development is dependent on forkhead transcription 
factors (Lee et al. 2005), and FOXA2 is the most critical gene in this family. While mice bearing 
null mutations in FOXA1 die within the first post-natal weeks of life (Kaestner et al. 1999) and null 
mutations in FOXA3 are phenotypically healthy (Shen et al. 2001), the mice with FOXA2 null 
mutations die during gastrulation due to node and notochord defects (Ang and Rossant 1994; 
Weinstein et al. 1994). FOXA2 is expressed in the liver in both hepatocytes and biliary epithelial 
cells, but it is not expressed in the columnar epithelium that comprises the gall bladder (Besnard 
et al. 2004). Unfortunately, no investigation of the levels of FOXA2 expressionin the extrahepatic 
biliary tree has been reported, but FOXA2 is a critical laterality and liver development gene.  
Hepatocyte-specific knockouts of Foxa2 in murine models have decreased transcription 
of bile acid transport genes on both the basolateral and canalicular membranes of the hepatocyte 
(Bochkis et al. 2008). This disruption results in intrahepatic cholestasis and liver injury. In addition, 
FOXA1 and FOXA2 are critical transcription factors in the liver known to regulate bile duct 
development. When both genes are conditionally ablated during a later stage of liver 
development, bile duct hyperplasia was observed in the intrahepatic biliary tree (Li et al. 2009b). 
These observations in this dosage-sensitive developmental gene implicate the whole gene 
deletion of FOXA2 in the father and proband of Family #2 as the pathogenic alteration that is 
responsible for their laterality issues and perhaps the BA finding in the proband. We are also 
looking to obtain DNA samples from the paternal grandparents to determine if this FOXA2 
deletion is a de novo in the father affected with heterotaxy. We believe that FOXA2 is an 
outstanding candidate gene for causing heterotaxy in association with biliary atresia, and further 
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work involving the screening of mutations as well as whole gene deletions of this gene in other 
BA patients with heterotaxy is in process. 
6.4. Materials and Methods 
Sample Collection 
 We suspected a genetic component to BA in the affected probands observed in two 
unrelated families, because of clinical findings in their family history. Family #1 is a case of male, 
dizygotic twins both affected with isolated extrahepatic biliary atresia born to healthy parents. In 
addition, the twins also have an unaffected brother. The family was enrolled through collaboration 
with Children’s Memorial Hospital (Chicago, IL) under an IRB-approved protocol. In Family #2, a 
female proband presented with BA, interrupted inferior vena cava (IVC), and malrotation. 
Interestingly, her father has heterotaxy and mild dysmorphic features, and he presented with situs 
inversus and polysplenia during early childhood, both findings regularly observed in syndromic 
BA patients. This family is enrolled into our study through an IRB-approved protocol, and the 
patient is actively being followed at CHOP. In both families, DNA was extracted from peripheral 
blood using the DNA extraction kit by 5Prime (Gaithersburg, MD).  
SNP Array Preparation 
 DNA samples from the entire nuclear family of Family #1, both parents, both dizygotic 
twins, and the unaffected sibling, were sent for SNP genotyping on the HumanHap 610 Quad 
BeadArray (Illumina, San Diego, CA) at the CAG. Because this array has since become 
unavailable, the samples from the parents and proband in Family #2 were genotyped using the 
OmniExpress BeadArray (Illumina, San Diego, CA) at the CAG. The Log R Ratio and B Allele 
Frequency from these files were used to call CNVs by the PennCNV software using the trio 
calling option (Wang et al. 2007). 
SNP Array Analysis of Family #1 
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 We sought to first identify a shared genetic component that could be responsible for BA 
in the dizygotic twins in Family #1. Because the affected twins were born to healthy, unaffected 
parents and this disease is uncommon, we expected that the following types of genetic variants 
were likely to be associated with this disorder, 1) germline mosaicism for a mutation in one of the 
parents that would appear to be de novo through analysis of whole blood samples in the twins, 2) 
rare compound heterozygous or homozygous variants contributing to a recessive disease, or 3) 
inherited rare variants that increase susceptibility to BA. Because of the recurrence of BA in two 
members in this family, we expect a genetic component with a moderate or large effect size. Thus, 
it is unlikely due to a common variant, since the incidence of BA is low. 
In our initial analysis, we examined all the CNVs that were shared by the probands. We 
were able to discern those unobserved in the parents as well as those observed in one or both 
parents to identify the transmission of these variants. To prioritize the CNVs of interest, we 
focused this analysis on CNVs containing genes and carefully inspected each gene for a 
relationship between them and BA. 
In addition, the SNP identity-by-descent (IBD), defined in this case as the number of 
parental alleles shared by two siblings, was calculated to identify regions of the genome that are 
from two different parental alleles (IBD = 0), share one parental allele (IBD = 1), and share both 
parental alleles (IBD = 2). IBD can be unequivocally determined only if both parental genotypes 
are heterozygous. The possible outcomes are summarized in Table 6-4. Germline mutations may 
occur in any of the IBD regions, but these can only be identified through direct sequencing. For 
the inherited variants, we will use IBD to delineate shared chromosomal regions that may contain 
alleles conferring risk to BA. 
A frameshift in IFNK (rs144060127) was confirmed using PCR with a forward primer set 
5'- GCC GCA ACC TTG GTT AAC TG -3' and a reverse primer set 5'- GCC AGG TGA CTC TTC 
TCA GGT -3'. Then, an additional IFNK variant (rs700785) was confirmed by the primer sets, 5' - 
163 
TAT ATA AAG GCA CAT GAA GGA AA - 3' and 5' - AGA GAT TTC GGA GGG AAA AGG AAT - 
3' representing the forward and reverse primer sets, respectively. 
SNP Array Analysis of Family #2 
The presence of recurrent heterotaxy in Family #2 prompted us to analyze this family 
differently and independently from Family #1. While the mother was healthy and unaffected, we 
suspected that there could be a genetic susceptibility component transmitted from the paternal 
allele because of the father’s abnormal clinical findings. Thus, we focused the analysis on de 
novo CNVs, paternally-inherited CNVs, and CNVs inherited from both parents. CNVs with 0 
copies of the region found in the proband must be inherited from both parents. CNVs with 4 
copies in the proband and duplicated in both parents were also candidates for association with 
the phenotype. We scanned candidate CNVs against the Database of Genomic Variants, 
suspecting that rare, unseen CNVs may be more harmful than common, polymorphic CNVs 
(Iafrate et al. 2004). 
A paternally-inherited deletion CNV on chromosome 20 that contained FOXA2 was 
identified to be potentially relevant to biliary development and BA. The deletion of FOXA2 was 
confirmed in the father and proband using the QX100 digital droplet PCR system by Bio-Rad 
(Hercules, CA). Both the unaffected mother and the healthy control did not appear to have a 
deletion over FOXA2, and they were used as normal genomic controls. We followed the 
suggested protocols from Bio-Rad using 20ng of genomic DNA from each sample and CNV 
probes by Life Technologies (Carlsbad, CA), hs01795534_cn in exon 2 of FOXA2 and 
hs00638261_cn in exon 26 of JAG1. The determination of copy number of both genes was 
normalized to the suggested reference assay for Rnase P (Catalog# 4403328). 
Next-Generation Sequencing 
 DNA from the father, mother, and affected probands in Family #1 were sent to 
PerkinElmer, Inc. (Waltham, MA) for whole exome sequencing. The SureSelect V4+UTR Exome 
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Capture Kit by Agilent Technologies (Santa Clara, CA) was used to perform target enrichment. 
Demultiplexed FASTQ files were received and processed using the variant calling process 
depicted in Figure 5-2. The reads were mapped to the GrCH37 reference genome using BWA (Li 
and Durbin 2009). The depth of coverage was calculated using SAMtools (Li et al. 2009a). The 
variant calling workflow, DRAW, was used to efficiently standardize the variant calling process 
(Lin et al. 2013). Variant calling was performed as described in Chapter 5, jointly using GATK 
(DePristo et al. 2011). 
 In addition, the affected probands from Family #1 were also sent to CompleteGenomics, 
Inc. (Mountain View, CA) for whole genome sequencing. The deliverables included sequenced 
reads with an average coverage of 40X as well as bioinformatics analysis of complex structural 
rearrangements, CNVs, and single nucleotide variants (SNVs). The analysis was performed using 
version 2.0 of the Standard Pipeline. 
Variant Analysis 
 Using the variants identified by software algorithms, we first investigated variants that 
were present in both exomes of the affected probands, but unobserved in the exomes of their 
mother and father. We expect to identify any germline mutations shared by the probands from 
this search of de novo variants from the blood samples of the parents and probands. To minimize 
false positives, i.e. inherited variants that are mistakenly identified as de novo due to a failure to 
identify the variant in a carrier parent, we filtered for LOF or missense variants that were rare 
(<5%) in the population, assuming that these are more likely to be pathogenic. The missense 
variants were annotated using PolyPhen-2 to predict their effects on the gene function (Adzhubei 
et al. 2010). To search for de novo variants called in the WGS datasets of the affected probands, 
we excluded all variants present in the parental exomes and kept only LOF or missense variants 
that were not observed in the normal population. This was our best filter for de novo variants in 
blood from the WGS dataset, since neither of the parental samples were sent for genome 
sequencing. In addition to de novo variant analysis of the exome and genome data, we also 
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critically examined genes with LOF variants that were present in regions with IBD ' 1 but rarely 
observed (MAF % 0.05) in the normal population. 
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Table 6-1. Summary of CNVs Shared Between the Two Affected Siblings. 
There are 19 CNVs shared between the two affected siblings in Family #1. Only 5 of these CNVs 
contained genes. None of the genes were suspected candidates for BA, as they were highly 
polymorphic genes. 
 
 
!""#$%&'()*+
!",-+
./01)#+
."2+
3.4*+
5)&6(7+
81,9+
4#)*)&:)+%&+
4'#)&(*+ ;)<3)=+>)&)*?+*&";.@?+0%;.@+
!"#$%&'($$&)*+&'($**',- '- (- &.',/-01&,2- ??
!"#3%))&'($(+))&,4)4- '- ,- $.'3$-01&,5- ??
!"#,%'43(*3$*+'4,44'&)- '- &- $./34-01&,2- ??
!"#)%)$'/3(4'+)$$$3$&*- 3- )- 3(.3&*-01&,5.-01&,2- ??
!"#/%&&(&*('+&)4&4/*- '- (- (.$(*-01&,5- ??
!"#/%3($3*))/+3(3*/,44- '- '/- ',4.*33-01&,5.-01&,2- 161231.1612&-
!"#'4%/$/*(*'(+/$//&(*&- '- 3- ).$&*-01&,5- ??
!"#''%&&3)4$'3+&&,,*,$*- 3- '/- /*.$'&-01&,2- 78,9''.78,9).78,:,.78,;$-
!"#''%/'&43(($+/'&'*$)'- '- /- '3.$*4-01&,5- ??
!"#''%'4,*4**3$+'4,*3*&(4- '- )- $(./&(-01&,2- ??
!"#',%$4$'3(3*+$4,$3/)&- 3- ''- $4(.($(-01&,5.-01&,2- 78,<'.78,<$.78,<&.78,2'.78,=$.78,>3-
!"#',%'4)3&43(,+'4)/,)4**- 3- )- ,(&.)/,-01&,5.-01&,2- 1612).<?114'$&.@?=944$$)-
!"#'&%$$,($&',+$$&4/3$,- 3- 3- '&./''-01&,2- ??
!"#'&%$,4&&,//+$,4&////- '- &- 3.,4'-01&,2- ??
!"#'*%3,,3/$'3+3,,)))3'- 3- *- $/.,'(-01&,2- ??
!"#'*%,$),(*/$+,$))'()4- '- )- '$.'*(-01&,5- ??
!"#'/%3/$)4('&+3/$)&,,/- 4- &- ,.&3,-01&,5.-01&,2- ??
!"#'/%)3$4'*$/+)3$4&*4$- ,- ,- 3.(*&-01&,2- ??
!"#A%*,&'/'&(+*,),&/'$- 3- *- '$*.)&,-01&,5- B:8C.D6EE9'&-
167 
 
Table 6-2. De Novo Variants in Affected Children in Family #1. 
Putative de novo variants shared between the two affected dizygotic twins were identified by 
absence in the parental exomes and low occurrence in the general population. Alternative alleles 
that were too long to list were represented by <DEL> to denote a deletion and <INS> to denote 
an insertion of sequence with respect to the reference genome. Only one variant was found in the 
whole exome and whole genome data for the affected twins, and it is a missense alteration of 
FBLN1. 
 
Zygosity Chr Position Ref Allele Alt Allele Gene Effect Protein Change PolyPhen-2
I. WES Analysis
het 1 34667784 A AC C1orf94 frameshift p.N458fs
het 11 6190994 C CG OR52B2 frameshift p.R188fs
het 19 16860085 T TCCC NWD1 in-frame p.211_212insP
het 19 41133206 A C LTBP4 missense p.T1468P Benign
het 22 45943039 C T FBLN1 missense p.R466W Possibly Damaging
II. WGS Analysis
het 3 33896724 C T PDCD6IP missense p.R698W Probably Damaging
het 3 98217036 T C OR5K2 missense p.L171S Benign
het 4 4199711 T C OTOP1 missense p.M284V Benign
het 5 21975244 A C CDH12 missense p.L161W Possibly Damaging
het 6 41621226 GGA GCC MDFI in-frame p.D219P Probably Damaging
het 6 132031751 C T ENPP3 missense p.S136N Benign
het 7 150093609 C CTGGTGA ZNF775 in-frame p.14_15insVM
hom 9 43876136 A G CNTNAP3B missense p.Q743R Benign
hom 9 111929419 CCG CGC FRRS1L in-frame p.R51A Benign
hom 10 88993813 T A NUTM2A missense p.V662D Benign
het 15 75556390 C G GOLGA6C missense p.S177C Benign
het 16 4310525 CTG CAC TFAP4 in-frame p.Q199V Benign
het 16 85743878 GGCTGCT G C16orf74 in-frame p.20_21delSS
hom 16 88599700 CTCTGG CC ZFPM1 frameshift p.L446fs
het 17 4837179 C <DEL> GP1BA in-frame p.428_431delSEPA
het 17 30302507 A T SUZ12 missense p.S200C Benign
het 17 40371361 GGG GCT STAT5B in-frame p.P267Q Possibly Damaging
het 18 14822483 G C ANKRD30B missense p.E762D Benign
het 19 501743 T <INS> MADCAM1 in-frame p.248_249insPDTTSQEPPDTTSQEP
het 19 55331297 AGG AA KIR3DL1 frameshift p.D163fs
het 19 59069667 A C UBE2M missense p.S28A Benign
het 20 62370231 C CCCTCCCTG LIME1 frameshift p.*296fs
het 21 40178041 CAG CGC ETS2 missense p.N141R Benign
hom 22 20780030 CG CCC SCARF2 frameshift p.A745fs
het 22 45943039 C T FBLN1 missense p.R466W Possibly Damaging
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Table 6-3. Analysis of CNVs in Family #2. 
Analysis of the proband’s CNVs in Family #2 consisted of an investigation of I. de novo CNVs, II. 
CNVs inherited from the father, and III. CNVs inherited from both parents. Each of these sets 
corresponds to different hypotheses on the disease etiology, namely I. occurrence of BA in the 
child is unrelated to the clinical features of heterotaxy and is due to a spontaneous alteration, II. 
BA is an associated finding of heterotaxy but with reduced penetrance, and III. BA is caused by a 
combination of CNVs on both parental alleles. From this list, the most suspicious variant was a 
heterozygous deletion of FOXA2 found in the child and the father, the only gene-altering CNV 
that is not observed in normal individuals. 
Region # SNPs Length CopyNumber Genes in Region (empty if none)
I. De Novo CNV
chr11:50697226-50780629 26 83,404 1
chr14:22794295-22828889 24 34,595 1
chr14:22882604-22917046 40 34,443 1
chr19:45050747-45059310 13 8,564 1 CEACAM22P
chr7:38316887-38342037 38 25,151 1
chrX:153660041-153738092 31 78,052 3 ATP6AP1,FAM3A,FAM50A,GDI1,LAGE3,
PLXNA3,SLC10A3,UBL4A
chrX:58430064-58534992 20 104,929 1
chrX:91835233-91835588 4 356 1 PCDH11X
 
II. Paternally Inherited CNV
chr1:35104655-35108276 4 3,622 1
chr11:51228256-51302261 15 74,006 1
chr11:81501218-81517261 15 16,044 1
chr12:37999378-38053317 15 53,940 1
chr12:38347638-38360252 13 12,615 1
chr13:21728134-21746637 18 18,504 3 SKA3
chr13:72478397-72480478 3 2,082 1
chr14:105002331-105005057 7 2,727 3
chr14:19223219-19267042 6 43,824 1
chr15:24349069-24496990 74 147,922 3 PWRN2
chr15:24680494-24731872 8 51,379 1
chr16:32511914-32629757 41 117,844 1
chr2:228243905-228258288 23 14,384 3 TM4SF20
chr20:22496147-22773103 269 276,957 1 FOXA2,LINC00261
chr20:26119470-26141291 31 21,822 3
chr3:60745635-60809914 83 64,280 1 FHIT
chr3:633604-661110 8 27,507 3
chr4:112238706-112241762 5 3,057 1
chr4:161048496-161072119 40 23,624 1
chr4:190194681-190196067 5 1,387 1
chr4:190956633-190986338 7 29,706 3
chr4:942439-999255 31 56,817 3 DGKQ,IDUA,SLC26A1,TMEM175
chr7:35095894-35158850 10 62,957 3 DPY19L2P1
chr7:62222994-62237501 8 14,508 1
chr8:15319937-15333108 20 13,172 3
chr8:87188572-87191463 4 2,892 1
chr9:11640367-11660139 19 19,773 1
 
III. CNV Inherited From Both Parents
chr1:104153766-104161227 9 7,462 0 AMY2A
chr10:134587640-134610186 13 22,547 4 INPP5A,NKX6-2
chr15:84279410-84281176 3 1,767 0 SH3GL3
chr19:1199676-1259079 23 59,404 4 ATP5D,C19orf26,MIDN,STK11
chr2:48851541-48856770 6 5,230 0 GTF2A1L,STON1-GTF2A1L
chr22:46448476-46465626 11 17,151 4 C22orf26,LOC150381
chr7:110183622-110184985 3 1,364 0
chr7:4159206-4160114 3 909 0 SDK1
chr8:51031221-51038149 6 6,929 0 SNTG1
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Table 6-4. Calculation of Identity-by-Descent Status using SNP Data. 
Given that a SNP is heterozygous in both affected parents, the IBD status can be calculated 
between two probands. However, if both probands were also heterozygous for any given SNP, 
then the IBD status is not determinable. 
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Figure 6-1. Pedigree of Two Families with BA. 
Family #1 (a) have a recurrent case of isolated BA affecting two dizygotic twins. They were born 
to healthy, unaffected parents and have a healthy older brother. In Family #2 (b), a child with BA 
and heterotaxy was born to a healthy mother and a father with heterotaxy. There were a notable 
number of miscarriages, suggesting a genetic incompatibility with life. 
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Figure 6-2. Circos Plots for Affected Probands in Family #1 
The Circos plot of proband 1 (a) and proband 2 (b) in Family #1 summarizes the structural variant 
and single nucleotide variant calls from whole genome sequencing. The red lines indicate the 
interchromosomal junctions, while the rings summarize the SNP frequencies and CNV (ploidy) 
calls for each genome. 
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Figure 6-3. Genome-Wide IBD Status for Affected Probands in Family #1. 
The identity-by-descent (IBD) of each discernable SNP marker was calculated, and the points 
represented above are markers that have IBD=1 (yellow) or IBD=2 (green). The regions of the 
genome where the two affected siblings do not share any alleles are omitted. 
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Figure 6-4. Recurrent Deletion CNV of 20p11.21 in Family #2. 
A 277kb deletion CNV spanning 20p11.21 (chr20:22496147-22773103) was observed in the 
father with heterotaxy and inherited by the affected proband. Both members of the family only 
have one copy of the allele in this region. 
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Figure 6-5. Genomic Annotation of Deletion CNV in 20p11.21 in Family #2. 
A recurrent deletion CNV in Family #2 observed in the father and passed to the affected child 
contains a full-gene deletion of FOXA2. This alteration in FOXA2 has never been seen in the 
Database of Genomic Variants. 
!"#"$%&'?
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Figure 6-6. Experimental Validation of Heterozygous Deletion of FOXA2. 
The trio in Family #2, containing the father, mother, and proband, and a control subject were 
tested using digital droplet PCR for deletions in FOXA2 and a control gene, JAG1. As expected, 
all four samples carry two copies of JAG1. Two copies of FOXA2 were detected in the control and 
the mother, while only one copy was detected in the father and proband. 
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CHAPTER 7: Future Work 
Understanding the Variable Expressivity of ALGS Syndrome 
 From this work, we have identified correlations between the multisystemic phenotypes in 
ALGS. There was significant positive correlation between presence of cardiovascular anomalies 
and two other phenotypes, severe liver disease and presence of butterfly vertebrae. Posterior 
embryotoxon and renal anomalies were not associated with any of the tested phenotypes. The 
biological significance of this correlation is unclear, and it may be due to similar functions of JAG1 
during development of these three systems. It could be that different organ systems have varying 
dosage sensitivity to JAG1 haploinsufficiency. The heart, liver, and skeletal systems could be 
more sensitive to the regulatory effects of JAG1 than the other affected systems. Future work 
performing functional studies varying the dosage of JAG1 during development can confirm if 
variable expressivity arises from JAG1 dosage. 
In addition, we observed that the type of mutation and transmission characteristics of the 
JAG1 allele were not associated with the main disease phenotypes of ALGS. Our sib-pair 
analysis and association test of polymorphisms on JAG1 did not find a significant association 
between normal JAG1 allele and disease phenotype. We could only conclude the absence of a 
strong modifying effect emanating from the normal JAG1 allele, as we lack the power to detect 
small effect sizes. 
Gene expression studies we performed exploring the consequences of JAG1 
haploinsufficiency revealed some interesting expression signatures. Genes in the HES and HEY 
families are known to be important downstream targets of Notch signaling. This study found that 
HEY2, a co-repressor of transcription, was downregulated in the deleted line of the endoderm, 
and it was the most significantly altered downstream Notch target and it. Genes regulated by 
HEY2 may be responsible for variable expressivity due to JAG1 haploinsufficiency. Moreover, 
pathway analysis revealed an enrichment of upregulated genes that are involved in nucleosome 
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and chromosome assembly. Additional biological replicates can help confirm the robustness of 
these gene expression alterations. 
 In a genome-wide, hypothesis-neutral search for genetic modifiers of liver disease 
severity, we found a risk allele 14kb upstream of THBS2 on 6q27, rs7382539, from our SNP 
association study. This region contains H3K27Ac and H3K4Me1 histone marks, suggesting it to 
be a poised enhancer. Because this genetic association appears to fall in a regulatory region, 
design and execution of experimental studies disrupting this regulatory region can help predict 
the biological consequences resulting from this alteration. Functional studies in mice have shown 
that THBS2 can enhance Jag-Notch binding (Meng et al. 2009), which implicates this gene as a 
genetic modifier for variable expressivity in ALGS. In the CNV association study, we have 
identified a deletion in 19q13.2 and duplication in 5p13.3 that may be associated with liver 
disease severity. Follow-up studies confirming these CNVs and characterization of the 
breakpoints, especially the duplications, are necessary before undertaking functional studies of 
CYP2A6, GOLPH3, and PDZD2, the genes affected by these two copy number alterations. 
Genetic Susceptibility to Biliary Atresia 
 Our studies to uncover candidate genes and alterations that contribute to the 
pathogenesis of BA revealed several novel findings and areas for future research. XPNPEP1 and 
ADD3 flank the 10q25.1 region containing the intergenic SNP signal uncovered from the Chinese 
GWAS of isolated BA. Fine-mapping of this region in a cohort with European ancestry yielded a 
stronger association signal in the intronic region of ADD3, and the immunohistochemistry studies 
suggest that deficiencies of ADD3 may confer susceptibility to BA. However, gene knockdown 
experiments in model organisms should be conducted in order to confirm the significance of 
ADD3 in BA. 
 Whole exome sequencing of 30 isolated BA probands suggest that this disease is 
genetically heterogeneous. Analysis of candidate genes known to be associated with BA suggest 
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that inherited, rare variants may contribute to disease etiology. Furthermore, additional gene 
candidates were identified in the cilia (DNAH3) and planar cell polarity pathways (DCHS1, 
SMAD9, and VPS13C). These genes have never been studied in the context of BA, and 
observations in knockdown constructs of these genes in model organisms may help demonstrate 
their role in this disease. 
 The investigation of a family with affected, dizygotic twins suggested that a maternally-
inherited frameshift variant that resulted in the truncation of IFNK could confer susceptibility to BA. 
This alteration appears to be three times more prominent in our disease cohort than in the 
general, healthy population, as it appears in 2 additional probands of our WES cohort. An 
additional proband was found to have a rare, missense variant in IFNK. Although this gene is not 
well-studied, we predict that defects in IFNK could impair the immune response to toxins and 
pathogens. A larger genetic association study may be able to confirm an enrichment of IFNK 
variants in BA patients. 
 The second family investigated has a proband that presented with BA and heterotaxy. 
The father also presented with symptoms at a young age confirmed for heterotaxy, but he did not 
have BA. From CNV analysis of this family, we uncovered a large deletion on 20p11.21 
encompassing only one gene, FOXA2, transmitted from the father to the proband. This critical 
liver transcription factor has been associated with the Nodal pathway, that is important for the 
proper development of body symmetry, as well as the development of the liver and biliary system. 
This deletion is not observed in the healthy control population, and we hypothesize that FOXA2 is 
a haploinsufficient gene. Furthermore, we suggest that FOXA2 causes heterotaxy and BA in this 
family. Further studies of this gene in the context of BA may lead to a better understanding of the 
disease etiology.  
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APPENDIX 
Table A1. Genes Differentially Expressed in Fibroblast, iPSCs, and Endoderm between the 
deleted (D) and non-deleted (D) lines. 
 
Mean: Mean Expression, FC: Fold Change (Deleted / Non-Deleted), FDR: False Discovery Rate 
Gene Symbol Chr Gene Name Mean,N-D
Mean,
D FC p FDR
CAMK1G 1 calcium/calmodulin-dependent protein kinase IG 10.2 6.0 0.05 5.9E-5 0.0%
TRPV2 17 transient receptor potential cation channel, subfamily V, member 2 9.7 5.9 0.07 7.6E-5 0.0%
HOXD10 2 homeobox D10 9.2 5.4 0.07 9.3E-5 0.0%
NCAM2 21 neural cell adhesion molecule 2 8.8 5.5 0.10 1.1E-4 0.0%
VAT1L 16 vesicle amine transport protein 1 homolog (T. californica)-like 9.7 6.6 0.12 1.3E-4 0.0%
PTGS2 1 prostaglandin-endoperoxide synthase 2 11.5 7.8 0.08 1.6E-4 0.0%
NEFM 8 neurofilament, medium polypeptide 10.0 6.4 0.08 1.9E-4 4.5%
CSRP1 1 cysteine and glycine-rich protein 1 9.6 6.7 0.13 5.3E-5 0.0%
NNAT 20 neuronatin 9.5 5.8 0.08 5.8E-5 0.0%
PCDHGA3 5 protocadherin gamma subfamily A, 3 4.6 6.9 4.87 6.3E-5 0.0%
CDYL2 16 chromodomain protein, Y-like 2 7.5 6.3 0.42 8.2E-5 0.0%
C18orf2 18 chromosome 18 open reading frame 2 3.2 4.8 3.00 1.0E-4 0.0%
TMTC1 12 transmembrane and tetratricopeptide repeat containing 1 8.2 9.4 2.34 1.1E-4 0.0%
PKIB 6 protein kinase (cAMP-dependent, catalytic) inhibitor beta 7.3 8.4 2.12 1.3E-4 0.0%
DNAJA4 15 DnaJ (Hsp40) homolog, subfamily A, member 4 7.7 6.4 0.40 1.4E-4 0.0%
TBX20 7 T-box 20 7.4 9.3 3.70 5.9E-5 0.0%
MTNR1A 4 melatonin receptor 1A 7.5 8.9 2.63 7.6E-5 0.0%
C18orf2 18 chromosome 18 open reading frame 2 3.1 5.2 4.29 9.3E-5 0.0%
HIST1H2AI 6 histone cluster 1, H2ai 6.8 8.6 3.50 1.1E-4 0.0%
LOC100506979 6 hypothetical LOC100506979 5.5 6.9 2.58 1.3E-4 0.0%
PDE12 3 phosphodiesterase 12 6.4 7.9 2.93 1.6E-4 0.0%
PLAC8 4 placenta-specific 8 5.3 7.1 3.49 1.8E-4 0.0%
C4orf11 4 chromosome 4 open reading frame 11 5.4 6.7 2.56 2.1E-4 0.0%
MSMB 10 microseminoprotein, beta- 5.3 6.9 3.05 2.3E-4 0.0%
HIST1H2BG 6 histone cluster 1, H2bg 7.6 9.2 2.89 2.4E-4 0.0%
HIST1H3H 6 histone cluster 1, H3h 9.7 10.9 2.40 2.6E-4 0.0%
LGR5 12 leucine-rich repeat containing G protein-coupled receptor 5 9.8 10.9 2.12 3.1E-4 0.0%
PCDHGA3 5 protocadherin gamma subfamily A, 3 4.8 6.8 3.95 3.3E-4 0.0%
DDX58 9 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 8.4 9.3 1.84 3.6E-4 3.2%
MYCT1 6 myc target 1 7.4 8.5 2.14 4.0E-4 3.2%
PCDHB5 5 protocadherin beta 5 8.8 10.6 3.49 4.3E-4 3.2%
OLR1 12 oxidized low density lipoprotein (lectin-like) receptor 1 6.6 8.5 3.67 4.5E-4 3.2%
PKIB 6 protein kinase (cAMP-dependent, catalytic) inhibitor beta 7.5 8.8 2.54 4.6E-4 3.2%
DLEU2 13 deleted in lymphocytic leukemia 2 (non-protein coding) 7.2 8.4 2.23 4.8E-4 3.2%
VIL1 2 villin 1 7.8 9.4 2.93 5.0E-4 3.2%
ARHGEF35 7 Rho guanine nucleotide exchange factor (GEF) 35 6.8 7.8 1.97 5.2E-4 3.2%
GPR128 3 G protein-coupled receptor 128 5.6 7.1 2.99 5.5E-4 3.2%
SNORA1 11 small nucleolar RNA, H/ACA box 1 4.9 6.2 2.53 6.0E-4 3.2%
EDN1 6 endothelin 1 6.8 8.2 2.59 6.2E-4 3.2%
INPP5F 10 inositol polyphosphate-5-phosphatase F 8.7 9.5 1.76 6.3E-4 3.2%
RPSAP58 19 ribosomal protein SA pseudogene 58 6.8 7.8 1.97 6.5E-4 3.2%
SLC38A5 X solute carrier family 38, member 5 9.4 10.6 2.28 6.7E-4 3.2%
KCNJ13 2 potassium inwardly-rectifying channel, subfamily J, member 13 5.1 6.9 3.64 7.0E-4 3.2%
GINS1 20 GINS complex subunit 1 (Psf1 homolog) 9.4 10.4 2.02 7.3E-4 3.2%
CYP2C8 10 cytochrome P450, family 2, subfamily C, polypeptide 8 4.3 5.1 1.81 7.5E-4 3.2%
HIST1H2BL 6 histone cluster 1, H2bl 7.7 9.3 2.84 8.0E-4 3.2%
ZNF677 19 zinc finger protein 677 5.9 6.9 1.91 8.2E-4 3.2%
TBX22 X T-box 22 5.6 6.9 2.39 8.5E-4 3.2%
LRRTM1 2 leucine rich repeat transmembrane neuronal 1 6.5 7.4 1.91 8.7E-4 3.2%
TXNIP 1 thioredoxin interacting protein 10.6 8.7 0.27 1.4E-4 4.1%
III. Endoderm
II. iPSC
I. Fibroblast
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